<!DOCTYPE html>
 <!--[if lt IE 7]> <html dir="ltr" lang="en-US" class="aui ltr no-js lt-ie9 lt-ie8 lt-ie7"> <![endif]--> <!--[if IE 7]> <html dir="ltr" lang="en-US" class="aui ltr no-js lt-ie9 lt-ie8"> <![endif]--> <!--[if IE 8]> <html dir="ltr" lang="en-US" class="aui ltr no-js lt-ie9"> <![endif]--> <!--[if gt IE 8]><!--> <html class="aui ltr" dir="ltr" lang="en-US" prefix="og: http://ogp.me/ns#"> <!--<![endif]--> <head> <title>Antioxidant treatments for schizophrenia - Magalhães, PVS - 2016 | Cochrane Library</title> <meta content="Antioxidant treatments for schizophrenia - Magalhães, PVS - 2016 | Cochrane Library" property="og:title"/> <meta content="https://www.cochranelibrary.com/cdsr/doi/10.1002/14651858.CD008919.pub2/full" property="og:url"/> <meta content="article" property="og:type"/> <meta content="https://www.cochranelibrary.com/cochrane-theme/images/cochrane_circulargraphic.png" property="og:image"/> <meta content="summary_large_image" name="twitter:card"/> <meta content="Antioxidant treatments for schizophrenia - Magalhães, PVS - 2016 | Cochrane Library" name="twitter:title"/> <meta content="https://www.cochranelibrary.com/cdsr/doi/10.1002/14651858.CD008919.pub2/full" name="twitter:url"/> <meta content="https://www.cochranelibrary.com/cochrane-theme/images/cochrane_circulargraphic.png" name="twitter:image"/> <meta content="initial-scale=1.0, width=device-width" name="viewport"/> <meta content="10.1002/14651858.CD008919.pub2" name="dc.identifier" scheme="DOI"/> <meta content="Antioxidant treatments for schizophrenia" name="citation_title"/> <meta content="Pedro V S Magalhães" name="citation_author"/> <meta content="Federal University of Rio Grande do Sul" name="citation_author_institution"/> <meta content="pedromaga2@gmail.com" name="citation_author_email"/> <meta content="Olivia Dean" name="citation_author"/> <meta content="The University of Melbourne" name="citation_author_institution"/> <meta content="Ana C Andreazza" name="citation_author"/> <meta content="University of Toronto" name="citation_author_institution"/> <meta content="Michael Berk" name="citation_author"/> <meta content="Deakin University" name="citation_author_institution"/> <meta content="Flávio Kapczinski" name="citation_author"/> <meta content="Hospital de Clínicas de Porto Alegre" name="citation_author_institution"/> <meta content="Cochrane Database of Systematic Reviews" name="citation_journal_title"/> <meta content="John Wiley &amp; Sons, Ltd" name="citation_publisher"/> <meta content="2" name="citation_issue"/> <meta content="10.1002/14651858.CD008919.pub2" name="citation_doi"/> <meta content="2016" name="citation_date"/> <meta content="2016/02/05" name="citation_online_date"/> <meta content="https://www.cochranelibrary.com/cdsr/doi/10.1002/14651858.CD008919.pub2/abstract" name="citation_abstract_html_url"/> <meta content="https://www.cochranelibrary.com/cdsr/doi/10.1002/14651858.CD008919.pub2/full" name="citation_fulltext_html_url"/> <meta content="https://www.cochranelibrary.com/cdsr/doi/10.1002/14651858.CD008919.pub2/pdf/full" name="citation_pdf_url"/> <meta content="1465-1858" name="citation_issn"/> <meta content="en" name="citation_language"/> <meta content="Acetylcysteine [therapeutic use]; Allopurinol [therapeutic use]; Antioxidants [*therapeutic use]; Antipsychotic Agents [*therapeutic use]; Ascorbic Acid [therapeutic use]; Dehydroepiandrosterone [therapeutic use]; Drug Therapy, Combination [methods]; Free Radical Scavengers [*therapeutic use]; Ginkgo biloba; Oxidative Stress [*drug effects]; Randomized Controlled Trials as Topic; Schizophrenia [*drug therapy, metabolism]; Selegiline [therapeutic use]; Vitamin E [therapeutic use]; Vitamins [therapeutic use]" name="citation_keywords"/> <link href="https://fonts.googleapis.com/css?family=Source+Sans+Pro:400,700,600,900" rel="stylesheet"/> <script src="https://cmp.osano.com/AzZdRbSORDOOzF9W/d594efc1-9663-477d-9528-6576640e64fd/osano.js"></script> <style> .osano-cm-widget{display: none;} </style> <script src="https://static.addtoany.com/menu/page.js"></script> <script async="" charset="utf-8" src="https://platform.twitter.com/widgets.js"></script> <script async="async" src="//script.crazyegg.com/pages/scripts/0056/6375.js" type="text/javascript"></script> <script type="text/javascript">window.dataLayer={};var xtend=function(){var a={};var b=false;var c=0;var d=arguments.length;if(Object.prototype.toString.call(arguments[0])==="[object Boolean]"){b=arguments[0];c++}var f=function(g){for(var h in g){if(Object.prototype.hasOwnProperty.call(g,h)){if(b&&Object.prototype.toString.call(g[h])==="[object Object]"){a[h]=xtend(true,a[h],g[h])}else{a[h]=g[h]}}}};for(;c<d;c++){var e=arguments[c];f(e)}return a};</script> <!-- Global site tag (gtag.js) - Google Analytics --> <script src="https://www.googletagmanager.com/gtag/js?id=UA-189672-63&amp;l=gDataLayer"></script> <script>window.gDataLayer=window.gDataLayer||[];function gtag(){gDataLayer.push(arguments)}gtag("js",new Date());gtag("config","UA-189672-63");</script> <script type="text/javascript">var o={auth:{customerIds:[],individualId:null,brandedCustomer:null,roles:["Guest"]}};window.dataLayer=xtend(true,window.dataLayer,o);</script> <script type="text/javascript">var o={page:{siteSection:"Content",languageCode:"en",cms:{pageTitle:"Content"}}};window.dataLayer=xtend(true,window.dataLayer,o);</script> <meta content="text/html; charset=utf-8" http-equiv="content-type"/> <link href="https://www.cochranelibrary.com/cochrane-theme/images/favicon.ico" rel="Shortcut Icon"/> <link href="https://www.cochranelibrary.com/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD008919.pub2&amp;doi=10.1002/14651858.CD008919.pub2&amp;type=cdsr&amp;contentLanguage=" rel="canonical"/> <link href="https://www.cochranelibrary.com/zh/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD008919.pub2&amp;doi=10.1002/14651858.CD008919.pub2&amp;type=cdsr&amp;contentLanguage=" hreflang="zh-HANS" rel="alternate"/> <link href="https://www.cochranelibrary.com/zh_HANT/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD008919.pub2&amp;doi=10.1002/14651858.CD008919.pub2&amp;type=cdsr&amp;contentLanguage=" hreflang="zh-HANT" rel="alternate"/> <link href="https://www.cochranelibrary.com/hr/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD008919.pub2&amp;doi=10.1002/14651858.CD008919.pub2&amp;type=cdsr&amp;contentLanguage=" hreflang="hr-HR" rel="alternate"/> <link href="https://www.cochranelibrary.com/nl/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD008919.pub2&amp;doi=10.1002/14651858.CD008919.pub2&amp;type=cdsr&amp;contentLanguage=" hreflang="nl-NL" rel="alternate"/> <link href="https://www.cochranelibrary.com/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD008919.pub2&amp;doi=10.1002/14651858.CD008919.pub2&amp;type=cdsr&amp;contentLanguage=" hreflang="x-default" rel="alternate"/> <link href="https://www.cochranelibrary.com/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD008919.pub2&amp;doi=10.1002/14651858.CD008919.pub2&amp;type=cdsr&amp;contentLanguage=" hreflang="en-US" rel="alternate"/> <link href="https://www.cochranelibrary.com/fr/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD008919.pub2&amp;doi=10.1002/14651858.CD008919.pub2&amp;type=cdsr&amp;contentLanguage=" hreflang="fr-FR" rel="alternate"/> <link href="https://www.cochranelibrary.com/de/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD008919.pub2&amp;doi=10.1002/14651858.CD008919.pub2&amp;type=cdsr&amp;contentLanguage=" hreflang="de-DE" rel="alternate"/> <link href="https://www.cochranelibrary.com/hi/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD008919.pub2&amp;doi=10.1002/14651858.CD008919.pub2&amp;type=cdsr&amp;contentLanguage=" hreflang="hi-HI" rel="alternate"/> <link href="https://www.cochranelibrary.com/hu/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD008919.pub2&amp;doi=10.1002/14651858.CD008919.pub2&amp;type=cdsr&amp;contentLanguage=" hreflang="hu-HU" rel="alternate"/> <link href="https://www.cochranelibrary.com/in/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD008919.pub2&amp;doi=10.1002/14651858.CD008919.pub2&amp;type=cdsr&amp;contentLanguage=" hreflang="in-ID" rel="alternate"/> <link href="https://www.cochranelibrary.com/ja/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD008919.pub2&amp;doi=10.1002/14651858.CD008919.pub2&amp;type=cdsr&amp;contentLanguage=" hreflang="ja-JP" rel="alternate"/> <link href="https://www.cochranelibrary.com/ko/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD008919.pub2&amp;doi=10.1002/14651858.CD008919.pub2&amp;type=cdsr&amp;contentLanguage=" hreflang="ko-KR" rel="alternate"/> <link href="https://www.cochranelibrary.com/ms/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD008919.pub2&amp;doi=10.1002/14651858.CD008919.pub2&amp;type=cdsr&amp;contentLanguage=" hreflang="ms-MY" rel="alternate"/> <link href="https://www.cochranelibrary.com/fa/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD008919.pub2&amp;doi=10.1002/14651858.CD008919.pub2&amp;type=cdsr&amp;contentLanguage=" hreflang="fa-IR" rel="alternate"/> <link href="https://www.cochranelibrary.com/pl/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD008919.pub2&amp;doi=10.1002/14651858.CD008919.pub2&amp;type=cdsr&amp;contentLanguage=" hreflang="pl-PL" rel="alternate"/> <link href="https://www.cochranelibrary.com/pt/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD008919.pub2&amp;doi=10.1002/14651858.CD008919.pub2&amp;type=cdsr&amp;contentLanguage=" hreflang="pt-PT" rel="alternate"/> <link href="https://www.cochranelibrary.com/ro/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD008919.pub2&amp;doi=10.1002/14651858.CD008919.pub2&amp;type=cdsr&amp;contentLanguage=" hreflang="ro-RO" rel="alternate"/> <link href="https://www.cochranelibrary.com/ru/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD008919.pub2&amp;doi=10.1002/14651858.CD008919.pub2&amp;type=cdsr&amp;contentLanguage=" hreflang="ru-RU" rel="alternate"/> <link href="https://www.cochranelibrary.com/es/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD008919.pub2&amp;doi=10.1002/14651858.CD008919.pub2&amp;type=cdsr&amp;contentLanguage=" hreflang="es-ES" rel="alternate"/> <link href="https://www.cochranelibrary.com/ta/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD008919.pub2&amp;doi=10.1002/14651858.CD008919.pub2&amp;type=cdsr&amp;contentLanguage=" hreflang="ta-IN" rel="alternate"/> <link href="https://www.cochranelibrary.com/th/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD008919.pub2&amp;doi=10.1002/14651858.CD008919.pub2&amp;type=cdsr&amp;contentLanguage=" hreflang="th-TH" rel="alternate"/> <link class="lfr-css-file" href="https://www.cochranelibrary.com/cochrane-theme/css/main.css?browserId=other&amp;themeId=cochrane_WAR_cochranetheme&amp;minifierType=css&amp;languageId=en_US&amp;b=6210&amp;t=1738734739000" rel="stylesheet" type="text/css"/> <link class="lfr-css-file" href="https://www.cochranelibrary.com/cochrane-theme/css/aui.css?browserId=other&amp;themeId=cochrane_WAR_cochranetheme&amp;minifierType=css&amp;languageId=en_US&amp;b=6210&amp;t=1738734739000" rel="stylesheet" type="text/css"/> <link href="/html/css/main.css?browserId=other&amp;themeId=cochrane_WAR_cochranetheme&amp;minifierType=css&amp;languageId=en_US&amp;b=6210&amp;t=1739773519000" rel="stylesheet" type="text/css"/> <link href="https://www.cochranelibrary.com/scolaris-content-display/css/main.css?browserId=other&amp;themeId=cochrane_WAR_cochranetheme&amp;minifierType=css&amp;languageId=en_US&amp;b=6210&amp;t=1739773465000" rel="stylesheet" type="text/css"/> <link href="https://www.cochranelibrary.com/notifications-portlet/notifications/css/main.css?browserId=other&amp;themeId=cochrane_WAR_cochranetheme&amp;minifierType=css&amp;languageId=en_US&amp;b=6210&amp;t=1739773465000" rel="stylesheet" type="text/css"/> <link href="https://www.cochranelibrary.com/html/portlet/login/css/main.css?browserId=other&amp;themeId=cochrane_WAR_cochranetheme&amp;minifierType=css&amp;languageId=en_US&amp;b=6210&amp;t=1739773548000" rel="stylesheet" type="text/css"/> <script type="text/javascript">var Liferay={Browser:{acceptsGzip:function(){return false},getMajorVersion:function(){return 80},getRevision:function(){return"537.36"},getVersion:function(){return"80.0"},isAir:function(){return false},isChrome:function(){return true},isFirefox:function(){return false},isGecko:function(){return true},isIe:function(){return false},isIphone:function(){return false},isLinux:function(){return true},isMac:function(){return false},isMobile:function(){return false},isMozilla:function(){return false},isOpera:function(){return false},isRtf:function(){return true},isSafari:function(){return true},isSun:function(){return false},isWap:function(){return false},isWapXhtml:function(){return false},isWebKit:function(){return true},isWindows:function(){return false},isWml:function(){return false}},Data:{NAV_SELECTOR:"#navigation",isCustomizationView:function(){return false},notices:[null]},ThemeDisplay:{getLayoutId:function(){return"7"},getLayoutURL:function(){return"https://www.cochranelibrary.com/en/content"},getParentLayoutId:function(){return"0"},isPrivateLayout:function(){return"false"},isVirtualLayout:function(){return false},getBCP47LanguageId:function(){return"en-US"},getCDNBaseURL:function(){return"https://www.cochranelibrary.com"},getCDNDynamicResourcesHost:function(){return""},getCDNHost:function(){return""},getCompanyId:function(){return"20155"},getCompanyGroupId:function(){return"20195"},getDefaultLanguageId:function(){return"en_US"},getDoAsUserIdEncoded:function(){return""},getLanguageId:function(){return"en_US"},getParentGroupId:function(){return"20182"},getPathContext:function(){return""},getPathImage:function(){return"/image"},getPathJavaScript:function(){return"/html/js"},getPathMain:function(){return"/en/c"},getPathThemeImages:function(){return"https://www.cochranelibrary.com/cochrane-theme/images"},getPathThemeRoot:function(){return"/cochrane-theme"},getPlid:function(){return"20757"},getPortalURL:function(){return"https://www.cochranelibrary.com"},getPortletSetupShowBordersDefault:function(){return true},getScopeGroupId:function(){return"20182"},getScopeGroupIdOrLiveGroupId:function(){return"20182"},getSessionId:function(){return""},getSiteGroupId:function(){return"20182"},getURLControlPanel:function(){return"/group/control_panel?refererPlid=20757"},getURLHome:function(){return"https\x3a\x2f\x2fwww\x2ecochranelibrary\x2ecom\x2fweb\x2fcochrane"},getUserId:function(){return"20159"},getUserName:function(){return""},isAddSessionIdToURL:function(){return false},isFreeformLayout:function(){return false},isImpersonated:function(){return false},isSignedIn:function(){return false},isStateExclusive:function(){return false},isStateMaximized:function(){return false},isStatePopUp:function(){return false}},PropsValues:{NTLM_AUTH_ENABLED:false}};var themeDisplay=Liferay.ThemeDisplay;Liferay.AUI={getAvailableLangPath:function(){return"available_languages.jsp?browserId=other&themeId=cochrane_WAR_cochranetheme&colorSchemeId=01&minifierType=js&languageId=en_US&b=6210&t=1513680837000"},getCombine:function(){return true},getComboPath:function(){return"/combo/?browserId=other&minifierType=&languageId=en_US&b=6210&t=1513680837000&"},getFilter:function(){return"min"},getJavaScriptRootPath:function(){return"/html/js"},getLangPath:function(){return"aui_lang.jsp?browserId=other&themeId=cochrane_WAR_cochranetheme&colorSchemeId=01&minifierType=js&languageId=en_US&b=6210&t=1513680837000"},getStaticResourceURLParams:function(){return"?browserId=other&minifierType=&languageId=en_US&b=6210&t=1513680837000"}};Liferay.authToken="9mpoajSI";Liferay.currentURL="\x2fweb\x2fcochrane\x2fcontent\x3ftemplateType\x3dfull\x26urlTitle\x3d\x2fcdsr\x2fdoi\x2f10\x2e1002\x2f14651858\x2eCD008919\x2epub2\x26doi\x3d10\x2e1002\x2f14651858\x2eCD008919\x2epub2\x26type\x3dcdsr\x26contentLanguage\x3d";Liferay.currentURLEncoded="\x252Fweb\x252Fcochrane\x252Fcontent\x253FtemplateType\x253Dfull\x2526urlTitle\x253D\x252Fcdsr\x252Fdoi\x252F10\x2e1002\x252F14651858\x2eCD008919\x2epub2\x2526doi\x253D10\x2e1002\x252F14651858\x2eCD008919\x2epub2\x2526type\x253Dcdsr\x2526contentLanguage\x253D";</script> <script src="/html/js/barebone.jsp?browserId=other&amp;themeId=cochrane_WAR_cochranetheme&amp;colorSchemeId=01&amp;minifierType=js&amp;minifierBundleId=javascript.barebone.files&amp;languageId=en_US&amp;b=6210&amp;t=1513680837000" type="text/javascript"></script> <script type="text/javascript"></script> <script type="text/javascript">var o={database:"CDSR",page:{pageType:"Article Full Text HTML"},article:{availableLanguage:["en","es","de","ru","ja","hr","pl","fa"],languageCode:"en",accessStatus:"delayed-free",doi:"10.1002/14651858.CD008919.pub2",title:"Antioxidant treatments for schizophrenia",firstPublishedDate:"Feb 5, 2016 12:00:00 AM",isCurrentVersion:true,editorialGroup:"Cochrane Schizophrenia Group",availableParts:["PDF Full","PDF Standard","PDF Abstract","HTML","Comments","Information","References","Stats","Related Content"]}};window.dataLayer=xtend(true,window.dataLayer,o);</script> <link class="lfr-css-file" href="https://www.cochranelibrary.com/cochrane-theme/css/custom.css?browserId=other&amp;themeId=cochrane_WAR_cochranetheme&amp;minifierType=css&amp;languageId=en_US&amp;b=6210&amp;t=1738734739000" rel="stylesheet" type="text/css"/> <style type="text/css"></style> <script async="" src="https://assets.adobedtm.com/59640f9fa510/7cad07cf7779/launch-a215d9c51521.min.js"></script> <!--[if lt IE 9]> <script src="/cochrane-theme/vendor/respond/dest/respond.min.js?t=1738734739000" type="text/javascript"></script> <![endif]--> </head> <body class="yui3-skin-sam controls-visible guest-site signed-out public-page site"> <div class="site-container"> <a href="#main-content" id="skip-to-content">Skip to Content</a> <div class="cookie-message cookie-message--hidden system-message-container" id="js-cookie-message"> <div class="container"> <a aria-label="Close cookies message" class="fa fa-times js-cookie-close pull-right" href="#"></a> <div class="system-message-wrapper container"> <i aria-hidden="true" class="fa fa-exclamation-triangle"></i> <div class="system-message-title">Cookies</div> <div class="system-message-description"> <p> Our site uses cookies to improve your experience. You can find out more about our use of cookies in About Cookies, including instructions on how to turn off cookies if you wish to do so. By continuing to browse this site you agree to us using cookies as described in <a href="http://olabout.wiley.com/WileyCDA/Section/id-813473.html">About Cookies</a>. </p> <a class="btn secondary js-cookie-close js-cookie-accept" href="#">I accept</a> </div> </div> </div> </div> <script>document.body.className=document.body.className+" js_enabled";</script><header> <div class="container"> <div class="branding"> <h1 class="brand-container"> <a href="https://www.cochranelibrary.com/en/"> <span class="brand-name">The Cochrane Library</span> <img alt="Cochrane Library logo" class="brand-logo" src="https://www.cochranelibrary.com/cochrane-theme/images/en-US_logo.png" title="Cochrane Library"/> </a> </h1> <span class="additional-branding"> <p class="brand-message"> <em>Trusted evidence.</em> <em>Informed decisions.</em> <em>Better health.</em> </p> </span> </div> <div class="desktop-search basic-search-container"> <div class="desktop-search-form"> <div class="portlet-boundary portlet-boundary_scolarissearchportlet_WAR_scolarissearch_ portlet-static portlet-static-end" id="p_p_id_scolarissearchportlet_WAR_scolarissearch_"> <span id="p_scolarissearchportlet_WAR_scolarissearch"></span> <section class="portlet" id="portlet_scolarissearchportlet_WAR_scolarissearch"> <header class="portlet-topper"> <h1 class="portlet-title"> <span class="" onmouseover="Liferay.Portal.ToolTip.show(this, 'Scolaris\x20Search\x20Portlet')"> <img alt="" id="owel__null__null" src="/scolaris-search/icon.png"/> <span class="taglib-text hide-accessible">Scolaris Search Portlet</span> </span> <span class="portlet-title-text">Scolaris Search Portlet</span> </h1> <menu class="portlet-topper-toolbar" id="portlet-topper-toolbar_scolarissearchportlet_WAR_scolarissearch" type="toolbar"> </menu> </header> <div class="portlet-content"> <div class="portlet-content-container"> <div class="portlet-body"> <div class="header-search"> <form action="https://www.cochranelibrary.com/en/content?p_auth=9mpoajSI&amp;p_p_id=scolarissearchportlet_WAR_scolarissearch&amp;p_p_lifecycle=1&amp;p_p_state=normal&amp;p_p_mode=view&amp;_scolarissearchportlet_WAR_scolarissearch_scolarisAction=redirectSearchResult" method="post"> <input name="searchType" type="hidden" value="basic"/> <input name="facetDisplayName" type="hidden" value=""/> <input name="facetQueryTerm" type="hidden" value=""/> <input name="facetQueryField" type="hidden" value=""/> <input name="facetCategory" type="hidden" value=""/> <fieldset class="fieldset"> <legend class="sr-only">Basic Search</legend> <div class="select search-by"> <select aria-label="Search by options" class="custom-select-enabled search-type" name="searchBy" title="Search by options"> <option value="1">Title Abstract Keyword</option> <option value="2">Record Title</option> <option value="3">Abstract</option> <option value="4">Author</option> <option value="5">Keyword</option> <option value="6">All Text</option> <option value="7">Publication Type</option> <option value="8">Source</option> <option value="9">DOI</option> <option value="14">Language</option> <option value="10">Accession Number</option> <option value="11">Trial Registry Number</option> <option value="12">Cochrane Group</option> <option value="13">Cochrane Topic</option> </select> </div> <div class="search-select-crg-container select" style="display: none;"> <select class="search-select-crg-list"></select> </div> <div class="search-select-topic-container select" data-topic-list-url="https://www.cochranelibrary.com/en/content?p_p_id=scolaristopics_WAR_scolaristopics&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=topics-list&amp;p_p_cacheability=cacheLevelPage" style="display: none;"> <select class="search-select-topic-list"></select> </div> <div class="search-select-cl-container select" style="display: none;"> <select class="search-select-cl-list"></select> </div> <div class="search-text-container"> <div class="control-group control-group-inline search-input-wrapper"> <input aria-label="Enter search term" class="field browser-search search-text ui-autocomplete-input" id="searchText" name="searchText" placeholder="Search" size="30" type="text" value=""/>
<div id="autocomplete-results"></div>
</div>
<div class="control-group control-group-inline search-button-wrapper">
<button aria-label="Search" class="searchByBtn" type="submit">
<i aria-hidden="true" class="fa fa-search"></i>
</button>
</div>
</div>
</fieldset>
</form>
</div>
<script>
    window.displayResultURL = 'https://www.cochranelibrary.com/en/content?p_p_id=scolarissearchportlet_WAR_scolarissearch&p_p_lifecycle=2&p_p_state=normal&p_p_mode=view&p_p_resource_id=getSuggestions&p_p_cacheability=cacheLevelPage&_scolarissearchportlet_WAR_scolarissearch_templateType=full&_scolarissearchportlet_WAR_scolarissearch_urlTitle=%2Fcdsr%2Fdoi%2F10.1002%2F14651858.CD008919.pub2&_scolarissearchportlet_WAR_scolarissearch_contentLanguage=&_scolarissearchportlet_WAR_scolarissearch_type=cdsr&_scolarissearchportlet_WAR_scolarissearch_doi=10.1002%2F14651858.CD008919.pub2';
    window.searchByOption = '';
</script>
</div>
</div>
</div>
<div style="display:none">
<input id="freelabel" name="freelabel" type="hidden" value="Free access"/>
<input id="openlabel" name="openlabel" type="hidden" value="Open access"/>
</div>
</section>
</div>
</div>
<div class="search-tools-nav">
<a class="btn secondary" href="/en/browse-by-topic">Browse</a>
<a class="btn primary advanced-search-button" href="/en/advanced-search">Advanced search</a>
</div>
</div>
<a class="toggle-menu-switch" href="#"><i aria-hidden="true" class="fa fa-bars"></i> <div class="toggle-menu-text">Open menu</div></a>
</div>
<div class="auxiliary-container">
<div class="container">
<div class="header-auxiliary-menu">
<div class="auxiliary-menu-item language-selector">
<div class="portlet-boundary portlet-boundary_scolarislanguageselector_WAR_scolarislanguageportlet_ portlet-static portlet-static-end" id="p_p_id_scolarislanguageselector_WAR_scolarislanguageportlet_INSTANCE_header_">
<span id="p_scolarislanguageselector_WAR_scolarislanguageportlet_INSTANCE_header"></span>
<section class="portlet" id="portlet_scolarislanguageselector_WAR_scolarislanguageportlet_INSTANCE_header">
<header class="portlet-topper">
<h1 class="portlet-title">
<span class="" onmouseover="Liferay.Portal.ToolTip.show(this, 'Scolaris\x20Language\x20Selector')">
<img alt="" id="bvrs__null__null" src="/scolaris-language-portlet/icon.png"/> <span class="taglib-text hide-accessible">Scolaris Language Selector</span> </span> <span class="portlet-title-text">Scolaris Language Selector</span> </h1> <menu class="portlet-topper-toolbar" id="portlet-topper-toolbar_scolarislanguageselector_WAR_scolarislanguageportlet_INSTANCE_header" type="toolbar"> </menu> </header> <div class="portlet-content"> <div class="portlet-content-container"> <div class="portlet-body"> <div class="language-display" data-content-languages="[de, en, es, fa, fr, hi, hr, id, ja, ko, hu, ms, nl, pl, pt, ru, ro, ta, th, zh_HANT, zh_HANS]"> <a class="open-language-modal" href="#" title="Select your preferred language"> <i class="fa fa-file-text"></i> Review language : English </a> <a class="open-language-modal" href="#" title="Select your preferred language"> <i class="fa fa-globe"></i> Website language : English </a> </div> <div class="language-selector-modal-content" data-modal-title="Language selection" data-size="large" style="display: none;"> <div class="form-content language-selector-modal"> <div class="row-fluid"> <div> <table class="mytable" style="border: 1px solid #f0f0f0" width="90%"> <tbody> <tr class="row-box"> <td><i class="fa fa-file-text icon-size"></i></td> <td><h3>Cochrane review language</h3> <p>Select your preferred language for Cochrane reviews and other content. Sections without translation will be in English.</p> </td> <td> <div> <select id="contentLanguageSelector" onchange="updateLang(this.value)"> <option class="content-language-option" data-languagecode="de" value="de"> Deutsch </option> <option class="content-language-option" data-languagecode="en" selected="" value="en"> English </option> <option class="content-language-option" data-languagecode="es" value="es"> Español </option> <option class="content-language-option" data-languagecode="fa" value="fa"> فارسی </option> <option class="content-language-option" data-languagecode="fr" value="fr"> Français </option> <option class="content-language-option" data-languagecode="hi" value="hi"> हिन्दी </option> <option class="content-language-option" data-languagecode="hr" value="hr"> Hrvatski </option> <option class="content-language-option" data-languagecode="id" value="id"> Bahasa Indonesia </option> <option class="content-language-option" data-languagecode="ja" value="ja"> 日本語 </option> <option class="content-language-option" data-languagecode="ko" value="ko"> 한국어 </option> <option class="content-language-option" data-languagecode="hu" value="hu"> Magyar </option> <option class="content-language-option" data-languagecode="ms" value="ms"> Bahasa Malaysia </option> <option class="content-language-option" data-languagecode="nl" value="nl"> Nederlands </option> <option class="content-language-option" data-languagecode="pl" value="pl"> Polski </option> <option class="content-language-option" data-languagecode="pt" value="pt"> Português </option> <option class="content-language-option" data-languagecode="ru" value="ru"> Русский </option> <option class="content-language-option" data-languagecode="ro" value="ro"> Română </option> <option class="content-language-option" data-languagecode="ta" value="ta"> தமிழ் </option> <option class="content-language-option" data-languagecode="th" value="th"> ภาษาไทย </option> <option class="content-language-option" data-languagecode="zh_HANT" value="zh_HANT"> 繁體中文 </option> <option class="content-language-option" data-languagecode="zh_HANS" value="zh_HANS"> 简体中文 </option> </select> </div> </td> </tr> <tr> <td colspan="1" style="height: 10px"></td> </tr> <tr class="row-box"> <td><i class="fa fa-globe icon-size"></i></td> <td> <div class="language-info"> <h3>Website language</h3> <p>Select your preferred language for the Cochrane Library website.</p> </div> </td> <td> <div class="language-dropdown"> <select id="portalLanguageSelector"> <option class="portal-language-selector" data-portallanguage="en" selected="" value="/en/cdsr/doi/10.1002/14651858.CD008919.pub2/full/en"> English </option> <option class="portal-language-selector" data-portallanguage="es" value="/es/cdsr/doi/10.1002/14651858.CD008919.pub2/full/es"> Español </option> </select> </div> </td> </tr> <tr> <td colspan="1" style="height: 10px"></td> </tr> </tbody> </table> </div> </div> <div style="text-align: right;"> <button class="btn primary btn-cancel" style="margin-left: 10px;" type="button">Cancel</button> <a class="btn secondary ok-btn" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage">Save</a> </div> </div> </div> </div> </div> </div> <div style="display:none"> <input id="freelabel" name="freelabel" type="hidden" value="Free access"/>
<input id="openlabel" name="openlabel" type="hidden" value="Open access"/>
</div>
</section>
</div>
</div>
<a class="auxiliary-menu-item signin last" href="https://www.cochranelibrary.com/c/portal/login?p_l_id=20757&amp;redirect=%2Fcdsr%2Fdoi%2F10.1002%2F14651858.CD008919.pub2%2Ffull" rel="nofollow">
<i class="icon fa fa-user"></i> Sign In
    </a>
<span class="auxiliary-container-extended"></span>
</div>
</div>
</div>
</header>
<div class="main-nav-wrapper">
<span class="main-nav-left-extended"></span>
<nav class="main container">
<ul>
<li class="nav-root-item parent">
<a href="#">Cochrane reviews<span class="icon fa fa-caret-down"></span></a>
<ul class="child">
<li class="child-nav-item" id="layout_nav_child_attr_14" role="presentation">
<a aria-labelledby="layout_14" href="https://www.cochranelibrary.com/en/cdsr/reviews" role="menuitem">
            Search reviews (CDSR)
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_15" role="presentation">
<a aria-labelledby="layout_15" href="https://www.cochranelibrary.com/en/cdsr/reviews/topics" role="menuitem">
            Browse reviews
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_18" role="presentation">
<a aria-labelledby="layout_18" href="https://www.cochranelibrary.com/en/cdsr/table-of-contents" role="menuitem">
            Issues
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_17" role="presentation">
<a aria-labelledby="layout_17" href="https://www.cochranelibrary.com/en/cdsr/editorials" role="menuitem">
            Editorials
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_19" role="presentation">
<a aria-labelledby="layout_19" href="https://www.cochranelibrary.com/en/special-collections" role="menuitem">
            Special Collections
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_20" role="presentation">
<a aria-labelledby="layout_20" href="https://www.cochranelibrary.com/en/cdsr/supplements" role="menuitem">
            Supplements
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_121" role="presentation">
<a aria-labelledby="layout_121" href="https://www.cochranelibrary.com/en/about/about-cochrane-reviews" role="menuitem">
            About Cochrane reviews
        </a>
</li>
</ul>
</li>
<li class="nav-root-item parent">
<a href="#">Searching for trials<span class="icon fa fa-caret-down"></span></a>
<ul class="child">
<li class="child-nav-item" id="layout_nav_child_attr_254" role="presentation">
<a aria-labelledby="layout_254" href="https://www.cochranelibrary.com/en/search/releases" role="menuitem">
            What's new (search and CENTRAL)
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_266" role="presentation">
<a aria-labelledby="layout_266" href="https://www.cochranelibrary.com/en/search-help" role="menuitem">
            Search help
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_252" role="presentation">
<a aria-labelledby="layout_252" href="https://www.cochranelibrary.com/en/search-help-quick-guides" role="menuitem">
            Search help quick guides
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_251" role="presentation">
<a aria-labelledby="layout_251" href="https://www.cochranelibrary.com/en/search-faqs" role="menuitem">
            Search FAQs
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_114" role="presentation">
<a aria-labelledby="layout_114" href="https://www.cochranelibrary.com/en/central/about-central" role="menuitem">
            About CENTRAL
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_115" role="presentation">
<a aria-labelledby="layout_115" href="https://www.cochranelibrary.com/en/central/central-creation" role="menuitem">
            How CENTRAL is created
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_241" role="presentation">
<a aria-labelledby="layout_241" href="https://www.cochranelibrary.com/en/retracted-trials" role="menuitem">
            Retracted publications in CENTRAL
        </a>
</li>
</ul>
</li>
<li class="nav-root-item parent">
<a href="#">Clinical Answers<span class="icon fa fa-caret-down"></span></a>
<ul class="child">
<li class="child-nav-item" id="layout_nav_child_attr_29" role="presentation">
<a aria-labelledby="layout_29" href="https://www.cochranelibrary.com/en/cca" role="menuitem">
            Browse Clinical Answers
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_91" role="presentation">
<a aria-labelledby="layout_91" href="https://www.cochranelibrary.com/en/cca/about" role="menuitem">
            About Clinical Answers
        </a>
</li>
</ul>
</li>
<li class="nav-root-item parent">
<a href="#">About<span class="icon fa fa-caret-down"></span></a>
<ul class="child">
<li class="child-nav-item" id="layout_nav_child_attr_116" role="presentation">
<a aria-labelledby="layout_116" href="https://www.cochranelibrary.com/en/about/about-cochrane-library" role="menuitem">
            About the Cochrane Library
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_13" role="presentation">
<a aria-labelledby="layout_13" href="https://www.cochranelibrary.com/en/cdsr/about-cdsr" role="menuitem">
            Cochrane Database of Systematic reviews
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_198" role="presentation">
<a aria-labelledby="layout_198" href="https://www.cochranelibrary.com/en/cdsr/editorial-policies" role="menuitem">
            Editorial policies
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_92" role="presentation">
<a aria-labelledby="layout_92" href="https://www.cochranelibrary.com/en/about/author-information" role="menuitem">
            Information for authors
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_212" role="presentation">
<a aria-labelledby="layout_212" href="https://www.cochranelibrary.com/en/about-pico" role="menuitem">
            About PICO
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_207" role="presentation">
<a aria-labelledby="layout_207" href="https://www.cochranelibrary.com/en/about/about-translations" role="menuitem">
            About translations
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_188" role="presentation">
<a aria-labelledby="layout_188" href="https://www.cochranelibrary.com/en/about/releases" role="menuitem">
            What's new
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_216" role="presentation">
<a aria-labelledby="layout_216" href="https://www.cochranelibrary.com/en/data" role="menuitem">
            Data reuse
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_235" role="presentation">
<a aria-labelledby="layout_235" href="https://www.cochranelibrary.com/en/about/about-cochrane-library/editorial-board" role="menuitem">
            Cochrane Library Editorial Board
        </a>
</li>
</ul>
</li>
<li class="nav-root-item parent">
<a href="#">Help<span class="icon fa fa-caret-down"></span></a>
<ul class="child">
<li class="child-nav-item" id="layout_nav_child_attr_259" role="presentation">
<a aria-labelledby="layout_259" href="https://m.info.wiley.com/webApp/cochranenewsletter?id=0" role="menuitem">
            Newsletter
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_177" role="presentation">
<a aria-labelledby="layout_177" href="https://www.wiley.com/en-us/customer-success/cochrane-library-training-hub" role="menuitem">
            Cochrane Library Training
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_44" role="presentation">
<a aria-labelledby="layout_44" href="https://www.cochranelibrary.com/en/help/access" role="menuitem">
            Access
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_150" role="presentation">
<a aria-labelledby="layout_150" href="https://www.cochranelibrary.com/en/help/permissions" role="menuitem">
            Permissions and reprints
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_93" role="presentation">
<a aria-labelledby="layout_93" href="https://www.cochranelibrary.com/en/help/media" role="menuitem">
            Media information
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_97" role="presentation">
<a aria-labelledby="layout_97" href="https://www.cochranelibrary.com/en/help/contact-us" role="menuitem">
            Contact us
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_125" role="presentation">
<a aria-labelledby="layout_125" href="https://www.cochranelibrary.com/en/about/terms-and-conditions" role="menuitem">
            Terms and conditions
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_176" role="presentation">
<a aria-labelledby="layout_176" href="https://cochranesupport.wiley.com/s/article/cochrane-library-known-issues" role="menuitem">
            Known issues
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_270" role="presentation">
<a aria-labelledby="layout_270" href="https://www.cochranelibrary.com/search-help" role="menuitem">
            Search help
        </a>
</li>
</ul>
</li>
<li class="about-link"><a href="https://www.cochrane.org/about-us" target="_blank"><span>About Cochrane</span><i class="fa fa-caret-right"></i></a></li>
</ul>
</nav>
</div>
<div class="portlet-boundary portlet-boundary_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_ portlet-static portlet-static-end" id="p_p_id_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_">
<span id="p_scolariscontentlanguagebanner_WAR_scolarislanguageportlet"></span>
<section class="portlet" id="portlet_scolariscontentlanguagebanner_WAR_scolarislanguageportlet">
<header class="portlet-topper">
<h1 class="portlet-title">
<span class="" onmouseover="Liferay.Portal.ToolTip.show(this, 'Scolaris\x20Content\x20Language\x20Banner\x20Portlet')">
<img alt="" id="etlj__null__null" src="/scolaris-language-portlet/icon.png"/> <span class="taglib-text hide-accessible">Scolaris Content Language Banner Portlet</span> </span> <span class="portlet-title-text">Scolaris Content Language Banner Portlet</span> </h1> <menu class="portlet-topper-toolbar" id="portlet-topper-toolbar_scolariscontentlanguagebanner_WAR_scolarislanguageportlet" type="toolbar"> </menu> </header> <div class="portlet-content"> <div class="portlet-content-container"> <div class="portlet-body"> </div> </div> </div> <div style="display:none"> <input id="freelabel" name="freelabel" type="hidden" value="Free access"/>
<input id="openlabel" name="openlabel" type="hidden" value="Open access"/>
</div>
</section>
</div>
<div class="" id="content">
<div class="columns-1" id="main-content" role="main">
<div class="portlet-layout row-fluid">
<div class="portlet-column portlet-column-only span12" id="column-1">
<div class="portlet-dropzone portlet-column-content portlet-column-content-only" id="layout-column_column-1">
<div class="portlet-boundary portlet-boundary_scolariscontentdisplay_WAR_scolariscontentdisplay_ portlet-static portlet-static-end scolaris-content-display-portlet" id="p_p_id_scolariscontentdisplay_WAR_scolariscontentdisplay_">
<span id="p_scolariscontentdisplay_WAR_scolariscontentdisplay"></span>
<section class="portlet" id="portlet_scolariscontentdisplay_WAR_scolariscontentdisplay">
<header class="portlet-topper">
<h1 class="portlet-title">
<span class="" onmouseover="Liferay.Portal.ToolTip.show(this, 'Scolaris\x20Content\x20Display')">
<img alt="" id="rjus__column1__0" src="/scolaris-content-display/icon.png"/> <span class="taglib-text hide-accessible">Scolaris Content Display</span> </span> <span class="portlet-title-text">Scolaris Content Display</span> </h1> <menu class="portlet-topper-toolbar" id="portlet-topper-toolbar_scolariscontentdisplay_WAR_scolariscontentdisplay" type="toolbar"> </menu> </header> <div class="portlet-content"> <div class="portlet-content-container"> <div class="portlet-body"> <div class="publication cdsr container"> <div class="article-navigation-container" id="cdsr-nav"> <nav class="article-navigation"> <ul class="tools-row"> <li> <li class="tools pdf pulldown-menu readcube-menu closed en_US"> <a class="pulldown-menu-trigger" href="#0"> <span class="pdf-icon"> <i class="icon fa fa-file-pdf-o"></i> <span>Download PDF</span> </span> <i aria-hidden="true" class="fa fa-caret-down"></i> </a> <ul class="pulldown-menu-items"> <li class=""> <a class="download media pdf-link-full pdf-link" href="/cdsr/doi/10.1002/14651858.CD008919.pub2/pdf/full/en" title="Article in PDF format"> <span class="readcube-label"> Full </span> <span class="readcube-description"> All content </span> </a> <a class="download media pdf-link-full readcube-epdf-link" href="/cdsr/doi/10.1002/14651858.CD008919.pub2/epdf/full/en" title="Article in PDF format"> <span class="readcube-label"> Full </span> <span class="readcube-description"> All content </span> </a> </li> <li class=""> <a class="download media pdf-link-abstract pdf-link" href="/cdsr/doi/10.1002/14651858.CD008919.pub2/pdf/abstract/en" title="Article in PDF format"> <span class="readcube-label"> Summary </span> <span class="readcube-description"> Abstract and plain language summary only </span> </a> <a class="download media pdf-link-abstract readcube-epdf-link" href="/cdsr/doi/10.1002/14651858.CD008919.pub2/epdf/abstract/en" title="Article in PDF format"> <span class="readcube-label"> Summary </span> <span class="readcube-description"> Abstract and plain language summary only </span> </a> </li> </ul> </li> <li class="tools cite cite-article-link" data-article-id="CD008919.PUB2" data-modal-title="Cite this review"> <span><i aria-hidden="true" class="icon fa fa-share"></i></span> <span>Cite this review</span> </li> </li> </ul> <ul class="tools-row tools-secondary"> <li> <li class="tools print print-cdsr-link" data-content-language="en" data-indicator-tooltip="scolaris.print.modal.language.tooltip.en" data-print-options="[{&quot;param&quot;: &quot;abstract&quot;,&quot;titles&quot;:[{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;Abstract&quot;},{&quot;language&quot;:&quot;es&quot;,&quot;title&quot;:&quot;Resumen&quot;},{&quot;language&quot;:&quot;fa&quot;,&quot;title&quot;:&quot;چکیده&quot;},{&quot;language&quot;:&quot;ja&quot;,&quot;title&quot;:&quot;アブストラクト&quot;}]},{&quot;param&quot;: &quot;pls&quot;,&quot;titles&quot;:[{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;Plain language summary&quot;},{&quot;language&quot;:&quot;de&quot;,&quot;title&quot;:&quot;Laienverständliche Zusammenfassung&quot;},{&quot;language&quot;:&quot;es&quot;,&quot;title&quot;:&quot;Resumen en términos sencillos&quot;},{&quot;language&quot;:&quot;fa&quot;,&quot;title&quot;:&quot;خلاصه به زبان ساده&quot;},{&quot;language&quot;:&quot;hr&quot;,&quot;title&quot;:&quot;Laički sažetak&quot;},{&quot;language&quot;:&quot;ja&quot;,&quot;title&quot;:&quot;一般語訳&quot;},{&quot;language&quot;:&quot;pl&quot;,&quot;title&quot;:&quot;Streszczenie prostym językiem&quot;},{&quot;language&quot;:&quot;ru&quot;,&quot;title&quot;:&quot;Резюме на простом языке&quot;}]},{&quot;param&quot;: &quot;conclusions&quot;,&quot;titles&quot;:[{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;Authors' conclusions&quot;}]},{&quot;param&quot;: &quot;summaryOfFindings&quot;,&quot;titles&quot;:[{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;Summary of findings&quot;}]},{&quot;param&quot;: &quot;background&quot;,&quot;titles&quot;:[{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;Background&quot;}]},{&quot;param&quot;: &quot;objectives&quot;,&quot;titles&quot;:[{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;Objectives&quot;}]},{&quot;param&quot;: &quot;methods&quot;,&quot;titles&quot;:[{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;Methods&quot;}]},{&quot;param&quot;: &quot;results&quot;,&quot;titles&quot;:[{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;Results&quot;}]},{&quot;param&quot;: &quot;discussion&quot;,&quot;titles&quot;:[{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;Discussion&quot;}]},{&quot;param&quot;: &quot;references&quot;,&quot;titles&quot;:[{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;References&quot;}]},{&quot;param&quot;: &quot;appendices&quot;,&quot;titles&quot;:[{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;Appendices&quot;},{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;Search strategies&quot;}]},{&quot;param&quot;: &quot;characteristics&quot;,&quot;titles&quot;:[{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;Characteristics of studies&quot;}]},{&quot;param&quot;: &quot;data&quot;,&quot;titles&quot;:[{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;Analyses&quot;}]},{&quot;param&quot;: &quot;information&quot;,&quot;titles&quot;:[{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;Information&quot;}]},{&quot;param&quot;: &quot;authors&quot;,&quot;titles&quot;:[{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;Authors&quot;}]},{&quot;param&quot;: &quot;history&quot;,&quot;titles&quot;:[{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;History&quot;}]}]" data-print-urlbase="/cdsr/doi/10.1002/14651858.CD008919.pub2/print"> <span><i class="icon fa fa-print"></i></span> <span>Print</span> </li> <li class="js-old-version-modal-trigger tools comments comment-on-review" data-article-id="CD008919.PUB2" data-english-only-message="Please note, that commenting is available in English only. Apologies for any inconvenience." data-href="/cdsr/doi/10.1002/14651858.CD008919.pub2/read-comments" data-new-version="" id="comment-on-review"> <span class="comment-icon"><i class="icon fa fa-comment"></i></span> <span class="comments-count">0</span> <span>Comment</span> </li> <li class="tools share-cdsr-link" data-share-url="/cdsr/doi/10.1002/14651858.CD008919.pub2/full"> <span><i class="icon fa fa-share-alt"></i></span> <span>Share</span> </li> <li class="tools follow"> <span class="article-not-followed cochrane-link signin follow-wrapper"> <span> <i class="icon fa fa-plus"></i> </span> <span> Follow </span> </span> </li> </li> </ul> <div class="metrics-wrapper"> <div class="metrics-count"> <span>Full text views: </span> <span>4490 <i class="icon fa fa-info-circle custom-tooltip" style="padding-left: 2px;color: #962d91;" title="Usage represents full text views on Cochrane Library since January 2022 or 2023. For articles published after this date, the usage represents views since the article was first published on Cochrane Library."> </i> </span> </div> </div> <div class="metrics-wrapper nav-link-section"> <div class="altmetric-embed" data-badge-type="1" data-condensed="true" data-doi="10.1002/14651858.CD008919.pub2" data-link-target="_blank"></div> <div class="inline-status-wrapper guidelines-count" data-count-plural="Cited in $1 guidelines" data-count-single="Cited in 1 guideline"> <a href="related-content#guidelines_data" title="Guidelines"></a> </div> </div> <ul class="nav-section-header"> <li> <h3>Contents</h3> </li> </ul> <ul class="nav-long-form nav-link-section"> <li class="cdsr-nav-link bold-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD008919.pub2/full"> Abstract </a> </li> <li class="cdsr-nav-link bold-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD008919.pub2/full#pico"> PICOs </a> </li> <li class="cdsr-nav-link bold-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD008919.pub2/full#CD008919-abs-0004"> Plain language summary </a> </li> <li class="cdsr-nav-link bold-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD008919.pub2/full#CD008919-sec-0215"> Authors' conclusions </a> </li> <li class="cdsr-nav-link bold-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD008919.pub2/full#CD008919-sec-0022"> Summary of findings </a> </li> <li class="cdsr-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD008919.pub2/full#CD008919-sec-0023"> Background </a> </li> <li class="cdsr-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD008919.pub2/full#CD008919-sec-0028"> Objectives </a> </li> <li class="cdsr-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD008919.pub2/full#CD008919-sec-0029"> Methods </a> </li> <li class="cdsr-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD008919.pub2/full#CD008919-sec-0106"> Results </a> </li> <li class="cdsr-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD008919.pub2/full#CD008919-sec-0206"> Discussion </a> </li> <li class="cdsr-nav-link"> <a class="figures-and-tables-link" href="/cdsr/doi/10.1002/14651858.CD008919.pub2/#"> Figures and tables </a> </li> <li class="cdsr-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD008919.pub2/references"> References </a> </li> </ul> <div class="nav-section-header"> <h3>Supplementary materials</h3> </div> <ul class="nav-long-form nav-link-section"> <li class="cdsr-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD008919.pub2/appendices#CD008919-sec-0223"> Search strategies </a> </li> <li class="cdsr-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD008919.pub2/references#characteristicStudies"> Characteristics of studies </a> </li> <li class="cdsr-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD008919.pub2/references#dataAndAnalyses"> Analyses </a> </li> <li class="cdsr-nav-link download-stats-data-link" data-download-href="/cdsr/doi/10.1002/14651858.CD008919.pub2/media/CDSR/CD008919/table_n/CD008919StatsDataOnly.rm5?content-disposition=attachment&amp;mime-type=application/octet-stream"> <a href="/cdsr/doi/10.1002/14651858.CD008919.pub2/media/CDSR/CD008919/table_n/CD008919StatsDataOnly.rm5?content-disposition=attachment&amp;mime-type=application/octet-stream"> Download data </a> </li> </ul> <ul class="tools-row"> <li> </li> </ul> <ul class="nav-section-header"> <li><h3>Related</h3></li> </ul> <ul class="linked-content linked-content-dropdown" id="linked-content-articles" tabindex="0"> <li class="linked-cca" data-type="cca"> <div class="linked-content-section"> <span class="linked-type">Cochrane Clinical Answers<span class="count"></span></span> <i aria-hidden="true" class="fa fa-caret-down"></i> </div> <div class="articles"></div> </li> <li class="linked-editorials" data-type="editorial"> <div class="linked-content-section"> <span class="linked-type">Editorials<span class="count"></span></span> <i aria-hidden="true" class="fa fa-caret-down"></i> </div> <div class="articles"></div> </li> <li class="linked-podcasts" data-type="podcast"> <div class="linked-content-section"> <span class="linked-type">Podcasts<span class="count"></span></span> <i aria-hidden="true" class="fa fa-caret-down"></i> </div> <div class="articles"></div> </li> <li class="linked-sc" data-type="sc"> <div class="linked-content-section"> <span class="linked-type">Special Collections<span class="count"></span></span> <i aria-hidden="true" class="fa fa-caret-down"></i> </div> <div class="articles"></div> </li> </ul> <div class="nav-section-header"> <h3>About this review</h3> </div> <ul class="nav-long-form nav-info nav-link-section"> <li class="cdsr-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD008919.pub2/information"> <i> <svg viewbox="0 0 24 24"> <path d="M11,9H13V7H11M12,20C7.59,20 4,16.41 4,12C4,7.59 7.59,4 12,4C16.41,4 20,7.59 20,12C20,16.41 16.41,20 12,20M12,2A10,10 0 0,0 2,12A10,10 0 0,0 12,22A10,10 0 0,0 22,12A10,10 0 0,0 12,2M11,17H13V11H11V17Z"></path> </svg> </i> Information </a> </li> <li class="cdsr-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD008919.pub2/information#authors"> <i> <svg viewbox="0 0 24 24"> <path d="M12,5.5A3.5,3.5 0 0,1 15.5,9A3.5,3.5 0 0,1 12,12.5A3.5,3.5 0 0,1 8.5,9A3.5,3.5 0 0,1 12,5.5M5,8C5.56,8 6.08,8.15 6.53,8.42C6.38,9.85 6.8,11.27 7.66,12.38C7.16,13.34 6.16,14 5,14A3,3 0 0,1 2,11A3,3 0 0,1 5,8M19,8A3,3 0 0,1 22,11A3,3 0 0,1 19,14C17.84,14 16.84,13.34 16.34,12.38C17.2,11.27 17.62,9.85 17.47,8.42C17.92,8.15 18.44,8 19,8M5.5,18.25C5.5,16.18 8.41,14.5 12,14.5C15.59,14.5 18.5,16.18 18.5,18.25V20H5.5V18.25M0,20V18.5C0,17.11 1.89,15.94 4.45,15.6C3.86,16.28 3.5,17.22 3.5,18.25V20H0M24,20H20.5V18.25C20.5,17.22 20.14,16.28 19.55,15.6C22.11,15.94 24,17.11 24,18.5V20Z"></path> </svg> </i> Authors </a> </li> <li class="cdsr-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD008919.pub2/information#history"> <i> <svg viewbox="0 0 24 24"> <path d="M13.5,8H12V13L16.28,15.54L17,14.33L13.5,12.25V8M13,3A9,9 0 0,0 4,12H1L4.96,16.03L9,12H6A7,7 0 0,1 13,5A7,7 0 0,1 20,12A7,7 0 0,1 13,19C11.07,19 9.32,18.21 8.06,16.94L6.64,18.36C8.27,20 10.5,21 13,21A9,9 0 0,0 22,12A9,9 0 0,0 13,3"></path> </svg> </i> Version history </a> </li> <li class="cdsr-nav-link"> <a href="/cdsr/doi/10.1002/14651858.CD008919.pub2/information#keywords"> <i> <svg viewbox="0 0 24 24"> <path d="M11 3C10.18 3 9.44 3.5 9.14 4.27L3.64 18.27C3.12 19.58 4.09 21 5.5 21H7.75C8.59 21 9.33 20.5 9.62 19.7L10.26 18H13.74L14.38 19.7C14.67 20.5 15.42 21 16.25 21H18.5C19.91 21 20.88 19.58 20.36 18.27L14.86 4.27C14.56 3.5 13.82 3 13 3M11 5H13L18.5 19H16.25L15.12 16H8.87L7.75 19H5.5M12 7.67L9.62 14H14.37Z"></path> </svg> </i> Keywords (MeSH, PICOs) </a> </li> <li class="cdsr-nav-link"> <a href="/cdsr/doi/10.1002/14651858.CD008919.pub2/related-content"> <i class="icon fa fa-sitemap fa-rotate-270"></i> Related content </a> </li> <li class="cdsr-nav-link translation-notes-link"> <a href="/cdsr/doi/10.1002/14651858.CD008919.pub2/#"> <i> <svg viewbox="0 0 24 24"> <path d="M12.87,15.07L10.33,12.56L10.36,12.53C12.1,10.59 13.34,8.36 14.07,6H17V4H10V2H8V4H1V6H12.17C11.5,7.92 10.44,9.75 9,11.35C8.07,10.32 7.3,9.19 6.69,8H4.69C5.42,9.63 6.42,11.17 7.67,12.56L2.58,17.58L4,19L9,14L12.11,17.11L12.87,15.07M18.5,10H16.5L12,22H14L15.12,19H19.87L21,22H23L18.5,10M15.88,17L17.5,12.67L19.12,17H15.88Z"></path> </svg> </i> Translation notes </a> </li> <li class="cdsr-nav-link"> <a class="request-permissions" data-copyright="Copyright © 2016 The Cochrane Collaboration. Published by John Wiley &amp; Sons, Ltd." data-creative-commons="false" href="/cdsr/doi/10.1002/14651858.CD008919.pub2/#"> <span class="request-permissions-icon"></span> Request permissions </a> </li> <li class="cdsr-nav-link"> <a href="/data"> <i class="icon fa fa-database"></i> Request data reuse </a> </li> </ul> </nav> </div> <article> <div class="cdsr-header-top"> <div class="cdsr-header-left"> <a class="publish-database" href="/">Cochrane Database of Systematic reviews</a> <span class="publish-type">Review - Intervention</span> </div> <div class="cdsr-header-right"> </div> </div> <header class="publication-header"> <h1 class="publication-title" lang="en">Antioxidant treatments for schizophrenia</h1> <div class="publication-metadata-block"> <div class="publication-authors"> <div class="publish-meta-wrapper"> <ul class="authors"> <li class="author"><a href="/cdsr/doi/10.1002/14651858.CD008919.pub2/information#CD008919-cr-0002"><i class="icon corresponding-author fa fa-envelope"></i>Pedro V S Magalhães</a></li> <li class="author"><a href="/cdsr/doi/10.1002/14651858.CD008919.pub2/information#CD008919-cr-0003">Olivia Dean</a></li> <li class="author"><a href="/cdsr/doi/10.1002/14651858.CD008919.pub2/information#CD008919-cr-0004">Ana C Andreazza</a></li> <li class="author"><a href="/cdsr/doi/10.1002/14651858.CD008919.pub2/information#CD008919-cr-0005">Michael Berk</a></li> <li class="author"><a href="/cdsr/doi/10.1002/14651858.CD008919.pub2/information#CD008919-cr-0006">Flávio Kapczinski</a></li> </ul> <span class="author declaration"> <a class="declarationsOfInterestLink" href="/cdsr/doi/10.1002/14651858.CD008919.pub2/information/en#CD008919-sec-0234">Authors' declarations of interest</a> </span> </div> </div> </div> <div class="publication-metadata-block"> <p> <span class="publish-date">Version published: 05 February 2016 </span> <a class="whatsNewLink" href="/cdsr/doi/10.1002/14651858.CD008919.pub2/information/en#versionTable">Version history</a> </p> <div class="doi-header"> <a href="https://doi.org/10.1002/14651858.CD008919.pub2">https://doi.org/10.1002/14651858.CD008919.pub2</a> </div> </div> </header> <div class="publication-control-bar"> <span class="publication-control-button publication-control-collapse"> Collapse all </span> <span class="publication-control-button publication-control-expand"> Expand all </span> </div> <section class="abstract"> <div class="section-header section-collapse-header" id="CD008919-abs-0001" lang="en"> <h2 class="title section-collapse-title"> Abstract <i aria-hidden="true" class="fa fa-caret-up section-collapse-icon"></i> </h2> <div class="section-language-toggles"> <span class="section-languages-legend">available in</span> <nav class="section-languages"> <li class="section-language"> <a class="is-active" href="full/en#CD008919-abs-0001">English</a> </li> <li class="section-language"> <a class="" href="full/es#CD008919-abs-0003">Español</a> </li> <li class="section-language"> <a class="" href="full/fa#CD008919-abs-0011">فارسی</a> </li> <li class="section-language"> <a class="" href="full/ja#CD008919-abs-0002">日本語</a> </li> </nav> </div> </div> <div class="abstract full_abstract" id="CD008919-abs-0001" lang="en"> <section id="CD008919-sec-0001"> <h3 class="title" id="CD008919-sec-0001">Background</h3> <p>There is accumulating evidence that progressive changes in brain structure and function take place as schizophrenia unfolds. Among many possible candidates, oxidative stress may be one of the mediators of neuroprogression, grey matter loss and subsequent cognitive and functional impairment. Antioxidants are exogenous or endogenous molecules that mitigate any form of oxidative stress or its consequences. They may act from directly scavenging free radicals to increasing anti‐oxidative defences. There is evidence that current treatments impact oxidative pathways and may to some extent reverse pro‐oxidative states in schizophrenia. The existing literature, however, indicates that these treatments do not fully restore the deficits in antioxidant levels or restore levels of oxidants in schizophrenia. As such, there has been interest in developing interventions aimed at restoring this oxidative balance beyond the benefits of antipsychotics in this direction. If antioxidants are to have a place in the treatment of this serious condition, the relevant and up‐to‐date information should be available to clinicians and investigators. </p> </section> <section id="CD008919-sec-0002"> <h3 class="title" id="CD008919-sec-0002">Objectives</h3> <p>To evaluate the effect of antioxidants as add‐on treatments to standard antipsychotic medication for improving acute psychotic episodes and core symptoms, and preventing relapse in people with schizophrenia. </p> </section> <section id="CD008919-sec-0003"> <h3 class="title" id="CD008919-sec-0003">Search methods</h3> <p>We searched the Cochrane Schizophrenia Group’s Study‐Based Register of Trials which is based on regular searches of CINAHL, BIOSIS, AMED, Embase, PubMed, MEDLINE, PsycINFO, and registries of clinical trials. There are no language, time, document type, or publication status limitations for inclusion of records in the register. We ran this search in November 2010, and again on 8 January 2015. We also inspected references of all identified studies for further trials and contacted authors of trials for additional information. </p> </section> <section id="CD008919-sec-0004"> <h3 class="title" id="CD008919-sec-0004">Selection criteria</h3> <p>We included reports if they were randomised controlled trials (RCTs) involving people with schizophrenia who had been allocated to either a substance with antioxidant potential or to a placebo as an adjunct to standard antipsychotic treatment. </p> </section> <section id="CD008919-sec-0005"> <h3 class="title" id="CD008919-sec-0005">Data collection and analysis</h3> <p>We independently extracted data from these trials and we estimated risk ratios (RR) or mean differences (MD), with 95% confidence intervals (CI). We assessed risk of bias for included studies and created a 'Summary of findings' table using GRADE. </p> </section> <section id="CD008919-sec-0006"> <h3 class="title" id="CD008919-sec-0006">Main results</h3> <p>The review includes 22 RCTs of varying quality and sample size studying <i>Ginkgo biloba</i> , N‐acetyl cysteine (NAC), allopurinol, dehydroepiandrosterone (DHEA), vitamin C, vitamin E or selegiline. Median follow‐up was eight weeks. Only three studies including a minority of the participants reported our <i>a priori</i> selected primary outcome of clinically important response. Short‐term data for this outcome (measured as at least 20% improvement in scores on Positive and Negative Syndrome Scale (PANSS)) were similar (3 RCTs, n = 229, RR 0.77, 95% CI 0.53 to 1.12, <i>low quality evidence</i> ). Studies usually reported only endpoint psychopathology rating scale scores. Psychotic symptoms were lower in those using an adjunctive antioxidant according to the PANSS ( 7 RCTS, n = 584, MD ‐6.00, 95% CI ‐10.35 to ‐1.65, <i>very low quality evidence</i> ) and the Brief Psychiatric Rating Scale (BPRS) (8 RCTS, n = 843, MD ‐3.20, 95% CI ‐5.63 to ‐0.78, <i>low quality evidence</i> ). There was no overall short‐term difference in leaving the study early (16 RCTs, n = 1584, RR 0.73, 95% CI 0.48 to 1.11, <i>moderate quality evidence</i> ), or in general functioning (2 RCTs, n = 52, MD ‐1.11, 95% CI ‐8.07 to 5.86, <i>low quality evidence</i> ). Adverse events were generally poorly reported. Three studies reported useable data for 'any serious adverse effect', results were equivocal (3 RCTs, n = 234, RR 0.65, 95% CI 0.19 to 2.27, <i>low quality evidence</i>). No evidence was available for relapse, quality of life or service use. </p> </section> <section id="CD008919-sec-0007"> <h3 class="title" id="CD008919-sec-0007">Authors' conclusions</h3> <p>Although 22 trials could be included in this review, the evidence provided is limited and mostly not relevant to clinicians or consumers. Overall, although there was low risk of attrition and selective data reporting bias within the trials, the trials themselves were not adequately powered and need more substantial follow‐up periods. There is a need for larger trials with longer periods of follow‐up to be conducted. Outcomes should be meaningful for those with schizophrenia, and include measures of improvement and relapse (not just rating scale scores), functioning and quality of life and acceptability and, importantly, safety data. </p> </section> </div> </section> <section class="pico-section" id="pico"> <h2 class="title section-collapse-title">PICOs <i class="icon fa fa-info-circle" title="The PICO model is widely used and taught in evidence-based health care as a strategy for formulating questions and search strategies and for characterizing clinical studies or meta-analyses. PICO stands for four different potential components of a clinical question: Patient, Population or Problem; Intervention; Comparison; Outcome."></i> <i aria-hidden="true" class="fa fa-caret-up section-collapse-icon"></i> </h2> <div class="section-content" style="display: block;"> <h3 class="keyword-heading">PICOs</h3> <div class="pico-table"> <div class="pico-column Population"> <h6>Population<span class="pico-count"></span></h6> <ul class="pico-terms"> </ul> </div> <div class="pico-column Intervention"> <h6>Intervention<span class="pico-count"></span></h6> <ul class="pico-terms"> </ul> </div> <div class="pico-column Comparison"> <h6>Comparison<span class="pico-count"></span></h6> <ul class="pico-terms"> </ul> </div> <div class="pico-column Outcome"> <h6>Outcome<span class="pico-count"></span></h6> <ul class="pico-terms"> </ul> </div> </div> <div class="pico-information"> <p><i class="icon fa fa-info-circle"></i> The PICO model is widely used and taught in evidence-based health care as a strategy for formulating questions and search strategies and for characterizing clinical studies or meta-analyses. PICO stands for four different potential components of a clinical question: Patient, Population or Problem; Intervention; Comparison; Outcome.</p> <p>See more on using PICO in the <a href="https://training.cochrane.org/handbook/current/chapter-02#section-2-3">Cochrane Handbook</a>.</p> </div> </div> </section> <section class="pls"> <div class="section-header section-collapse-header" id="CD008919-abs-0004" lang="en"> <h2 class="title section-collapse-title"> Plain language summary <i aria-hidden="true" class="fa fa-caret-up section-collapse-icon"></i> </h2> <div class="section-language-toggles"> <span class="section-languages-legend">available in</span> <nav class="section-languages"> <li class="section-language"> <a class="is-active" href="full/en#CD008919-abs-0004">English</a> </li> <li class="section-language"> <a class="" href="full/de#CD008919-abs-0005">Deutsch</a> </li> <li class="section-language"> <a class="" href="full/es#CD008919-abs-0010">Español</a> </li> <li class="section-language"> <a class="" href="full/fa#CD008919-abs-0012">فارسی</a> </li> <li class="section-language"> <a class="" href="full/hr#CD008919-abs-0008">Hrvatski</a> </li> <li class="section-language"> <a class="" href="full/ja#CD008919-abs-0007">日本語</a> </li> <li class="section-language"> <a class="" href="full/pl#CD008919-abs-0009">Polski</a> </li> <li class="section-language"> <a class="" href="full/ru#CD008919-abs-0006">Русский</a> </li> </nav> </div> </div> <div class="abstract abstract_plainLanguageSummary" id="CD008919-abs-0004" lang="en"> <h3>Antioxidants as add‐on treatment for people with schizophrenia</h3> <p>Antioxidants are substances that protect cells from the damage caused by unstable molecules known as free radicals (causing oxidative stress). It is well known that adding antioxidant‐rich fruits and vegetables to your daily diet will strengthen your ability to fight infection and disease. There is recent evidence that progressive brain changes take place as schizophrenia unfolds. Among many possible explanations, oxidative stress may be one of the factors contributing to the deterioration of the brain and its grey matter, leading to difficulties in people’s thinking and everyday functioning. The aim of this review is to evaluate the effect of antioxidants as an add‐on treatment to standard antipsychotic medication. In particular, by reducing (or lessening) psychotic episodes and core symptoms, and preventing relapse </p> <p>Searches for randomised trials were run in 2010 and 2012, review authors found 22 relevant trials that randomised a total of 2041 people with schizophrenia. The trials compared the effects of taking a variety of antioxidants (allopurinol, <i>Ginkgo biloba</i> , N‐acetyl cysteine (NAC), selegiline, vitamins C and E) compared with placebo. Most results showed no real differences between the antioxidants and placebo although there was evidence <i>Ginkgo biloba</i> had a positive effect on psychotic symptoms in the short term. The quality of this evidence was moderate. </p> <p>However, overall, the trials suffered from a lack of real‐world outcomes, such as clinical response, rates of relapse, quality of life, functioning, safety and satisfaction or acceptability of treatment. Adverse effects were also poorly reported with some studies not providing any data for adverse effects. </p> <p><i>Ginkgo biloba</i> and NAC emerged from the trials as the most promising, so should have priority in the design of future trials that are larger, longer and better reported than the 22 studies available at the present time. </p> <p>Ben Gray, Senior Peer Researcher, McPin Foundation: <a href="http://mcpin.org/" target="_blank">http://mcpin.org/</a> </p> </div> </section> <section id="vls" style="display: none"> <div class="section-header section-collapse-header"> <h2 class="title section-collapse-title">Visual summary<i aria-hidden="true" class="fa fa-caret-up section-collapse-icon"></i></h2> </div> <a href="" target="_blank"><img alt="visual summary" src=""/></a> </section> <section class="conclusions"> <div class="section-header section-collapse-header" id="CD008919-sec-0215" lang="en"> <h2 class="title section-collapse-title"> Authors' conclusions <i aria-hidden="true" class="fa fa-caret-up section-collapse-icon"></i> </h2> </div> <section class="authorsConclusions" lang="en"> <div class="section-header" id="CD008919-sec-0215"></div> <h3 class="title" id="CD008919-sec-0216">Implications for practice</h3> <section id="CD008919-sec-0216"> <section id="CD008919-sec-0217"> <h5 class="title">1. For clinicians</h5> <p>The many difficulties with included studies, amongst them low quality and sample size and a lack of clinically meaningful outcomes, preclude us from giving general suggestions regarding the use of adjunctive substances with antioxidant potential in people with schizophrenia. Another concern was the poor reporting of adverse events throughout the trials. </p> <p>Specifically, however, the data indicate the adjunctive use of allopurinol should not be encouraged at this point, since an adequately powered trial failed to show any benefit </p> </section> <section id="CD008919-sec-0218"> <h5 class="title">2. For people with schizophrenia</h5> <p>Although there is preliminary data that suggests substances with antioxidant potential may be of use, definitive studies are lacking. This means there is substantial uncertainty on the potential benefit and risks these different compounds carry. </p> </section> <section id="CD008919-sec-0219"> <h5 class="title">3. For policy makers</h5> <p>Currently,there is not enough good‐quality evidence to suggest the use of allopurinol for schizophrenia is appropriate. </p> </section> </section> <h3 class="title" id="CD008919-sec-0220">Implications for research</h3> <section id="CD008919-sec-0220"> <p>As different substances have different pharmacological properties and clinical effects, it is more useful to think about these medications not as antioxidants, but as distinct drugs with antioxidant potential. As such, it is preferable to discuss implications for each drug, and not for antioxidants in general. There is medium‐quality evidence for the adjunctive efficacy of <i>Ginkgo biloba</i>, with relatively large numbers of people randomised to receive it, mostly in China. These studies are also short‐term ones and lack measures that are most useful to patients and clinicians. The only trial we located on adjunctive N‐acetyl cysteine (NAC), on the other hand, was of high quality and measured outcomes over a longer period of time and suggested benefit for negative symptoms of schizophrenia. </p> <p>Overall, available data suggest that real‐world studies, adequately powered with more substantial follow‐up periods need to be conducted if clinicians and people with schizophrenia are to adopt adjunctive antioxidants in everyday practice. <a href="#CD008919-tbl-0002">Table 1</a> suggests a design for such a study. Outcomes should be meaningful for those with schizophrenia, and include measures of improvement and relapse (not just rating scale scores), functioning and quality of life and acceptability and, importantly, safety data. Because of the various features discussed, ginkgo and NAC emerged from the trials located as the most promising interventions, and should have priority in the design of further trials. </p> <div class="table" id="CD008919-tbl-0002"> <table><a class="open-table-viewer open-in-figure-viewer" href="#0">Open in table viewer</a><div class="table-heading"><span class="table-label">Table 1.</span> <span class="table-title">Suggested design of future trial</span></div> <tbody> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>Methods</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Allocation: centralised sequence generation with table of random numbers or computer‐generated code, stratified by severity of illness, sequence concealed till interventions assigned.<br/> Blinding: those recruiting and assigning participants, those assessing outcomes, all blind to allocated group, blinding could be tested.<br/> Duration: minimum of 24 weeks </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>Participants</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Diagnosis: schizophrenia, if operational criteria used these should be in the context of routine care.<br/> N = 450*.<br/> Age: adults.<br/> Sex: men and women.<br/> Setting: anywhere. </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>Interventions</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>1. Adjunctive placebo</p> <p>2. Adjunctive antioxidant (preferably <i>Ginkgo biloba</i> EGb or NAC) </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>Outcomes</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Quality of life: healthy days,** SF‐36***.<br/> Service outcomes: days in hospital, time attending psychiatric outpatient clinic.<br/> Satisfaction with care: patients/carers.<br/> Global state: CGI.***<br/> Mental state: CGI.<br/> Social functioning: to include occupational status.<br/> Adverse effects: including mortality.<br/> Economic data. </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>Notes</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>* size of study to detect a 10% difference in improvement with 80% certainty.<br/> ** Primary outcome.<br/> *** If scales are used to measure outcome then there should be binary cut off points, defined before study starts, of clinically important improvement. </p> </td> </tr> </tbody> </table> <div class="table-footnote"> <p>CGI ‐ Clinical Global Impression; NAC ‐ N‐acetyl cysteine; SF 36 ‐ Short form 36</p> </div> </div> </section> </section> </section> <section class="summaryOfFindings"> <div class="section-header section-collapse-header" id="CD008919-sec-0022" lang="en"> <h2 class="title section-collapse-title"> Summary of findings <i aria-hidden="true" class="fa fa-caret-up section-collapse-icon"></i> </h2> </div> <section class="summaryOfFindings" lang="en"> <div class="section-header" id="CD008919-sec-0022"></div> <div class="table" id="CD008919-tbl-0001"> <table class="summary-of-findings framed"><a class="open-table-viewer open-in-figure-viewer" href="#0">Open in table viewer</a><div class="table-heading"><span class="table-label">Summary of findings for the main comparison.</span> <span class="table-title">Adjunctive antioxidants for schizophrenia versus placebo</span></div> <tbody> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="7" rowspan="1" valign=""> <p><b>Adjunctive antioxidants for schizophrenia</b> </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="7" rowspan="1" valign=""> <p><b>Patient or population:</b> people with schizophrenia<br/> <b>Settings:</b> Inpatients and outpatients<br/> <b>Intervention:</b> Adjunctive antioxidants </p> </td> </tr> <tr class="table-header separated"> <td align="left" class="table-header" colspan="1" rowspan="3" valign="top"> <p><b>Outcomes</b> </p> </td> <td align="left" class="table-tint table-highlight" colspan="2" rowspan="1" valign="top"> <p><b>Illustrative comparative risks* (95% CI)</b> </p> </td> <td align="left" class="table-header" colspan="1" rowspan="3" valign="top"> <p><b>Relative effect<br/> (95% CI)</b> </p> </td> <td align="left" class="table-header" colspan="1" rowspan="3" valign="top"> <p><b>No of Participants<br/> (studies)</b> </p> </td> <td align="left" class="table-header" colspan="1" rowspan="3" valign="top"> <p><b>Quality of the evidence<br/> (GRADE)</b> </p> </td> <td align="left" class="table-header" colspan="1" rowspan="3" valign="top"> <p><b>Comments</b> </p> </td> </tr> <tr class="table-header separated"> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>Assumed risk</b> </p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>Corresponding risk</b> </p> </td> </tr> <tr class="table-header separated"> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b> Control</b> </p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b> Adjunctive antioxidants</b> </p> </td> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="4" valign="top"> <p><b>Global state: improvement, short term</b> <br/> PANSS<br/> Follow‐up: 6 to 8 weeks </p> </td> <td align="" class="table-tint table-highlight" colspan="2" rowspan="1" valign=""> <p><b>Study population</b> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="4" valign="top"> <p><b>RR 0.77</b> <br/> (0.53 to 1.12) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="4" valign="top"> <p>229<br/> (3 studies) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="4" valign="top"> <p>⊕⊕⊝⊝<br/> <b>low</b><sup>1,2</sup> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="4" valign="top"> <p>‐</p> </td> </tr> <tr class="separated"> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>1000 per 1000</b> </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>690 per 1000</b> <br/> (360 to 1000) </p> </td> </tr> <tr class="separated"> <td align="" class="table-tint table-highlight" colspan="2" rowspan="1" valign=""> <p><b>Moderate</b> </p> </td> </tr> <tr class="separated"> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>1000 per 1000</b> </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>690 per 1000</b> <br/> (360 to 1000) </p> </td> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Total PANSS scores, short term</b> <br/> PANSS<br/> Follow‐up: 6 to 12 weeks </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"></td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>The mean total PANSS scores in the intervention groups was<br/> <b>6.0 lower</b> <br/> (10.53 lower to 1.65 lower) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"></td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>584<br/> (7 studies) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>⊕⊝⊝⊝<br/> <b>very low</b><sup>1,2,3</sup> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>‐</p> </td> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Total BPRS scores, short term</b> <br/> BPRS<br/> Follow‐up: 6 to 16 weeks </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"></td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>The mean total BPRS scores in the intervention groups was<br/> <b>3.2 lower</b> <br/> (5.63 lower to 0.78 lower) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"></td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>843<br/> (8 studies) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>⊕⊕⊝⊝<br/> <b>low</b><sup>1,3,4</sup> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>‐</p> </td> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>General functioning ‐ short term</b> <br/> GAS<br/> Follow‐up: 6 weeks </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"></td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>The mean general functioning ‐ short term in the intervention groups was<br/> <b>1.11 lower</b> <br/> (8.07 lower to 5.86 higher) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"></td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>52</p> <p>(2 studies)</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>⊕⊕⊝⊝<br/> <b>low</b><sup>1,5</sup> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>‐</p> </td> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>General functioning ‐ medium term</b> <br/> GAS<br/> Follow‐up: 24 weeks </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"></td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>The mean general functioning ‐ medium term in the intervention groups was<br/> <b>2.84 higher</b> <br/> (2.09 lower to 7.77 higher) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"></td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>135<br/> (1 study) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>⊕⊕⊕⊕<br/> <b>high</b> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>‐</p> </td> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="4" valign="top"> <p><b>Leaving the study early, short term</b> <br/> Follow‐up: 6 to 16 weeks </p> </td> <td align="" class="table-tint table-highlight" colspan="2" rowspan="1" valign=""> <p><b>Study population</b> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="4" valign="top"> <p><b>RR 0.73</b> <br/> (0.48 to 1.11) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="4" valign="top"> <p>1584<br/> (16 studies) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="4" valign="top"> <p>⊕⊕⊕⊝<br/> <b>moderate</b><sup>1,4</sup> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="4" valign="top"> <p>‐</p> </td> </tr> <tr class="separated"> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>96 per 1000</b> </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>72 per 1000</b> <br/> (39 to 132) </p> </td> </tr> <tr class="separated"> <td align="" class="table-tint table-highlight" colspan="2" rowspan="1" valign=""> <p><b>Moderate</b> </p> </td> </tr> <tr class="separated"> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>91 per 1000</b> </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>68 per 1000</b> <br/> (37 to 126) </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="4" valign="top"> <p><b>Adverse effects: 1. Serious (any time point) ‐ any serious adverse effect</b> <br/> Various methods </p> </td> <td align="" class="table-tint table-highlight" colspan="2" rowspan="1" valign=""> <p><b>Study population</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="4" valign="top"> <p><b>RR 0.65</b> <br/> (0.19 to 2.27) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="4" valign="top"> <p>234<br/> (3 studies) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="4" valign="top"> <p>⊕⊕⊝⊝<br/> <b>low</b><sup>1</sup> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="4" valign="top"> <p>‐</p> </td> </tr> <tr class="separated"> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign=""> <p><b>60 per 1000</b> </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign=""> <p><b>39 per 1000</b> <br/> (11 to 137) </p> </td> </tr> <tr class="separated"> <td align="" class="table-tint table-highlight" colspan="2" rowspan="1" valign=""> <p><b>Moderate</b> </p> </td> </tr> <tr class="separated"> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign=""> <p><b>59 per 1000</b> </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign=""> <p><b>38 per 1000</b> <br/> (11 to 134) </p> </td> </tr> </tbody> <tfoot> <tr> <td colspan="7"> <div class="table-footnote"> <p><sup>1</sup> Unclear process of allocation concealment in included studies<br/> <sup>2</sup> High heterogeneity<br/> <sup>3</sup> Difference in rating scale scores not necessarily reflects meaningful clinical change<br/> <sup>4</sup> Heterogeneity high, but reduced when results are grouped by specific agent tested<br/> <sup>5</sup> Very limited number of patients available </p> </div> </td> </tr> </tfoot> </table> </div> </section> </section> <section class="background"> <div class="section-header section-collapse-header" id="CD008919-sec-0023" lang="en"> <h2 class="title section-collapse-title"> Background <i aria-hidden="true" class="fa fa-caret-up section-collapse-icon"></i> </h2> </div> <section class="background" lang="en"> <div class="section-header" id="CD008919-sec-0023"></div> <section id="CD008919-sec-0024"> <h3 class="title" id="CD008919-sec-0024">Description of the condition</h3> <p>Schizophrenia is a severely debilitating and progressive illness. Although not especially highly prevalent, it carries a disproportionate share of illness‐related disability, partially due to its early age at onset, associated impact in functioning, and chronic course. This effect is even more devastating as the illness tends to be deteriorating, with increased disability and personal and societal burden (<a href="./references#CD008919-bbs2-0051" title="BerkM . Neuroprogression: pathways to progressive brain changes in bipolar disorder. International Journal of Neuropsychopharmacology2009;12(4):441‐5. [PUBMED: 18922203] ">Berk 2009</a>; <a href="./references#CD008919-bbs2-0072" title="LiebermanJA , MalaspinaD , JarskogLF . Preventing clinical deterioration in the course of schizophrenia: the potential for neuroprotection. CNS Spectrums2006;11(4):Suppl 1‐13; Quiz Suppl 14‐5. [PUBMED: 16641837] ">Lieberman 2006</a>). Furthermore, only a minority of this burden is currently averted with standard treatment (<a href="./references#CD008919-bbs2-0078" title="RosslerW , SalizeHJ , vanOsJ , Riecher‐RosslerA . Size of burden of schizophrenia and psychotic disorders. European Neuropsychopharmacology2005;15(4):399‐409. [PUBMED: 15925493] ">Rossler 2005</a>). </p> <p>There is accumulating evidence that progressive changes in brain structure and function take place as the disease unfolds (<a href="./references#CD008919-bbs2-0056" title="DeLisiLE . The concept of progressive brain change in schizophrenia: implications for understanding schizophrenia. Schizophrenia Bulletin2008;34(2):312‐21. [PUBMED: 18263882] ">DeLisi 2008</a>). Among many possible candidates, oxidative stress may be one of the mediators of neuroprogression, grey matter loss and subsequent cognitive and functional impairment (<a href="./references#CD008919-bbs2-0054" title="DeanOM , Van DenBuuseM , BushAI , CopolovDL , NgF , DoddS , et al. A role for glutathione in the pathophysiology of bipolar disorder and schizophrenia? Animal models and relevance to clinical practice. Current Medicinal Chemistry2009;16(23):2965‐76. [PUBMED: 19689277] ">Dean 2009</a>; <a href="./references#CD008919-bbs2-0072" title="LiebermanJA , MalaspinaD , JarskogLF . Preventing clinical deterioration in the course of schizophrenia: the potential for neuroprotection. CNS Spectrums2006;11(4):Suppl 1‐13; Quiz Suppl 14‐5. [PUBMED: 16641837] ">Lieberman 2006</a>; <a href="./references#CD008919-bbs2-0085" title="WoodSJ , YucelM , PantelisC , BerkM . Neurobiology of schizophrenia spectrum disorders: the role of oxidative stress. Annals of the Academy of Medicine2009;38(5):396‐6. [PUBMED: 19521638] ">Wood 2009</a>). Specifically, oxidative imbalance has been evidenced by the increased levels of 8‐OH deoxyguanosine, (an indicator of DNA damage and potentially of apoptotic (programmed cell death) events), protein carbonylation (leading to cellular dysfunction), and lipid peroxidation (potentially leading to alterations in membrane structure and permeability) shown in individuals with schizophrenia. Oxidative defences have also been shown to be impaired, including decreased glutathione (the primary antioxidant in the brain) levels, polymorphisms in gene pathways associated with oxidative defence and changes in other antioxidants including superoxide, dismutase, catalase and glutathione peroxidase (<a href="./references#CD008919-bbs2-0085" title="WoodSJ , YucelM , PantelisC , BerkM . Neurobiology of schizophrenia spectrum disorders: the role of oxidative stress. Annals of the Academy of Medicine2009;38(5):396‐6. [PUBMED: 19521638] ">Wood 2009</a>). </p> </section> <section id="CD008919-sec-0025"> <h3 class="title" id="CD008919-sec-0025">Description of the intervention</h3> <p>Antioxidants are exogenous or endogenous molecules that mitigate any form of oxidative stress or its consequences. They may act from directly scavenging free radicals to increasing anti‐oxidative defences (<a href="./references#CD008919-bbs2-0082" title="UttaraB , SinghAV , ZamboniP , MahajanRT . Oxidative stress and neurodegenerative diseases: a review of upstream and downstream antioxidant therapeutic options. Current Neuropharmacology2009;7(1):65‐74. [PUBMED: 19721819] ">Uttara 2009</a>). In this fashion, antioxidants with different mechanisms have been studied in different progressive illnesses (<a href="./references#CD008919-bbs2-0051" title="BerkM . Neuroprogression: pathways to progressive brain changes in bipolar disorder. International Journal of Neuropsychopharmacology2009;12(4):441‐5. [PUBMED: 18922203] ">Berk 2009</a>). </p> <p>There is evidence that current treatments impact on oxidative pathways and may to some extent reverse pro‐oxidative states in schizophrenia. Second generation antipsychotics have been shown to have effects in neuroprotection, the existing literature, however, indicates that these treatments do not fully restore the deficits in antioxidant levels or restore levels of oxidants in schizophrenia (<a href="./references#CD008919-bbs2-0071" title="LiebermanJA , TollefsonGD , CharlesC , ZipurskyR , SharmaT , KahnRS , KeefeRS , GreenAI , GurRE , McEvoyJ , PerkinsD , HamerRM , GuH , TohenM , HGDH Study Group. Antipsychotic drug effects on brain morphology in first‐episode psychosis. Archives of General Psychiatry2005;62(4):361‐70. [PUBMED: 15809403] ">Lieberman 2005</a>; <a href="./references#CD008919-bbs2-0076" title="PadurariuM , CiobicaA , DobrinI , StefanescuC . Evaluation of antioxidant enzymes activities and lipid peroxidation in schizophrenic patients treated with typical and atypical antipsychotics. Neuroscience Letters2010;479(3):317‐20. [PUBMED: 20561936] ">Padurariu 2010</a>; <a href="./references#CD008919-bbs2-0084" title="WangHD , DeutchAY . Dopamine depletion of the prefrontal cortex induces dendritic spine loss: reversal by atypical antipsychotic drug treatment. Neuropsychopharmacology2008;33(6):1276‐86. [PUBMED: 17687264] ">Wang 2008</a>). </p> </section> <section id="CD008919-sec-0026"> <h3 class="title" id="CD008919-sec-0026">How the intervention might work</h3> <p>Oxidative stress occurs when there is an overproduction of free radicals or a deficiency in antioxidant defences (<a href="./references#CD008919-bbs2-0085" title="WoodSJ , YucelM , PantelisC , BerkM . Neurobiology of schizophrenia spectrum disorders: the role of oxidative stress. Annals of the Academy of Medicine2009;38(5):396‐6. [PUBMED: 19521638] ">Wood 2009</a>). This has had theoretical appeal to neurodegenerative disorders, since the brain is considered particularly vulnerable to oxidative damage. This process has been implicated in many psychiatric disorders, and most robust evidence of its importance comes from studies of schizophrenia (<a href="./references#CD008919-bbs2-0074" title="NgF , BerkM , DeanO , BushAI . Oxidative stress in psychiatric disorders: evidence base and therapeutic implications. International Journal of Neuropsychopharmacology2008;11(6):851‐76. [PUBMED: 18205981] ">Ng 2008</a>). The underlying mechanisms underpinning the process of disease neuroprogression and subsequent brain changes are incompletely understood. There is, however, some evidence pointing to central and peripheral pro‐oxidative changes, including lower oxidative defences and oxidative damage to proteins, lipids and DNA (<a href="./references#CD008919-bbs2-0085" title="WoodSJ , YucelM , PantelisC , BerkM . Neurobiology of schizophrenia spectrum disorders: the role of oxidative stress. Annals of the Academy of Medicine2009;38(5):396‐6. [PUBMED: 19521638] ">Wood 2009</a>). </p> <p>As such, there has been interest in developing interventions aimed at restoring this oxidative balance beyond the benefits of antipsychotics in this direction (<a href="./references#CD008919-bbs2-0054" title="DeanOM , Van DenBuuseM , BushAI , CopolovDL , NgF , DoddS , et al. A role for glutathione in the pathophysiology of bipolar disorder and schizophrenia? Animal models and relevance to clinical practice. Current Medicinal Chemistry2009;16(23):2965‐76. [PUBMED: 19689277] ">Dean 2009</a>). Some work has been done investigating the modulation of antioxidants as a therapeutic target for the treatment of schizophrenia. Similarly, mechanisms of action are believed to vary between compounds. Omega‐3 for example, is proposed to have some direct antioxidant properties, but works primarily by protecting against oxidative attack by reinforcing lipid membranes and lipid‐associated structures (such as myelin).  Alternatively, N‐acetyl cysteine (NAC) is believed to act predominantly on the glutathione pathway and may also modulate glutamate function (<a href="./references#CD008919-bbs2-0054" title="DeanOM , Van DenBuuseM , BushAI , CopolovDL , NgF , DoddS , et al. A role for glutathione in the pathophysiology of bipolar disorder and schizophrenia? Animal models and relevance to clinical practice. Current Medicinal Chemistry2009;16(23):2965‐76. [PUBMED: 19689277] ">Dean 2009</a>). </p> </section> <section id="CD008919-sec-0027"> <h3 class="title" id="CD008919-sec-0027">Why it is important to do this review</h3> <p>The investigation on oxidative stress in schizophrenia has increased exponentially in the past decade (<a href="./references#CD008919-bbs2-0074" title="NgF , BerkM , DeanO , BushAI . Oxidative stress in psychiatric disorders: evidence base and therapeutic implications. International Journal of Neuropsychopharmacology2008;11(6):851‐76. [PUBMED: 18205981] ">Ng 2008</a>). If antioxidants are to have a place in the treatment of this serious condition, the relevant and up‐to‐date information should be available to clinicians and investigators. </p> </section> </section> </section> <section class="objectives"> <div class="section-header section-collapse-header" id="CD008919-sec-0028" lang="en"> <h2 class="title section-collapse-title"> Objectives <i aria-hidden="true" class="fa fa-caret-up section-collapse-icon"></i> </h2> </div> <section class="objectives" lang="en"> <div class="section-header" id="CD008919-sec-0028"></div> <p>To evaluate the effect of antioxidants as add‐on treatments to standard antipsychotic medication for improving acute psychotic episodes and core symptoms, and preventing relapse in people with schizophrenia. </p> </section> </section> <section class="methods"> <div class="section-header section-collapse-header" id="CD008919-sec-0029" lang="en"> <h2 class="title section-collapse-title"> Methods <i aria-hidden="true" class="fa fa-caret-up section-collapse-icon"></i> </h2> </div> <section class="methods" lang="en"> <div class="section-header" id="CD008919-sec-0029"></div> <section id="CD008919-sec-0030"> <h3 class="title">Criteria for considering studies for this review</h3> <section id="CD008919-sec-0031"> <h4 class="title">Types of studies</h4> <p>All relevant randomised trials. We excluded quasi‐randomised studies, such as those allocating by using alternate days of the week. As the level of blindness has not been definitely linked to bias (<a href="./references#CD008919-bbs2-0077" title="PetitiDB . Meta‐Analysis, Decision Analysis, and Cost‐Effectiveness Analysis: Methods for Quantitative Synthesis in Medicine. 2nd Edition. New York: Oxford University Press, 2000. ">Petiti 2000</a>), studies with any level of blinding were eligible. Non‐English language was not an obstacle to inclusion. </p> </section> <section id="CD008919-sec-0032"> <h4 class="title">Types of participants</h4> <p>Adults (18+ years) with schizophrenia or other types of schizophrenia‐like psychosis (e.g. schizophreniform and schizoaffective disorders), irrespective of diagnostic criteria used. There is no clear evidence that the schizophrenia‐like psychoses are caused by fundamentally different disease processes or require different treatment approaches (<a href="./references#CD008919-bbs2-0053" title="CarpenterWTJr , BuchananRW . Schizophrenia. New England Journal of Medicine1994;33(10):681‐90. ">Carpenter 1994</a>). </p> <p>We are interested in making sure that information is as relevant to the current care of people with schizophrenia as possible so if information was provided in the trials, we proposed to clearly highlight the current clinical state (acute, early post‐acute, partial remission, remission) as well as the stage (prodromal, first episode, early illness, persistent) and as to whether the studies primarily focused on people with particular problems (for example, negative symptoms, treatment‐resistant illnesses). </p> </section> <section id="CD008919-sec-0033"> <h4 class="title">Types of interventions</h4> <section id="CD008919-sec-0034"> <h5 class="title">1. Antioxidants</h5> <p>Any pharmacologically active substance explicitly administered with the purpose of antioxidation. </p> </section> <section id="CD008919-sec-0035"> <h5 class="title"> 2. Placebo</h5> <p>As antipsychotics are interventions with a large evidence‐base of efficacy, we included only add‐on studies. In these, participants already using a first line agent are randomised to an antioxidant or placebo in addition to their previous treatment. Although we required that participants were on antipsychotics, more 'naturalistic' studies including those on 'poly‐therapy' could be included, provided participants are randomised to placebo or an antioxidant. Alternatively, for maintenance studies they could be randomised to stay on the antioxidant or have it substituted for a placebo. </p> </section> </section> <section id="CD008919-sec-0036"> <h4 class="title">Types of outcome measures</h4> <p>We grouped outcomes into immediate (four weeks or less), short‐term (4‐12 weeks), medium‐term (13‐26 weeks) and long‐term (over 26 weeks). </p> <section id="CD008919-sec-0037"> <h5 class="title">Primary outcomes</h5> <section id="CD008919-sec-0038"> <h6 class="title">1. Global state</h6> <p>1.1 No clinically important response as defined by the individual studies</p> <p>For example, global impression less than much improved or less than 50% reduction on a rating scale. </p> </section> </section> <section id="CD008919-sec-0039"> <h5 class="title">Secondary outcomes</h5> <section id="CD008919-sec-0040"> <h6 class="title">1. Leaving the studies early</h6> <p>1.1 Any reason, adverse events, or inefficacy of treatment</p> </section> <section id="CD008919-sec-0041"> <h6 class="title">2. Global state</h6> <p>2.1 No clinically important change in global state (as defined by individual studies)</p> <p>2.2 Relapse (as defined by the individual studies)</p> </section> <section id="CD008919-sec-0042"> <h6 class="title">3. Mental state</h6> <p>3.1 No clinically important change in general mental state score</p> <p>3.2 Average endpoint general mental state score</p> <p>3.3 Average change in general mental state scores</p> <p>3.4 No clinically important change in specific symptoms (positive symptoms of schizophrenia, negative symptoms of schizophrenia) </p> <p>3.5 Average endpoint specific symptom score</p> <p>3.6 Average change in specific symptom scores</p> </section> <section id="CD008919-sec-0043"> <h6 class="title">4. General functioning</h6> <p>4.1 No clinically important change in general functioning</p> <p>4.2 Average endpoint general functioning score</p> <p>4.3 Average change in general functioning scores</p> </section> <section id="CD008919-sec-0044"> <h6 class="title">5. Quality of life/satisfaction with treatment</h6> <p>5.1 No clinically important change in general quality of life</p> <p>5.2 Average endpoint general quality of life score</p> <p>5.3 Average change in general quality of life scores</p> </section> <section id="CD008919-sec-0045"> <h6 class="title">6. Cognitive functioning</h6> <p>6.1 No clinically important change in overall cognitive functioning</p> <p>6.2 Average endpoint of overall cognitive functioning score</p> <p>6.3 Average change of overall cognitive functioning scores</p> </section> <section id="CD008919-sec-0046"> <h6 class="title">7. Service use</h6> <p>7.1 Number of participants hospitalised</p> <p>7.2 Duration of hospitalisation</p> </section> <section id="CD008919-sec-0047"> <h6 class="title">8. Adverse effects</h6> <p>8.1 Number of participants with at least one adverse effect</p> <p>8.2 Clinically important specific adverse effects (cardiac effects, death, movement disorders and associated effects, sedation, seizures, weight gain, effects on white blood cell count) </p> <p>8.3 Average endpoint in specific adverse effects</p> <p>8.4 Average change in specific adverse effects</p> </section> <section id="CD008919-sec-0048"> <h6 class="title">9. Laboratory data</h6> <p>9.1 Change in tests of oxidative stress</p> <p>9.2 Change in tests of antioxidant defences / potential</p> </section> <section id="CD008919-sec-0049"> <h6 class="title">'Summary of findings table</h6> <p>We anticipated including the following short‐ or medium‐term outcomes in a <a href="./full#CD008919-tbl-0001">summary of findings Table for the main comparison</a>. </p> <section id="CD008919-sec-0050"> <p><b>1. Global state</b></p> <p>1.1 Clinically significant response ‐ as defined by each of the studies</p> <p>1.2 Relapse</p> </section> <section id="CD008919-sec-0051"> <p><b>2. Mental state</b></p> <p>2.1 Clinically significant response in mental state ‐ as defined by each of the studies</p> </section> <section id="CD008919-sec-0052"> <p><b>3. Service utilisation outcome</b></p> <p>3.1 Hospital admission</p> <p>3.2 Days in hospital</p> </section> <section id="CD008919-sec-0053"> <p><b>4. Adverse effect</b></p> <p>4.1 Any important adverse event</p> </section> <section id="CD008919-sec-0054"> <p><b>5. Quality of life</b></p> <p>5.1 Improved to an important extent</p> <p>see <a href="#CD008919-sec-0238">Differences between protocol and review</a> </p> </section> </section> </section> </section> </section> <section id="CD008919-sec-0055"> <h3 class="title">Search methods for identification of studies</h3> <section id="CD008919-sec-0056"> <h4 class="title">Electronic searches</h4> <section id="CD008919-sec-0057"> <h5 class="title">Cochrane Schizophrenia Group’s Trials Register</h5> <p>On January 08, 2015, the Trials Search Co‐ordinator (TSC) searched the Cochrane Schizophrenia Group’s Study‐Based Register of Trials using the following search strategy: </p> <p>*Antioxidant* in Intervention Field of STUDY</p> <p>In such a study‐based register, searching the major concept retrieves all the synonym keywords and relevant studies because all the studies have already been organised based on their interventions and linked to the relevant topics. </p> <p>The Cochrane Schizophrenia Group’s Register of Trials is compiled by systematic searches of major resources (including AMED, BIOSIS, CINAHL, Embase, MEDLINE, PsycINFO, PubMed, and registries of clinical trials) and their monthly updates, handsearches, grey literature, and conference proceedings (see <a href="http://onlinelibrary.wiley.com/o/cochrane/clabout/articles/SCHIZ/frame.html" target="_blank">Group’s Module</a>). There is no language, date, document type, or publication status limitations for inclusion of records into the register. </p> <p>For previous searches, please see <a href="./appendices#CD008919-sec-0224">Appendix 1</a>. </p> </section> </section> <section id="CD008919-sec-0058"> <h4 class="title">Searching other resources</h4> <section id="CD008919-sec-0059"> <h5 class="title">1. Reference searching</h5> <p>We inspected the reference lists of all retrieved articles, previous reviews and major text books of schizophrenia for additional trials. </p> </section> <section id="CD008919-sec-0060"> <h5 class="title">2. Personal contact</h5> <p>If necessary, we contacted the authors of significant papers, as well as other experts in the field, and asked for their knowledge of further studies, published or unpublished, relevant to the review. We noted any responses in the <a href="./references#CD008919-sec-0240" title="">Characteristics of included studies</a> </p> </section> </section> </section> <section id="CD008919-sec-0061"> <h3 class="title" id="CD008919-sec-0061">Data collection and analysis</h3> <section id="CD008919-sec-0062"> <h4 class="title">Selection of studies</h4> <p>Review authors PVM and OD independently inspected citations from the searches and identified relevant abstracts. MB independently re‐inspected a random 20% sample of the citations and abstracts to ensure reliability. PVM and OD obtained full reports of the abstracts meeting the review criteria and inspected them. Again, MB re‐inspected a random 20% of these full reports in order to ensure reliable selection. There were no disputes whether any particular study should be included. </p> </section> <section id="CD008919-sec-0063"> <h4 class="title">Data extraction and management</h4> <section id="CD008919-sec-0064"> <h5 class="title">1. Extraction</h5> <p>Review author PVM extracted data from all included studies. In addition, to ensure reliability, OD independently extracted data from all studies. We made attempts to contact authors through an open‐ended request in order to obtain missing information or for clarification whenever necessary. </p> </section> <section id="CD008919-sec-0065"> <h5 class="title">2. Management</h5> <section id="CD008919-sec-0066"> <h6 class="title">2.1 Forms</h6> <p>We extracted data extracted onto standard, pre‐designed, simple forms.</p> </section> <section id="CD008919-sec-0067"> <h6 class="title">2.2 Scale‐derived data</h6> <p>We included continuous data from rating scales only if:<br/> a. the psychometric properties of the measuring instrument have been described in a peer‐reviewed journal (<a href="./references#CD008919-bbs2-0073" title="MarshallM , LockwoodA , BradleyC , AdamsC , JoyC , FentonM . Unpublished rating scales: a major source of bias in randomised controlled trials of treatments for schizophrenia. British Journal of Psychiatry2000;176:249‐52. [PUBMED: 10755072] ">Marshall 2000</a>); and<br/> b. the measuring instrument has not been written or modified by one of the trialists for that particular trial. </p> <p>Ideally, the measuring instrument should either be i. a self‐report or ii. completed by an independent rater or relative (not the therapist). We realise that this is not often reported clearly, in <a href="#CD008919-sec-0107">Description of studies</a> we noted if this is the case or not. </p> </section> <section id="CD008919-sec-0068"> <h6 class="title">2.3 Endpoint versus change data</h6> <p>There are advantages of both endpoint and change data. Change data can remove a component of between‐person variability from the analysis. On the other hand, calculation of change needs two assessments (baseline and endpoint), which can be difficult in unstable and difficult to measure conditions such as schizophrenia. We decided primarily to use endpoint data, and only use change data if the former were not available. We planned to combined endpoint and change data in the analysis as we preferred to use mean differences (MD) rather than standardised mean differences throughout (<a href="./references#CD008919-bbs2-0064" title="HigginsJPT , GreenS (editors) . Cochrane Handbook for Systematic Reviews of Interventions Version 5.0.2 [updated September 2011]. The Cochrane Collaboration, 2011. Available from www.cochrane‐handbook.org. ">Higgins 2011</a>). </p> </section> <section id="CD008919-sec-0069"> <h6 class="title">2.4 Skewed data</h6> <p>Continuous data on clinical and social outcomes are often not normally distributed. To avoid the pitfall of applying parametric tests to non‐parametric data, we aimed to apply the following standards to relevant data before inclusion. </p> <p>Change data</p> <p>When continuous data are presented on a scale that includes a possibility of negative values (such as change data), it is difficult to tell whether data are skewed or not. We would have presented and entered change data into statistical analyses. </p> <p>Endpoint data</p> <p>Endpoint scores on scales often have a finite start and end point and we applied the following rules: </p> <p> <ol id="CD008919-list-0001"> <li> <p>standard deviations (SDs) and means are reported in the paper or obtainable from the authors; </p> </li> <li> <p>when a scale starts from the finite number zero, the standard deviation (SD), when multiplied by two, is less than the mean (as otherwise the mean is unlikely to be an appropriate measure of the centre of the distribution) (<a href="./references#CD008919-bbs2-0047" title="AltmanDG , BlandJM . Detecting skewness from summary information. BMJ1996;313(7066):1200. ">Altman 1996</a>); </p> </li> <li> <p>if a scale starts from a positive value (such as the Positive and Negative Syndrome Scale (PANSS) (<a href="https://archie.cochrane.org/sections/documents/view?version=z1512211049305032002366624137834%26format=REVMAN#REF-Kay-1986" target="_blank">Kay 1986</a>), which can have values from 30 to 210), the calculation described above would be modified to take the scale starting point into account. In these cases skew is present if 2 SD &gt; (S‐S min), where S is the mean score and 'S min' is the minimum score. </p> </li> </ol> </p> <p>Had we found endpoint data from studies of fewer than 200 participants we planned to present these as other data within the data and analyses section rather than entering such data into statistical analyses. </p> <p>Skewed endpoint data pose less of a problem when looking at means if the sample size is large and if we found skewed endpoint data from studies of over 200 participants we entered such data from these studies into statistical analyses. </p> </section> <section id="CD008919-sec-0070"> <h6 class="title">2.5 Common measure</h6> <p>To facilitate comparison between trials, we intended to convert variables that can be reported in different metrics, such as days in hospital (mean days per year, per week or per month) to a common metric (e.g. mean days per month), although no such occasions appeared. </p> </section> <section id="CD008919-sec-0071"> <h6 class="title">2.6 Conversion of continuous data to binary data</h6> <p>Where possible, we made efforts to convert outcome measures to dichotomous data. This can be done by identifying cut‐off points on rating scales and dividing participants accordingly into 'clinically improved' or 'not clinically improved'. It is generally assumed that if there is a 50% reduction in a scale‐derived score such as the Brief Psychiatric Rating Scale (BPRS, <a href="./references#CD008919-bbs2-0075" title="OverallJE , GorhamDR . The Brief Psychiatric Rating Scale. Psychological Reports1962;10:799‐812. ">Overall 1962</a>) or the Positive and Negative Syndrome Scale (PANSS, <a href="./references#CD008919-bbs2-0067" title="KaySR , OplerLA , FiszbeinA . Positive and negative syndrome scale (PANSS) manual. North Tonawanda, NY: Multi‐Health Systems, 1986. ">Kay 1986</a>), this could be considered as a clinically significant response (<a href="./references#CD008919-bbs2-0068" title="LeuchtS , KaneJM , KisslingW , HamannJ , EtschelE , EngelR . Clinical implications of Brief Psychiatric Rating Scale scores. British Journal of Psychiatry2005;187:366‐71. [PUBMED: 16199797] ">Leucht 2005</a>; <a href="./references#CD008919-bbs2-0069" title="LeuchtS , KaneJM , KisslingW , HamannJ , EtschelE , EngelRR . What does the PANSS mean?. Schizophrenia Research2005;79(2‐3):231‐8. [PUBMED: 15982856] ">Leucht 2005a</a>). If data based on these thresholds were not available, we used the primary cut‐off presented by the original authors. </p> </section> <section id="CD008919-sec-0072"> <h6 class="title">2.7 Direction of graphs</h6> <p>We entered data in such a way that the area to the left of the line of no effect indicates a favourable outcome adjunctive antioxidant. Where keeping to this made it impossible to avoid outcome titles with clumsy double‐negatives (e.g. 'Not un‐improved'), we reported data where the left of the line indicates an unfavourable outcome. </p> </section> <section id="CD008919-sec-0073"> <h6 class="title">2.8 Multiple doses</h6> <p>When a study investigating a number of fixed doses of an antioxidant was included, we used the method described in section 16.5 of the <i>Cochrane Handbook for Systematic Reviews of Interventions</i> (<a href="./references#CD008919-bbs2-0064" title="HigginsJPT , GreenS (editors) . Cochrane Handbook for Systematic Reviews of Interventions Version 5.0.2 [updated September 2011]. The Cochrane Collaboration, 2011. Available from www.cochrane‐handbook.org. ">Higgins 2011</a>) to combine data from multiple groups. </p> </section> </section> </section> <section id="CD008919-sec-0074"> <h4 class="title">Assessment of risk of bias in included studies</h4> <p>Again review authors PM and OD worked independently to assess risk of bias using criteria described in the Cochrane Handbook for Systematic Reviews of Interventions (<a href="./references#CD008919-bbs2-0064" title="HigginsJPT , GreenS (editors) . Cochrane Handbook for Systematic Reviews of Interventions Version 5.0.2 [updated September 2011]. The Cochrane Collaboration, 2011. Available from www.cochrane‐handbook.org. ">Higgins 2011</a>) to assess trial quality. This set of criteria is based on evidence of associations between overestimate of effect and high risk of bias of the article, such as sequence generation, allocation concealment, blinding, incomplete outcome data and selective reporting. </p> <p>Where inadequate details of randomisation and other characteristics of trials were provided, we contacted authors of the studies in order to obtain further information. There was no disagreement in quality assessment. </p> <p>The level of risk of bias was noted in both the text of the review in the <a href="./full#CD008919-tbl-0001">summary of findings Table for the main comparison</a>, and in <a href="#CD008919-fig-0001">Figure 1</a> and <a href="#CD008919-fig-0002">Figure 2</a>. </p> <div class="figure" id="CD008919-fig-0001"> <div class="figure-caption-wrapper-top"> <nav class="inline-nav-list has-dividers"> <ul> <li><a class="open-in-figure-viewer" href="#0">Open in figure viewer</a></li> </ul> </nav> <div class="figure-label">Figure 1</div> </div> <hr class="top"/><img alt="'Risk of bias' graph: review authors' judgements about each risk of bias item presented as percentages across all included studies." data-id="CD008919-fig-0001" src="/cdsr/doi/10.1002/14651858.CD008919.pub2/media/CDSR/CD008919/image_n/nCD008919-AFig-FIG01.png"/><hr class="bottom"/> <div class="figure-caption-wrapper-bottom"> <div class="figure-caption"> <p>'Risk of bias' graph: review authors' judgements about each risk of bias item presented as percentages across all included studies. </p> </div> </div> </div> <div class="figure" id="CD008919-fig-0002"> <div class="figure-caption-wrapper-top"> <nav class="inline-nav-list has-dividers"> <ul> <li><a class="open-in-figure-viewer" href="#0">Open in figure viewer</a></li> </ul> </nav> <div class="figure-label">Figure 2</div> </div> <hr class="top"/><img alt="'Risk of bias' summary: review authors' judgements about each risk of bias item for each included study." data-id="CD008919-fig-0002" src="/cdsr/doi/10.1002/14651858.CD008919.pub2/media/CDSR/CD008919/image_n/nCD008919-AFig-FIG02.png"/><hr class="bottom"/> <div class="figure-caption-wrapper-bottom"> <div class="figure-caption"> <p>'Risk of bias' summary: review authors' judgements about each risk of bias item for each included study. </p> </div> </div> </div> </section> <section id="CD008919-sec-0075"> <h4 class="title">Measures of treatment effect</h4> <section id="CD008919-sec-0076"> <h5 class="title">1. Binary data</h5> <p>For binary outcomes, we calculated a standard estimation of the risk ratio (RR) and its 95% confidence interval (CI). It has been shown that RR is more intuitive (<a href="./references#CD008919-bbs2-0052" title="BoisselJP , CucheratM , LiW , ChatellierG , GueyffierF , BuyseM , et al. The problem of therapeutic efficacy indices. 3. Comparison of the indices and their use [Apercu sur la problematique des indices d'efficacite therapeutique, 3: comparaison des indices et utilisation. Groupe d'Etude des Indices D'efficacite]. Therapie1999;54(4):405‐11. [PUBMED: 10667106] ">Boissel 1999</a>) than odds ratios and that odds ratios tend to be interpreted as RR by clinicians (<a href="./references#CD008919-bbs2-0055" title="DeeksJ . Issues in the selection for meta‐analyses of binary data. Proceedings of the 8th International Cochrane Colloquium; 2000 Oct 25‐28; Cape town. Cape Town: The Cochrane Collaboration, 2000. ">Deeks 2000</a>). The Number Needed to Treat/Harm (NNT/H) statistic with its confidence intervals is intuitively attractive to clinicians but is problematic, both in its accurate calculation in meta‐analyses and interpretation (<a href="./references#CD008919-bbs2-0065" title="HuttonJL . Number needed to treat and number needed to harm are not the best way to report and assess the results of randomised clinical trials. British Journal of Haematology2009;146(1):27‐30. ">Hutton 2009</a>). For binary data presented in the 'Summary of findings' table, where possible, we calculated illustrative comparative risks. </p> </section> <section id="CD008919-sec-0077"> <h5 class="title">2. Continuous data</h5> <p>For continuous outcomes we estimated mean difference (MD) between groups. We preferred not to calculate effect size measures (standardised mean difference SMD) unless necessary. However, if scales of very considerable similarity were used, we presumed there was a small difference in measurement, and calculated effect size and transformed the effect back to the units of one or more of the specific instruments. </p> </section> </section> <section id="CD008919-sec-0078"> <h4 class="title">Unit of analysis issues</h4> <section id="CD008919-sec-0079"> <h5 class="title">1. Cluster trials</h5> <p>There were no cluster‐randomised trials included in the review.</p> </section> <section id="CD008919-sec-0080"> <h5 class="title">2. Cross‐over trials</h5> <p>A major concern of cross‐over trials is the carry‐over effect. It occurs if an effect (e.g. pharmacological, physiological or psychological) of the treatment in the first phase is carried over to the second phase. As a consequence on entry to the second phase, the participants can differ systematically from their initial state despite a wash‐out phase. For the same reason cross‐over trials are not appropriate if the condition of interest is unstable (<a href="./references#CD008919-bbs2-0059" title="ElbourneD , AltmanDG , HigginsJPT , CurtinaF , WorthingtondHV , VaileA . Meta‐analyses involving cross‐over trials: methodological issues. International Journal of Epidemiology2002;31(1):140‐9. ">Elbourne 2002</a>). As both effects are very likely in severe mental illness, we included randomised cross‐over trials, but only used data form the first phase. </p> </section> <section id="CD008919-sec-0081"> <h5 class="title">3. Studies with multiple treatment groups</h5> <p>Where a study involved more than two treatment arms, if relevant, we presented the additional treatment arms in comparisons. If data were binary, we simply added these and combined within the two‐by‐two table. </p> </section> </section> <section id="CD008919-sec-0082"> <h4 class="title">Dealing with missing data</h4> <section id="CD008919-sec-0083"> <h5 class="title">1. Overall loss of credibility</h5> <p>At some degree of loss of follow‐up, data must lose credibility (<a href="./references#CD008919-bbs2-0086" title="XiaJ , AdamsCE , BhagatN , BhagatV , BhoopathiP , El‐SayehH , et al. Loss to outcomes stakeholder survey: the LOSS study. Psychiatric Bulletin2009;33(7):254‐7. ">Xia 2009</a>). We chose that, for any particular outcome, should more than 40% of data be unaccounted for, we would not reproduce these data or use them within analyses. </p> </section> <section id="CD008919-sec-0084"> <h5 class="title">2. Binary</h5> <p>In the case where attrition for a binary outcome is between 0% and 40% and where these data are not clearly described, data would be presented on a 'once‐randomised‐always‐analyse' basis (an intention‐to‐treat (ITT) analysis). Those leaving the study early are all assumed to have the same rates of negative outcome as those who completed, with the exception of the outcome of death and adverse effects. A sensitivity analysis was planned but was not undertaken since very few studies reported on binary improvement and those that reported used ITT analysis. </p> </section> <section id="CD008919-sec-0085"> <h5 class="title">3. Continuous</h5> <section id="CD008919-sec-0086"> <h6 class="title">3.1 Attrition</h6> <p>In the case where attrition for a continuous outcome was between 0% and 40% and completer‐only data were reported, we reproduced these. </p> </section> <section id="CD008919-sec-0087"> <h6 class="title">3.2 Standard deviations</h6> <p>There were no instances where standard deviations were not reported.</p> </section> <section id="CD008919-sec-0088"> <h6 class="title">3.3 Last observation carried forward (LOCF)</h6> <p>We anticipated that in some studies the method of last observation carried forward (LOCF) would be employed within study reports. As with all methods of imputation to deal with missing data, LOCF introduces uncertainty about the reliability of the results (<a href="./references#CD008919-bbs2-0070" title="LeuchtS , EngelRR , BaumlJ , DavisJM . Is the superior efficacy of new generation antipsychotics an artifact of LOCF?. Schizophrenia Bulletin2007;33(1):183‐91. [PUBMED: 16905632] ">Leucht 2007</a>). Therefore, where LOCF data were used in the trial, if less than 50% of the data had been assumed, we reproduced these data and indicated that they are the product of LOCF assumptions. </p> </section> </section> </section> <section id="CD008919-sec-0089"> <h4 class="title">Assessment of heterogeneity</h4> <section id="CD008919-sec-0090"> <h5 class="title">1. Clinical heterogeneity</h5> <p>We considered all included studies initially, without seeing comparison data, to judge clinical heterogeneity. We inspected all studies for clearly outlying people or situations which we had not predicted would arise. When such situations or participant groups existed, they are discussed. </p> </section> <section id="CD008919-sec-0091"> <h5 class="title">2. Methodological heterogeneity</h5> <p>We considered all included studies initially, without seeing comparison data, to judge methodological heterogeneity. We inspected all studies for clearly outlying methods which we had not predicted would arise. We discussed such methodological outliers if they arose. </p> </section> <section id="CD008919-sec-0092"> <h5 class="title">3. Statistical heterogeneity</h5> <section id="CD008919-sec-0093"> <h6 class="title">3.1 Visual inspection</h6> <p>We visually inspected graphs to investigate the possibility of statistical heterogeneity.</p> </section> <section id="CD008919-sec-0094"> <h6 class="title">3.2 Employing the I<sup>2</sup> statistic </h6> <p>Heterogeneity between studies was investigated by considering the I<sup>2</sup> method alongside the Chi<sup>2</sup> 'P' value. The I<sup>2</sup> provides an estimate of the percentage of inconsistency thought to be due to chance (<a href="./references#CD008919-bbs2-0063" title="HigginsJP , ThompsonSG , DeeksJJ , AltmanDG . Measuring inconsistency in meta‐analyses. BMJ2003;327:557‐60. ">Higgins 2003</a>). The importance of the observed value of I<sup>2</sup> depends on i. magnitude and direction of effects and ii. strength of evidence for heterogeneity (e.g. a 'P' value from Chi<sup>2</sup>  test, or a confidence interval for I<sup>2</sup>). an I<sup>2</sup> estimate greater than or equal to around 50% accompanied by a statistically significant Chi<sup>2</sup> statistic, was interpreted as evidence of substantial levels of heterogeneity (Section 9.5.2 ‐ <a href="./references#CD008919-bbs2-0064" title="HigginsJPT , GreenS (editors) . Cochrane Handbook for Systematic Reviews of Interventions Version 5.0.2 [updated September 2011]. The Cochrane Collaboration, 2011. Available from www.cochrane‐handbook.org. ">Higgins 2011</a>). When substantial levels of heterogeneity were found, we explored reasons for heterogeneity (<a href="#CD008919-sec-0097">Subgroup analysis and investigation of heterogeneity</a>). </p> </section> </section> </section> <section id="CD008919-sec-0095"> <h4 class="title">Assessment of reporting biases</h4> <p>Reporting biases arise when the dissemination of research findings is influenced by the nature and direction of results (<a href="./references#CD008919-bbs2-0058" title="EggerM , Davey‐SmithG , SchneiderM , MinderCSO . Bias in meta‐analysis detected by a simple, graphical test. BMJ1997;13:629‐34. ">Egger 1997</a>). These are described in Section 10 of the <i>Cochrane Handbook for Systematic Reviews of Interventions</i> (<a href="./references#CD008919-bbs2-0064" title="HigginsJPT , GreenS (editors) . Cochrane Handbook for Systematic Reviews of Interventions Version 5.0.2 [updated September 2011]. The Cochrane Collaboration, 2011. Available from www.cochrane‐handbook.org. ">Higgins 2011</a>). We are aware that funnel plots may be useful in investigating reporting biases but are of limited power to detect small‐study effects. We did not use funnel plots for outcomes where there are 10 or fewer studies, or where all studies were of similar sizes. </p> </section> <section id="CD008919-sec-0096"> <h4 class="title">Data synthesis</h4> <p>Although the choice of model for meta‐analysis remains controversial (<a href="./references#CD008919-bbs2-0061" title="FreemantleN , MasonJ , EcclesM . Deriving treatment recommendations from evidence within randomized trials. The role and limitation of meta‐analysis. International Journal of Technology Assessment in Health Care1999;15(2):304‐15. [PUBMED: 10507190] ">Freemantle 1999</a>), a random‐effects model (<a href="./references#CD008919-bbs2-0057" title="DerSimonianR , LairdN . Meta‐analysis in clinical trials. Controlled Clinical Trials1986;7(3):177‐88. [PUBMED: 3802833] ">DerSimonian 1986</a>), which assumes that studies analysed actually comes from pool of hypothetical studies, was used in this meta‐analysis. The random‐effects methods does put added weight onto the smaller of the studies ‐ those that may be most prone to bias. We nevertheless favoured using a random‐effects model. </p> </section> <section id="CD008919-sec-0097"> <h4 class="title">Subgroup analysis and investigation of heterogeneity</h4> <section id="CD008919-sec-0098"> <h5 class="title">1. Subgroup</h5> <p>We conducted subgroup analyses regarding the specific antioxidant used.</p> <p>We were interested in making sure that information is as relevant to the current care of people with schizophrenia and broad clinical groups (see <a href="#CD008919-sec-0032">Types of participants</a>). We intended to be able to present these data according to current clinical state, stage and for people with particular problems. This was not possible, however, because none of the studies reported relevant subgroups. </p> </section> <section id="CD008919-sec-0099"> <h5 class="title">2. Investigation of heterogeneity</h5> <section id="CD008919-sec-0100"> <h6 class="title">2.1 Unanticipated heterogeneity</h6> <p>If inconsistency was high, we reported this.</p> </section> <section id="CD008919-sec-0101"> <h6 class="title">2.2 Anticipated heterogeneity</h6> <p>We did not anticipate important levels of heterogeneity.</p> </section> </section> </section> <section id="CD008919-sec-0102"> <h4 class="title">Sensitivity analysis</h4> <section id="CD008919-sec-0103"> <h5 class="title">1. Quality</h5> <p>We aimed to include trials in a sensitivity analysis if they were described in some way as to imply randomisation, but there were no such instances. </p> </section> <section id="CD008919-sec-0104"> <h5 class="title">2. Handling of missing observations</h5> <p>Where assumptions have had to be made regarding people lost to follow‐up (see <a href="#CD008919-sec-0082">Dealing with missing data</a>), we compared the findings of the primary outcomes when we used our assumption compared with completer data only. </p> </section> <section id="CD008919-sec-0105"> <h5 class="title">3. Statistical model for the synthesis</h5> <p>For the primary outcome, if there was substantial heterogeneity, we checked if using a fixed‐effect model substantively changed the final result. </p> </section> </section> </section> </section> </section> <section class="results"> <div class="section-header section-collapse-header" id="CD008919-sec-0106" lang="en"> <h2 class="title section-collapse-title"> Results <i aria-hidden="true" class="fa fa-caret-up section-collapse-icon"></i> </h2> </div> <section class="results" lang="en"> <div class="section-header" id="CD008919-sec-0106"></div> <section id="CD008919-sec-0107"> <h3 class="title">Description of studies</h3> <p>Please see <a href="./references#CD008919-sec-0240" title="">Characteristics of included studies</a>; <a href="./references#CD008919-sec-0241" title="">Characteristics of excluded studies</a>; <a href="./references#CD008919-sec-0242" title="">Characteristics of studies awaiting classification</a>. </p> <section id="CD008919-sec-0108"> <h4 class="title">Results of the search</h4> <p>Electronic searches in 2010, 2012 and 2015 identified 147 references with no additional records identified through personal contact or inspecting references of retrieved articles. After duplicates were removed, we screened 109 records. Forty‐six potentially relevant records were obtained and scrutinised and 24 of these reports either did not meet the inclusion criteria and had to be excluded (seven) or were unclear and are awaiting classification pending further information (17). Twenty‐two trials are therefore included (<a href="#CD008919-fig-0003">Figure 3</a>). </p> <div class="figure" id="CD008919-fig-0003"> <div class="figure-caption-wrapper-top"> <nav class="inline-nav-list has-dividers"> <ul> <li><a class="open-in-figure-viewer" href="#0">Open in figure viewer</a></li> </ul> </nav> <div class="figure-label">Figure 3</div> </div> <hr class="top"/><img alt="Study flow diagram." data-id="CD008919-fig-0003" src="/cdsr/doi/10.1002/14651858.CD008919.pub2/media/CDSR/CD008919/image_n/nCD008919-AFig-FIG03.png"/><hr class="bottom"/> <div class="figure-caption-wrapper-bottom"> <div class="figure-caption"> <p>Study flow diagram.</p> </div> </div> </div> </section> <section id="CD008919-sec-0109"> <h4 class="title">Included studies</h4> <section id="CD008919-sec-0110"> <h5 class="title">1. Allocation</h5> <p>All included studies were stated to be randomised and double‐blinded. All were, as per protocol, add‐on trials. </p> </section> <section id="CD008919-sec-0111"> <h5 class="title">2. Design</h5> <p>All included studies had a parallel longitudinal design. Only two of 22 studies used a cross‐over design with two periods and had data available from the first period (<a href="./references#CD008919-bbs2-0008" title="BrunsteinMG , GhisolfiES , RamosFL , LaraDR . A clinical trial of adjuvant allopurinol therapy for moderately refractory schizophrenia. Journal of Clinical Psychiatry2005;66(2):213‐9. [PUBMED: 15705007] ">Brunstein 2005</a>; <a href="./references#CD008919-bbs2-0011" title="DorevitchA , KalianM , ShlafmanM , LernerV . Treatment of long‐term tardive dyskinesia with vitamin E. Biological Psychiatry1997;41(1):114‐6. [MEDLINE: 8988802] ">Dorevitch 1997a</a>). </p> </section> <section id="CD008919-sec-0112"> <h5 class="title">3. Duration</h5> <p>All but three studies were short‐term studies. <a href="./references#CD008919-bbs2-0005" title="BerkM , CopolovD , DeanO , LuK , JeavonsS , SchapkaitzI , et al. N‐acetyl cysteine as a glutathione precursor for schizophrenia‐a double‐blind, randomized, placebo‐controlled trial. Biological Psychiatry2008;64(5):361‐8. ">Berk 2008b</a> was a medium‐term study (24 weeks) and <a href="./references#CD008919-bbs2-0001" title="AdlerLA , PeselowE , RotrosenJ , DuncanE , LeeM , RosenthalM , et al. Vitamin E treatment of tardive dyskinesia. American Journal of Psychiatry1993;150(9):1405‐7. Adler LA , EdsonR , LavoriP , PeselowE , DuncanE , RosenthalM , et al. Long‐term treatment effects of vitamin E for tardive dyskinesia. Biological Psychiatry 1998;15:868‐72. ">Adler 1993a</a> and <a href="./references#CD008919-bbs2-0002" title="AdlerLA , RotrosenJ , EdsonR , LavoriP , LohrJ , HitzemannR , et al. Vitamin E treatment for tardive dyskinesia. Archives of General Psychiatry1999;56(9):836‐41. [MEDLINE: 12892048] ">Adler 1999</a> were long‐term studies. We made the decision to group <a href="./references#CD008919-bbs2-0017" title="LuoHC , ShenYC , MengFQ . Therapeutic effect of shuxuening combining neuroleptics for the treatment of chronic schizophrenia‐‐a double blind study. Zhongguo Zhong xi yi jie he za zhi Zhongguo Zhongxiyi jiehe zazhi = Chinese Journal of Integrated Traditional and Western Medicine / Zhongguo Zhong xi yi jie he xue hui, Zhongguo Zhong yi yan jiu yuan zhu ban1997;17(3):139‐42. ">Luo 1997</a> with short‐term studies, since it was the only study with a 16‐week duration and it was similar to other ginkgo studies in this review in terms of diagnosis and other methodological aspects. Overall, the median follow‐up was eight weeks. </p> </section> <section id="CD008919-sec-0113"> <h5 class="title">4. Participants</h5> <p>Participants total 2041 people. The number of participants ranged from 16 to 545 (median 46). Nineteen of the 22 studies reported using Diagnostic and Statistical Manual (DSM‐III, DSM‐IIIR or DSM‐IV) criteria to diagnose schizophrenia. Six studies also required patients to present with tardive dyskinesia for inclusion. Of the studies that reported the patients' sex, men were over‐represented in most; slightly over two men to one woman. </p> </section> <section id="CD008919-sec-0114"> <h5 class="title">5. Setting</h5> <p>Six trials were conducted in the USA, four in China, four in Iran, three in Israel and one each in Brazil, India, Romania, Australia and Turkey. Nine trials were conducted in inpatient and 11 in outpatient settings, two in mixed settings. </p> </section> <section id="CD008919-sec-0115"> <h5 class="title">6. Interventions</h5> <section id="CD008919-sec-0116"> <h6 class="title">6.1 Adjunctive antioxidants</h6> <p>Four studies employed adjunctive <i>Ginkgo biloba</i> extract, from 120 to 360 mg/day (<a href="./references#CD008919-bbs2-0012" title="DorukA , UzunO , OzsahinA . A placebo‐controlled study of extract of ginkgo biloba added to clozapine in patients with treatment‐resistant schizophrenia. International Clinical Psychopharmacology2008;23(4):223‐7. [PUBMED: 18545061] ">Doruk 2008</a>; <a href="./references#CD008919-bbs2-0017" title="LuoHC , ShenYC , MengFQ . Therapeutic effect of shuxuening combining neuroleptics for the treatment of chronic schizophrenia‐‐a double blind study. Zhongguo Zhong xi yi jie he za zhi Zhongguo Zhongxiyi jiehe zazhi = Chinese Journal of Integrated Traditional and Western Medicine / Zhongguo Zhong xi yi jie he xue hui, Zhongguo Zhong yi yan jiu yuan zhu ban1997;17(3):139‐42. ">Luo 1997</a>; <a href="./references#CD008919-bbs2-0020" title="ZhangXY , ZhouDF , ZhangPY , WuGY , SuJM , CaoLY . A double‐blind, placebo‐controlled trial of extract of Ginkgo biloba added to haloperidol in treatment‐resistant patients with schizophrenia. Journal of Clinical Psychiatry2001;62(11):878‐83. [PUBMED: 11775047] ">Zhang 2001a</a>; <a href="./references#CD008919-bbs2-0022" title="ZhangWF , TanYL , ZhangXY , ChanRC , WuHR , ZhouDF . Extract of Ginkgo biloba treatment for tardive dyskinesia in schizophrenia: a randomized, double‐blind, placebo‐controlled trial. Journal of Clinical Psychiatry2011;72(5):615‐21. [PUBMED: 20868638] ZhangXY , ZhouDF , SuJM , ZhangPY . The effects of extract of ginkgo biloba added to haloperidol on superoxide dismutase in inpatients with chronic schizophrenia. Journal of Clinical Psychopharmacology2001;21(1):85‐8. ">Zhang 2011</a>); five selegiline, from 5 to 15 mg/day (<a href="./references#CD008919-bbs2-0004" title="AmiriA , NoorbalaAA , NejatisafaAA , GhoreishiA , DerakhshanMK , Khodaie‐ArdakaniMR , et al. Efficacy of selegiline add on therapy to risperidone in the treatment of the negative symptoms of schizophrenia: a double‐blind randomized placebo‐controlled study. Human Psychopharmacology2008;23(2):79‐86. [MEDLINE: 17972359] ">Amiri 2008</a>; <a href="./references#CD008919-bbs2-0006" title="BodkinJA , SirisSG , BermanzohnPC , HennenJ , ColeJO . Double‐blind, placebo‐controlled, multicenter trial of selegiline augmentation of antipsychotic medication to treat negative symptoms in outpatients with schizophrenia. American Journal of Psychiatry2005;162(2):388‐90. [MEDLINE: 15677608] ">Bodkin 2005</a>; <a href="./references#CD008919-bbs2-0007" title="BordbarMR , AbdollahianE , HojjatK , SamaricA . Effects of selegiline on negative symptoms in schizophrenia: A double‐blind clinical trial. Iranian Journal of Psychiatry and Clinical Psychology2008;14(2):131‐9. ">Bordbar 2008</a>; <a href="./references#CD008919-bbs2-0014" title="GoffDC , RenshawPF , SaridSegalO , DreyfussDA , AmicoET , CirauloDA . A placebo‐controlled trial of selegiline (L‐deprenyl) in the treatment of tardive dyskinesia. Biological Psychiatry1993;33(10):700‐6. [MEDLINE: 8102552] ">Goff 1993</a>; <a href="./references#CD008919-bbs2-0015" title="JungermanT , RabinowitzD , KleinE . Deprenyl augmentation for treating negative symptoms of schizophrenia: a double blind, controlled study. Journal of Clinical Psychopharmacology1999;19(6):522‐5. [MEDLINE: 10587287] ">Jungerman 1999</a>); four allopurinol, from 300 to 600 mg/day (<a href="./references#CD008919-bbs2-0003" title="AkhondzadehS , SafarcheratiA , AminiH . Beneficial antipsychotic effects of allopurinol as add‐on therapy for schizophrenia: a double blind, randomized and placebo controlled trial. Progress in Neuro‐Psychopharmacology &amp; Biological Psychiatry2005;29(2):253‐9. [PUBMED: 15694232] ">Akhondzadeh 2005</a>; <a href="./references#CD008919-bbs2-0008" title="BrunsteinMG , GhisolfiES , RamosFL , LaraDR . A clinical trial of adjuvant allopurinol therapy for moderately refractory schizophrenia. Journal of Clinical Psychiatry2005;66(2):213‐9. [PUBMED: 15705007] ">Brunstein 2005</a>; <a href="./references#CD008919-bbs2-0010" title="DickersonFB , StallingsCR , OrigoniAE , SullensA , KhushalaniS , SandsonN , et al. A double‐blind trial of adjunctive allopurinol for schizophrenia. Schizophrenia Research2009;109(1‐3):66‐9. [PUBMED: 19195842] ">Dickerson 2009</a>; <a href="./references#CD008919-bbs2-0019" title="WeiserM , GershonAA , RubinsteinK , PetcuC , LadeaM , SimaD , et al. A randomized controlled trial of allopurinol vs. placebo added on to antipsychotics in patients with schizophrenia or schizoaffective disorder. Schizophrenia Research2012;138(1):35‐8. [PUBMED: 22483162] ">Weiser 2012</a>); five, vitamin E (<a href="./references#CD008919-bbs2-0001" title="AdlerLA , PeselowE , RotrosenJ , DuncanE , LeeM , RosenthalM , et al. Vitamin E treatment of tardive dyskinesia. American Journal of Psychiatry1993;150(9):1405‐7. Adler LA , EdsonR , LavoriP , PeselowE , DuncanE , RosenthalM , et al. Long‐term treatment effects of vitamin E for tardive dyskinesia. Biological Psychiatry 1998;15:868‐72. ">Adler 1993a</a>; <a href="./references#CD008919-bbs2-0002" title="AdlerLA , RotrosenJ , EdsonR , LavoriP , LohrJ , HitzemannR , et al. Vitamin E treatment for tardive dyskinesia. Archives of General Psychiatry1999;56(9):836‐41. [MEDLINE: 12892048] ">Adler 1999</a>; <a href="./references#CD008919-bbs2-0011" title="DorevitchA , KalianM , ShlafmanM , LernerV . Treatment of long‐term tardive dyskinesia with vitamin E. Biological Psychiatry1997;41(1):114‐6. [MEDLINE: 8988802] ">Dorevitch 1997a</a>; <a href="./references#CD008919-bbs2-0016" title="LohrJB , CaligiuriMP . A double‐blind placebo‐controlled study of vitamin E treatment of tardive dyskinesia. Journal of Clinical Psychiatry1996;57(4):167‐73. ">Lohr 1996</a>; <a href="./references#CD008919-bbs2-0021" title="ZhangXY , ZhouDF , CaoLY , XuCQ , Chen daC , WuGY . The effect of vitamin e treatment on tardive dyskinesia and blood superoxide dismutase: a double‐blind placebo‐controlled trial. Journal of Clinical Psychopharmacology2004;24(1):83‐6. [MEDLINE: 14709952] ">Zhang 2004</a>), from 1200 IU to 1600 IU/day; two N‐acetyl cysteine (NAC) (<a href="./references#CD008919-bbs2-0005" title="BerkM , CopolovD , DeanO , LuK , JeavonsS , SchapkaitzI , et al. N‐acetyl cysteine as a glutathione precursor for schizophrenia‐a double‐blind, randomized, placebo‐controlled trial. Biological Psychiatry2008;64(5):361‐8. ">Berk 2008b</a>; <a href="./references#CD008919-bbs2-0013" title="FarokhniaM , AzarkolahA , AdinehfarF , Khodaie‐ArdakaniMR , HosseiniSM , YekehtazH , et al. N‐acetylcysteine as an adjunct to risperidone for treatment of negative symptoms in patients with chronic schizophrenia: a randomized, double‐blind, placebo‐controlled study. Clinical Neuropharmacology2013;36(6):185‐92. [PUBMED: 24201233] ">Farokhnia 2013</a>); and one each dehydroepiandrosterone (DHEA) (<a href="./references#CD008919-bbs2-0018" title="RitsnerMS , GibelA , ShleiferT , BoguslavskyI , ZayedA , MaayanR , et al. Pregnenolone and dehydroepiandrosterone as an adjunctive treatment in schizophrenia and schizoaffective disorder: an 8‐week, double‐blind, randomized, controlled, 2‐center, parallel‐group trial. The Journal of Clinical Psychiatry2010;71(10):1351‐62. [PUBMED: 20584515] ">Ritsner 2010</a>) and vitamin C (<a href="./references#CD008919-bbs2-0009" title="DakhaleGN , KhanzodeSD , KhanzodeSS , SaojiA . Supplementation of vitamin C with atypical antipsychotics reduces oxidative stress and improves the outcome of schizophrenia. Psychopharmacology2005;182(4):494‐8. [MEDLINE: 16133138] ">Dakhale 2005</a>). </p> </section> <section id="CD008919-sec-0117"> <h6 class="title">6.2 Comparison group</h6> <p>An adjunctive placebo was used as a comparison group, with no further details given in most studies. </p> </section> </section> <section id="CD008919-sec-0118"> <h5 class="title">7. Outcomes</h5> <section id="CD008919-sec-0119"> <h6 class="title">7.1 General</h6> <p>Although we intended to report on a host of clinically relevant outcomes, only a few clinical outcomes, generally derived from rating scales and quite limited oxidative stress data were reported in the included studies. </p> <p>Some outcomes were presented in graphs, P values or a statement of significant or non‐significant difference. This made it impossible to use data for synthesis. </p> <p>Notably, very few studies (only <a href="./references#CD008919-bbs2-0005" title="BerkM , CopolovD , DeanO , LuK , JeavonsS , SchapkaitzI , et al. N‐acetyl cysteine as a glutathione precursor for schizophrenia‐a double‐blind, randomized, placebo‐controlled trial. Biological Psychiatry2008;64(5):361‐8. ">Berk 2008b</a>, <a href="./references#CD008919-bbs2-0008" title="BrunsteinMG , GhisolfiES , RamosFL , LaraDR . A clinical trial of adjuvant allopurinol therapy for moderately refractory schizophrenia. Journal of Clinical Psychiatry2005;66(2):213‐9. [PUBMED: 15705007] ">Brunstein 2005</a> and <a href="./references#CD008919-bbs2-0010" title="DickersonFB , StallingsCR , OrigoniAE , SullensA , KhushalaniS , SandsonN , et al. A double‐blind trial of adjunctive allopurinol for schizophrenia. Schizophrenia Research2009;109(1‐3):66‐9. [PUBMED: 19195842] ">Dickerson 2009</a>) reported any clinically meaningful measure of clinical response. </p> </section> <section id="CD008919-sec-0120"> <h6 class="title">7.2 Scales used to measure psychopathology, functioning and adverse effects</h6> <p>The two scales most employed to measure symptoms were the Brief Psychiatric Rating Scale (BPRS) and the Positive and Negative Syndrome Scale (PANSS). </p> <p>7.2.1 BPRS (<a href="./references#CD008919-bbs2-0075" title="OverallJE , GorhamDR . The Brief Psychiatric Rating Scale. Psychological Reports1962;10:799‐812. ">Overall 1962</a> <br/> The BPRS is a one‐page, 16‐ or 18‐item rating scale developed more than 50 years ago. It assesses a range of psychotic and affective symptoms. The original purpose was rapid evaluation of clinical change irrespective of origin in the broad range of psychiatric patients.  </p> <p>7.2.2 PANSS (<a href="./references#CD008919-bbs2-0067" title="KaySR , OplerLA , FiszbeinA . Positive and negative syndrome scale (PANSS) manual. North Tonawanda, NY: Multi‐Health Systems, 1986. ">Kay 1986</a>).<br/> The PANSS originated from a need to reduce the heterogeneity of schizophrenia, based on a positive–negative dichotomy for explaining and understanding variability in the aetiology of schizophrenia, treatment and prognosis.  </p> <p>7.2.3 SANS (<a href="./references#CD008919-bbs2-0048" title="AndreasenNC . Methods for assessing positive and negative symptoms. Modern problems of pharmacopsychiatry1990;24:73‐88. [PUBMED: 2336066] ">Andreasen 1990</a>)<br/> Also often employed to determine positive and negative symptoms were Andreasen's Schedule for the Assessment of Positive Symptoms (SAPS) and Schedule for the Assessment of Negative Symptoms .  </p> <p>7.2.4 GAS (<a href="./references#CD008919-bbs2-0060" title="EndicottJ , SpitzerRL , FleissJL , CohenJ . The global assessment scale. A procedure for measuring overall severity of psychiatric disturbance. Archives of General Psychiatry1976;33(6):766‐71. [PUBMED: 938196] ">Endicott 1976</a>) and GAF (<a href="./references#CD008919-bbs2-0066" title="JonesSH , ThornicroftG , CoffeyM , DunnG . A brief mental health outcome scale‐reliability and validity of the Global Assessment of Functioning (GAF). British Journal of Psychiatry: the journal of mental science1995;166(5):654‐9. [PUBMED: 7620753] ">Jones 1995</a>). </p> <p>The Global Assessment of Functioning (GAF), and its older version, the Global Assessment Scale (GAS) were used in two studies. These are general functioning scales developed to be clinically useful and easy to administer, but with the caveat that they do not separate functioning from symptoms. </p> <p>7.2.5 TESS (<a href="./references#CD008919-bbs2-0062" title="GuyW . Treatment Emergent Symptom Scale. ECDEU Assessment Manual for Psychopharmacology. National Institutes for Mental Health, 1991. ">Guy 1991</a>) </p> <p>The Treatment Emergent Symptom Scale (TESS) measures side‐effects severity. It can be used as a total score or as six subscores that gather symptoms related to different body systems. </p> </section> <section id="CD008919-sec-0121"> <h6 class="title">7.3 Laboratory methods used to measure oxidative stress and antioxidant defences</h6> <p>Three studies reported on laboratory methods. <a href="./references#CD008919-bbs2-0009" title="DakhaleGN , KhanzodeSD , KhanzodeSS , SaojiA . Supplementation of vitamin C with atypical antipsychotics reduces oxidative stress and improves the outcome of schizophrenia. Psychopharmacology2005;182(4):494‐8. [MEDLINE: 16133138] ">Dakhale 2005</a> reported serum malondialdehyde (MDA) levels, according to methods described by Satoh (<a href="./references#CD008919-bbs2-0079" title="SatohK . Serum lipid peroxide in cerebrovascular disorders determined by a new colorimetric method. Clinica Chimica Acta; international journal of clinical chemistry1978;90(1):37‐43. [PUBMED: 719890] ">Satoh 1978</a>). MDA is an oxidative stress marker, the final product of peroxidation processes and oxidative damage in cells (<a href="./references#CD008919-bbs2-0083" title="ValkoM , LeibfritzD , MoncolJ , CroninMT , MazurM , TelserJ . Free radicals and antioxidants in normal physiological functions and human disease. International journal of Biochemistry &amp; Cell Biology2007;39(1):44‐84. [PUBMED: 16978905] ">Valko 2007</a>). <a href="./references#CD008919-bbs2-0020" title="ZhangXY , ZhouDF , ZhangPY , WuGY , SuJM , CaoLY . A double‐blind, placebo‐controlled trial of extract of Ginkgo biloba added to haloperidol in treatment‐resistant patients with schizophrenia. Journal of Clinical Psychiatry2001;62(11):878‐83. [PUBMED: 11775047] ">Zhang 2001a</a> and <a href="./references#CD008919-bbs2-0021" title="ZhangXY , ZhouDF , CaoLY , XuCQ , Chen daC , WuGY . The effect of vitamin e treatment on tardive dyskinesia and blood superoxide dismutase: a double‐blind placebo‐controlled trial. Journal of Clinical Psychopharmacology2004;24(1):83‐6. [MEDLINE: 14709952] ">Zhang 2004</a> reported on superoxide dysmutase (SOD, an antioxidant enzyme) serum levels with radioimmunoassay, described in <a href="./references#CD008919-bbs2-0020" title="ZhangXY , ZhouDF , ZhangPY , WuGY , SuJM , CaoLY . A double‐blind, placebo‐controlled trial of extract of Ginkgo biloba added to haloperidol in treatment‐resistant patients with schizophrenia. Journal of Clinical Psychiatry2001;62(11):878‐83. [PUBMED: 11775047] ">Zhang 2001a</a>. </p> </section> </section> </section> <section id="CD008919-sec-0122"> <h4 class="title">Excluded studies</h4> <p>We excluded seven studies, either because they did not measure any outcome of interest (<a href="./references#CD008919-bbs2-0024" title="DorevitchA , LernerV , ShalfmanM , KalianM . Lack of effect of vitamin E on serum creatine phosphokinase in patients with long‐term tardive dyskinesia. International Clinical Psychopharmacology1997;12(3):171‐3. [PUBMED: 9248874] ">Dorevitch 1997</a>; <a href="./references#CD008919-bbs2-0025" title="ElkashefAM , RuskinPE , BacherN , BarrettD . Vitamin E in the treatment of tardive dyskinesia. American Journal of Psychiatry1990;147(4):505‐6. ">Elkashef 1990</a>; <a href="./references#CD008919-bbs2-0029" title="Suresh KumarPN , AndradeC , BhaktaSG , SinghNM . Melatonin in schizophrenic outpatients with insomnia: a double‐blind, placebo‐controlled study. Journal of Clinical Psychiatry2007;68(2):237‐41. [PUBMED: 17335321] ">Suresh 2007</a>), were not adjunctive or randomised trials (<a href="./references#CD008919-bbs2-0023" title="BhavaniAD , SenNN , PunekarBD . Impact of ascorbic acid administration on memory, attention, intelligence and motor functions in schizophrenics. Transactions of all India Institute of Mental Health1962;3:80‐8. ">Bhavani 1962</a>; <a href="./references#CD008919-bbs2-0027" title="KapurS , GanguliR , UlrichR , RaghuU . Use of random‐sequence riboflavin as a marker of medication compliance in chronic schizophrenics. Schizophrenia Research1991;6(1):49‐53. [MEDLINE: 1686184] ">Kapur 1991</a>), randomised participants to combined interventions (<a href="./references#CD008919-bbs2-0028" title="ReesL , KingGM . Desoxycortone acetate and ascorbic acid in the treatment of schizophrenia. Journal of Mental Science1951;97:376‐80. ">Rees 1951</a>) or participants were not diagnosed with schizophrenia (<a href="./references#CD008919-bbs2-0026" title="ErantiVS , GangadharBN , JanakiramaiahN . Haloperidol induced extrapyramidal reaction: lack of protective effect by vitamin E. Psychopharmacology1998;140(4):418‐20. [MEDLINE: 9888616] ">Eranti 1998</a>). </p> <section id="CD008919-sec-0123"> <h5 class="title">Awaiting classification</h5> <p>There are 17 trials awaiting classification pending provision of more information.</p> </section> <section id="CD008919-sec-0124"> <h5 class="title">Ongoing studies</h5> <p>There are currently no ongoing studies we are aware of.</p> </section> </section> </section> <section id="CD008919-sec-0125"> <h3 class="title">Risk of bias in included studies</h3> <p><a href="#CD008919-fig-0001">Figure 1</a> and <a href="#CD008919-fig-0002">Figure 2</a> are graphical overviews of the risk of bias in the included studies. </p> <section id="CD008919-sec-0126"> <h4 class="title">Allocation</h4> <p>All 22 included studies were randomised but not all described how this was achieved, and were not generally clear about allocation concealment. Only nine (<a href="./references#CD008919-bbs2-0002" title="AdlerLA , RotrosenJ , EdsonR , LavoriP , LohrJ , HitzemannR , et al. Vitamin E treatment for tardive dyskinesia. Archives of General Psychiatry1999;56(9):836‐41. [MEDLINE: 12892048] ">Adler 1999</a>; <a href="./references#CD008919-bbs2-0003" title="AkhondzadehS , SafarcheratiA , AminiH . Beneficial antipsychotic effects of allopurinol as add‐on therapy for schizophrenia: a double blind, randomized and placebo controlled trial. Progress in Neuro‐Psychopharmacology &amp; Biological Psychiatry2005;29(2):253‐9. [PUBMED: 15694232] ">Akhondzadeh 2005</a>; <a href="./references#CD008919-bbs2-0004" title="AmiriA , NoorbalaAA , NejatisafaAA , GhoreishiA , DerakhshanMK , Khodaie‐ArdakaniMR , et al. Efficacy of selegiline add on therapy to risperidone in the treatment of the negative symptoms of schizophrenia: a double‐blind randomized placebo‐controlled study. Human Psychopharmacology2008;23(2):79‐86. [MEDLINE: 17972359] ">Amiri 2008</a>; <a href="./references#CD008919-bbs2-0005" title="BerkM , CopolovD , DeanO , LuK , JeavonsS , SchapkaitzI , et al. N‐acetyl cysteine as a glutathione precursor for schizophrenia‐a double‐blind, randomized, placebo‐controlled trial. Biological Psychiatry2008;64(5):361‐8. ">Berk 2008b</a>; <a href="./references#CD008919-bbs2-0007" title="BordbarMR , AbdollahianE , HojjatK , SamaricA . Effects of selegiline on negative symptoms in schizophrenia: A double‐blind clinical trial. Iranian Journal of Psychiatry and Clinical Psychology2008;14(2):131‐9. ">Bordbar 2008</a>; <a href="./references#CD008919-bbs2-0009" title="DakhaleGN , KhanzodeSD , KhanzodeSS , SaojiA . Supplementation of vitamin C with atypical antipsychotics reduces oxidative stress and improves the outcome of schizophrenia. Psychopharmacology2005;182(4):494‐8. [MEDLINE: 16133138] ">Dakhale 2005</a>; <a href="./references#CD008919-bbs2-0013" title="FarokhniaM , AzarkolahA , AdinehfarF , Khodaie‐ArdakaniMR , HosseiniSM , YekehtazH , et al. N‐acetylcysteine as an adjunct to risperidone for treatment of negative symptoms in patients with chronic schizophrenia: a randomized, double‐blind, placebo‐controlled study. Clinical Neuropharmacology2013;36(6):185‐92. [PUBMED: 24201233] ">Farokhnia 2013</a>; <a href="./references#CD008919-bbs2-0018" title="RitsnerMS , GibelA , ShleiferT , BoguslavskyI , ZayedA , MaayanR , et al. Pregnenolone and dehydroepiandrosterone as an adjunctive treatment in schizophrenia and schizoaffective disorder: an 8‐week, double‐blind, randomized, controlled, 2‐center, parallel‐group trial. The Journal of Clinical Psychiatry2010;71(10):1351‐62. [PUBMED: 20584515] ">Ritsner 2010</a>; <a href="./references#CD008919-bbs2-0022" title="ZhangWF , TanYL , ZhangXY , ChanRC , WuHR , ZhouDF . Extract of Ginkgo biloba treatment for tardive dyskinesia in schizophrenia: a randomized, double‐blind, placebo‐controlled trial. Journal of Clinical Psychiatry2011;72(5):615‐21. [PUBMED: 20868638] ZhangXY , ZhouDF , SuJM , ZhangPY . The effects of extract of ginkgo biloba added to haloperidol on superoxide dismutase in inpatients with chronic schizophrenia. Journal of Clinical Psychopharmacology2001;21(1):85‐8. ">Zhang 2011</a>) gave further details about sequence generation. Eight studies (<a href="./references#CD008919-bbs2-0002" title="AdlerLA , RotrosenJ , EdsonR , LavoriP , LohrJ , HitzemannR , et al. Vitamin E treatment for tardive dyskinesia. Archives of General Psychiatry1999;56(9):836‐41. [MEDLINE: 12892048] ">Adler 1999</a>; <a href="./references#CD008919-bbs2-0005" title="BerkM , CopolovD , DeanO , LuK , JeavonsS , SchapkaitzI , et al. N‐acetyl cysteine as a glutathione precursor for schizophrenia‐a double‐blind, randomized, placebo‐controlled trial. Biological Psychiatry2008;64(5):361‐8. ">Berk 2008b</a>; <a href="./references#CD008919-bbs2-0006" title="BodkinJA , SirisSG , BermanzohnPC , HennenJ , ColeJO . Double‐blind, placebo‐controlled, multicenter trial of selegiline augmentation of antipsychotic medication to treat negative symptoms in outpatients with schizophrenia. American Journal of Psychiatry2005;162(2):388‐90. [MEDLINE: 15677608] ">Bodkin 2005</a>; <a href="./references#CD008919-bbs2-0013" title="FarokhniaM , AzarkolahA , AdinehfarF , Khodaie‐ArdakaniMR , HosseiniSM , YekehtazH , et al. N‐acetylcysteine as an adjunct to risperidone for treatment of negative symptoms in patients with chronic schizophrenia: a randomized, double‐blind, placebo‐controlled study. Clinical Neuropharmacology2013;36(6):185‐92. [PUBMED: 24201233] ">Farokhnia 2013</a>; <a href="./references#CD008919-bbs2-0015" title="JungermanT , RabinowitzD , KleinE . Deprenyl augmentation for treating negative symptoms of schizophrenia: a double blind, controlled study. Journal of Clinical Psychopharmacology1999;19(6):522‐5. [MEDLINE: 10587287] ">Jungerman 1999</a>; <a href="./references#CD008919-bbs2-0018" title="RitsnerMS , GibelA , ShleiferT , BoguslavskyI , ZayedA , MaayanR , et al. Pregnenolone and dehydroepiandrosterone as an adjunctive treatment in schizophrenia and schizoaffective disorder: an 8‐week, double‐blind, randomized, controlled, 2‐center, parallel‐group trial. The Journal of Clinical Psychiatry2010;71(10):1351‐62. [PUBMED: 20584515] ">Ritsner 2010</a>; <a href="./references#CD008919-bbs2-0019" title="WeiserM , GershonAA , RubinsteinK , PetcuC , LadeaM , SimaD , et al. A randomized controlled trial of allopurinol vs. placebo added on to antipsychotics in patients with schizophrenia or schizoaffective disorder. Schizophrenia Research2012;138(1):35‐8. [PUBMED: 22483162] ">Weiser 2012</a>; <a href="./references#CD008919-bbs2-0022" title="ZhangWF , TanYL , ZhangXY , ChanRC , WuHR , ZhouDF . Extract of Ginkgo biloba treatment for tardive dyskinesia in schizophrenia: a randomized, double‐blind, placebo‐controlled trial. Journal of Clinical Psychiatry2011;72(5):615‐21. [PUBMED: 20868638] ZhangXY , ZhouDF , SuJM , ZhangPY . The effects of extract of ginkgo biloba added to haloperidol on superoxide dismutase in inpatients with chronic schizophrenia. Journal of Clinical Psychopharmacology2001;21(1):85‐8. ">Zhang 2011</a>) reported a satisfactory method of concealment. </p> </section> <section id="CD008919-sec-0127"> <h4 class="title">Blinding</h4> <p>All studies were reported as double‐blind trials with participants blinded to treatment. Not all studies were clear about rater blinding. One study is in the <a href="./references#CD008919-bbs1-0003" title="">Studies awaiting classification</a> section because it is unclear whether it was a single‐blind or open‐label study (<a href="./references#CD008919-bbs2-0046" title="XuX , JiY , HeM . The efficacy of Ginkgo biloba tablet inadjuvant treatment of schizophrenia. Shanghai Medical andPharmaceutical Journal2002;23:456‐7. ">Xu 2002</a>). </p> </section> <section id="CD008919-sec-0128"> <h4 class="title">Incomplete outcome data</h4> <p>Several studies reported using some form of intention‐to‐treat analysis to account for incomplete data, usually last observation carried forward (LOCF) (<a href="./references#CD008919-bbs2-0002" title="AdlerLA , RotrosenJ , EdsonR , LavoriP , LohrJ , HitzemannR , et al. Vitamin E treatment for tardive dyskinesia. Archives of General Psychiatry1999;56(9):836‐41. [MEDLINE: 12892048] ">Adler 1999</a>; <a href="./references#CD008919-bbs2-0003" title="AkhondzadehS , SafarcheratiA , AminiH . Beneficial antipsychotic effects of allopurinol as add‐on therapy for schizophrenia: a double blind, randomized and placebo controlled trial. Progress in Neuro‐Psychopharmacology &amp; Biological Psychiatry2005;29(2):253‐9. [PUBMED: 15694232] ">Akhondzadeh 2005</a>; <a href="./references#CD008919-bbs2-0004" title="AmiriA , NoorbalaAA , NejatisafaAA , GhoreishiA , DerakhshanMK , Khodaie‐ArdakaniMR , et al. Efficacy of selegiline add on therapy to risperidone in the treatment of the negative symptoms of schizophrenia: a double‐blind randomized placebo‐controlled study. Human Psychopharmacology2008;23(2):79‐86. [MEDLINE: 17972359] ">Amiri 2008</a>; <a href="./references#CD008919-bbs2-0005" title="BerkM , CopolovD , DeanO , LuK , JeavonsS , SchapkaitzI , et al. N‐acetyl cysteine as a glutathione precursor for schizophrenia‐a double‐blind, randomized, placebo‐controlled trial. Biological Psychiatry2008;64(5):361‐8. ">Berk 2008b</a>; <a href="./references#CD008919-bbs2-0006" title="BodkinJA , SirisSG , BermanzohnPC , HennenJ , ColeJO . Double‐blind, placebo‐controlled, multicenter trial of selegiline augmentation of antipsychotic medication to treat negative symptoms in outpatients with schizophrenia. American Journal of Psychiatry2005;162(2):388‐90. [MEDLINE: 15677608] ">Bodkin 2005</a>; <a href="./references#CD008919-bbs2-0008" title="BrunsteinMG , GhisolfiES , RamosFL , LaraDR . A clinical trial of adjuvant allopurinol therapy for moderately refractory schizophrenia. Journal of Clinical Psychiatry2005;66(2):213‐9. [PUBMED: 15705007] ">Brunstein 2005</a>; <a href="./references#CD008919-bbs2-0009" title="DakhaleGN , KhanzodeSD , KhanzodeSS , SaojiA . Supplementation of vitamin C with atypical antipsychotics reduces oxidative stress and improves the outcome of schizophrenia. Psychopharmacology2005;182(4):494‐8. [MEDLINE: 16133138] ">Dakhale 2005</a>; <a href="./references#CD008919-bbs2-0010" title="DickersonFB , StallingsCR , OrigoniAE , SullensA , KhushalaniS , SandsonN , et al. A double‐blind trial of adjunctive allopurinol for schizophrenia. Schizophrenia Research2009;109(1‐3):66‐9. [PUBMED: 19195842] ">Dickerson 2009</a>; <a href="./references#CD008919-bbs2-0019" title="WeiserM , GershonAA , RubinsteinK , PetcuC , LadeaM , SimaD , et al. A randomized controlled trial of allopurinol vs. placebo added on to antipsychotics in patients with schizophrenia or schizoaffective disorder. Schizophrenia Research2012;138(1):35‐8. [PUBMED: 22483162] ">Weiser 2012</a>; <a href="./references#CD008919-bbs2-0020" title="ZhangXY , ZhouDF , ZhangPY , WuGY , SuJM , CaoLY . A double‐blind, placebo‐controlled trial of extract of Ginkgo biloba added to haloperidol in treatment‐resistant patients with schizophrenia. Journal of Clinical Psychiatry2001;62(11):878‐83. [PUBMED: 11775047] ">Zhang 2001a</a>; <a href="./references#CD008919-bbs2-0022" title="ZhangWF , TanYL , ZhangXY , ChanRC , WuHR , ZhouDF . Extract of Ginkgo biloba treatment for tardive dyskinesia in schizophrenia: a randomized, double‐blind, placebo‐controlled trial. Journal of Clinical Psychiatry2011;72(5):615‐21. [PUBMED: 20868638] ZhangXY , ZhouDF , SuJM , ZhangPY . The effects of extract of ginkgo biloba added to haloperidol on superoxide dismutase in inpatients with chronic schizophrenia. Journal of Clinical Psychopharmacology2001;21(1):85‐8. ">Zhang 2011</a>). One study explicitly reported all participants completed the trial (<a href="./references#CD008919-bbs2-0015" title="JungermanT , RabinowitzD , KleinE . Deprenyl augmentation for treating negative symptoms of schizophrenia: a double blind, controlled study. Journal of Clinical Psychopharmacology1999;19(6):522‐5. [MEDLINE: 10587287] ">Jungerman 1999</a>). Two studies were classified as high risk for stating using a completer analysis (<a href="./references#CD008919-bbs2-0007" title="BordbarMR , AbdollahianE , HojjatK , SamaricA . Effects of selegiline on negative symptoms in schizophrenia: A double‐blind clinical trial. Iranian Journal of Psychiatry and Clinical Psychology2008;14(2):131‐9. ">Bordbar 2008</a>; <a href="./references#CD008919-bbs2-0014" title="GoffDC , RenshawPF , SaridSegalO , DreyfussDA , AmicoET , CirauloDA . A placebo‐controlled trial of selegiline (L‐deprenyl) in the treatment of tardive dyskinesia. Biological Psychiatry1993;33(10):700‐6. [MEDLINE: 8102552] ">Goff 1993</a>) or failing to report any attrition (<a href="./references#CD008919-bbs2-0016" title="LohrJB , CaligiuriMP . A double‐blind placebo‐controlled study of vitamin E treatment of tardive dyskinesia. Journal of Clinical Psychiatry1996;57(4):167‐73. ">Lohr 1996</a>; <a href="./references#CD008919-bbs2-0021" title="ZhangXY , ZhouDF , CaoLY , XuCQ , Chen daC , WuGY . The effect of vitamin e treatment on tardive dyskinesia and blood superoxide dismutase: a double‐blind placebo‐controlled trial. Journal of Clinical Psychopharmacology2004;24(1):83‐6. [MEDLINE: 14709952] ">Zhang 2004</a>). </p> </section> <section id="CD008919-sec-0129"> <h4 class="title">Selective reporting</h4> <p>Selective reporting was not a major issue for this review. Most studies reported primary outcomes of interest. We classified two studies as high risk primarily because of endpoint rating scale data not reported (<a href="./references#CD008919-bbs2-0011" title="DorevitchA , KalianM , ShlafmanM , LernerV . Treatment of long‐term tardive dyskinesia with vitamin E. Biological Psychiatry1997;41(1):114‐6. [MEDLINE: 8988802] ">Dorevitch 1997a</a>; <a href="./references#CD008919-bbs2-0021" title="ZhangXY , ZhouDF , CaoLY , XuCQ , Chen daC , WuGY . The effect of vitamin e treatment on tardive dyskinesia and blood superoxide dismutase: a double‐blind placebo‐controlled trial. Journal of Clinical Psychopharmacology2004;24(1):83‐6. [MEDLINE: 14709952] ">Zhang 2004</a>). </p> </section> <section id="CD008919-sec-0130"> <h4 class="title">Other potential sources of bias</h4> <p>We found no other obvious potential sources of bias.</p> </section> </section> <section id="CD008919-sec-0131"> <h3 class="title" id="CD008919-sec-0131">Effects of interventions</h3> <p>See: <a href="./full#CD008919-tbl-0001"><b>Summary of findings for the main comparison</b> Adjunctive antioxidants for schizophrenia versus placebo</a> </p> <section id="CD008919-sec-0132"> <h4 class="title">COMPARISON 1: ADJUNCTIVE ANTIOXIDANTS versus PLACEBO</h4> <section id="CD008919-sec-0133"> <h5 class="title">1.1 Global state: 1. No clinically important response (20% improvement PANSS)</h5> <p>Studies tended not to include categorical measures of response (only three out of the 20 included studies). Only two short‐term studies and one medium‐term study reported clinical response as a 20% reduction in the PANSS. These results did not demonstrate an advantage for adjunctive antioxidants 3 RCTS, n = 229, risk ratio (RR) 0.77, 95% confidence interval (CI) 0.53 to 1.12 <a href="./references#CD008919-fig-0004" title="">Analysis 1.1</a>), </p> <section id="CD008919-sec-0134"> <h6 class="title">1.1.1 Allopurinol: PANSS improvement: short term</h6> <p>In this subgroup we found two relevant trials (n = 94). There was no significant difference between adjunctive allopurinol and placebo (RR 0.69 95% CI 0.36 to 1.32). This subgroup had important levels of heterogeneity (Chi<sup>2</sup> = 7.36; df = 1; P = 0.007; I<sup>2</sup> = 86%). </p> </section> <section id="CD008919-sec-0135"> <h6 class="title">1.1.2 N‐acetyl cysteine (NAC): PANSS improvement: medium term</h6> <p>In this subgroup we only found one relevant trial (n = 135). There was no significant difference between adjunctive NAC and placebo (RR 1.01 95% CI 0.53 to 1.92). </p> </section> </section> <section id="CD008919-sec-0136"> <h5 class="title">1.2 Leaving the study early:</h5> <section id="CD008919-sec-0137"> <h6 class="title">1.2.1 Short term (all antioxidants)</h6> <p>Use of any adjunctive antioxidant did not change the risk of leaving the study early in the short term (16 RCTs, 1584 people, RR 0.73, 95% CI 0.48 to 1.11 <a href="./references#CD008919-fig-0005" title="">Analysis 1.2</a>). There was also no significant difference in retention in the medium term (1 RCT, n = 140, RR 0.99, 95% CI 0.67 to 1.48 <a href="./references#CD008919-fig-0006" title="">Analysis 1.3</a>), or in two long‐term studies (2 RCTS, n = 195, RR 0.90 95% CI 0.59 to 1.35 <a href="./references#CD008919-fig-0007" title="">Analysis 1.4</a> ). </p> <p>Data could be subgrouped into individual antioxidant treatments (Figure 1).</p> <section id="CD008919-sec-0138"> <p><b>1.2.1.1 Allopurinol</b></p> <p>In this subgroup we found four relevant trials (n = 388). There was no significant difference between adjunctive allopurinol and placebo (RR 0.83 95% CI 0.55 to 1.24). </p> </section> <section id="CD008919-sec-0139"> <p><b>1.2.1.2 Ginkgo biloba</b></p> <p>In this subgroup we found four relevant trials (n = 857). There was no significant difference between adjunctive ginkgo and placebo (RR 0.42 95% CI 0.17 to 1.03). </p> </section> <section id="CD008919-sec-0140"> <p><b>1.2.1.3 Selegiline</b></p> <p>In this subgroup we found three relevant trials (n = 153). There was no significant difference between adjunctive selegiline and placebo (RR 5.22 95% CI 0.90 to 30.31). </p> </section> <section id="CD008919-sec-0141"> <p><b>1.2.1.4 Vitamin C</b></p> <p>In this subgroup we only found one relevant trial (n = 40) (<a href="./references#CD008919-bbs2-0009" title="DakhaleGN , KhanzodeSD , KhanzodeSS , SaojiA . Supplementation of vitamin C with atypical antipsychotics reduces oxidative stress and improves the outcome of schizophrenia. Psychopharmacology2005;182(4):494‐8. [MEDLINE: 16133138] ">Dakhale 2005</a>). There was no significant difference between adjunctive vitamin C and placebo (RR 0.25 95% CI 0.03 to 2.05). </p> </section> <section id="CD008919-sec-0142"> <p><b>1.2.1.5 Vitamin E</b></p> <p>In this subgroup we found two relevant trials (n = 68). There was no significant difference between adjunctive vitamin E and placebo (RR 0.97 95% CI 0.06 to 14.48) This subgroup had moderate levels of heterogeneity (Chi<sup>2</sup> = 1.67; df = 1; P = 0.197; I<sup>2</sup> = 40%). </p> </section> <section id="CD008919-sec-0143"> <p><b>1.2.1.6 NAC</b></p> <p>In this subgroup we only found one relevant trial (n = 46) (<a href="./references#CD008919-bbs2-0013" title="FarokhniaM , AzarkolahA , AdinehfarF , Khodaie‐ArdakaniMR , HosseiniSM , YekehtazH , et al. N‐acetylcysteine as an adjunct to risperidone for treatment of negative symptoms in patients with chronic schizophrenia: a randomized, double‐blind, placebo‐controlled study. Clinical Neuropharmacology2013;36(6):185‐92. [PUBMED: 24201233] ">Farokhnia 2013</a>). There was no significant difference between adjunctive NAC and placebo (RR 1.00 95% CI 0.15 to 6.51). </p> </section> <section id="CD008919-sec-0144"> <p><b>1.2.1.7 DHEA</b></p> <p>In this subgroup we only found one relevant trial (n = 32) (<a href="./references#CD008919-bbs2-0018" title="RitsnerMS , GibelA , ShleiferT , BoguslavskyI , ZayedA , MaayanR , et al. Pregnenolone and dehydroepiandrosterone as an adjunctive treatment in schizophrenia and schizoaffective disorder: an 8‐week, double‐blind, randomized, controlled, 2‐center, parallel‐group trial. The Journal of Clinical Psychiatry2010;71(10):1351‐62. [PUBMED: 20584515] ">Ritsner 2010</a>). There was no significant difference between adjunctive DHEA and placebo (RR 0.60 95% CI 0.17 to 2.10). </p> </section> </section> <section id="CD008919-sec-0145"> <h6 class="title">1.2.2 Medium term (NAC)</h6> <p>Medium‐term data for leaving the study early were provided by only one relevant trial (n = 140) (<a href="./references#CD008919-bbs2-0005" title="BerkM , CopolovD , DeanO , LuK , JeavonsS , SchapkaitzI , et al. N‐acetyl cysteine as a glutathione precursor for schizophrenia‐a double‐blind, randomized, placebo‐controlled trial. Biological Psychiatry2008;64(5):361‐8. ">Berk 2008b</a>). There was no significant difference between adjunctive NAC and placebo (RR 0.99 95% CI 0.67 to 1.48, <a href="./references#CD008919-fig-0006" title="">Analysis 1.3</a>). </p> </section> <section id="CD008919-sec-0146"> <h6 class="title">1.2.3 Long term (Vitamin E)</h6> <p>Two trials (n = 195) provided long‐term data for leaving the study early. There was no significant difference between adjunctive vitamin E and placebo (RR 0.9 95% CI 0.59 to 1.35, <a href="./references#CD008919-fig-0007" title="">Analysis 1.4</a>). </p> </section> </section> <section id="CD008919-sec-0147"> <h5 class="title">1.3 Mental state</h5> <p>Thirteen studies measured mental state using the BPRS or PANSS. Pooling individual antioxidant short‐term data favoured antioxidants, however there were substantial levels of heterogeneity. Results varied for individual antioxidants. Medium‐term data were presented by one trial only, as were long‐term data; both studies found no significant advantage of antioxidant over placebo at these time points. </p> <section id="CD008919-sec-0148"> <h6 class="title">1.3.1 Mental state : 1a. General ‐ short‐term BPRS total endpoint</h6> <p>Eight studies provided short‐term BPRS endpoint data; a favourable effect for antioxidants was found (n = 843, mean difference (MD) ‐3.20,95% CI ‐5.63 to ‐0.78) I<sup>2</sup> = 74%). There was substantial heterogeneity for this outcome.(Chi² = 27.41, df = 7 (P = 0.0003); I² = 74%). <a href="./references#CD008919-fig-0008" title="">Analysis 1.5</a> </p> <p>Overall, data were favourable, however, when data were subgrouped into individual antioxidant treatments, the results varied. </p> <section id="CD008919-sec-0149"> <p><b>1.3.1.1 Ginkgo biloba</b></p> <p>Data from three short‐term studies showed a favourable effect for <i>Ginkgo biloba</i> (3 RCTS, n = 663, MD ‐2.74, 95% CI ‐5.29 to ‐0.20). This subgroup had important levels of heterogeneity (Chi<sup>2</sup> = 8.73; df = 2; P = 0.013; I<sup>2</sup> = 77%) </p> </section> <section id="CD008919-sec-0150"> <p><b>1.3.1.2 Selegiline</b></p> <p>No effect was found for selegiline (3 RCTS, n = 111, MD ‐0.31, 95% CI ‐4.03 to 3.41)</p> </section> <section id="CD008919-sec-0151"> <p><b>1.3.1.3 Vitamin C</b></p> <p>One small study showed a favourable effect for vitamin C (n = 40, MD ‐9.66, 95% CI ‐ 13.27 to ‐6.05) </p> </section> <section id="CD008919-sec-0152"> <p><b>1.3.1.4 Vitamin E</b></p> <p>A favourable effect was not found for vitamin E (n = 29, MD ‐7.92, 95% CI ‐17.20 to 1.36) </p> </section> </section> <section id="CD008919-sec-0153"> <h6 class="title">1.3.2 Mental state: 1b. General ‐ short‐term PANSS</h6> <p>Overall, there was substantial heterogeneity regarding differences of any antioxidant and placebo in mental state scores for the PANSS (Chi² = 16.96, df = 5 (P = 0.005); I² = 71%). Data showed a favourable effect for antioxidants (7 RCTS, n = 584, MD ‐6.00, 95% CI ‐10.35 to ‐1.65) (<a href="./references#CD008919-fig-0009" title="">Analysis 1.6</a>).<br/> <br/> Data could be subgrouped into individual antioxidants. </p> <section id="CD008919-sec-0154"> <p><b>1.3.2.1 Allopurinol</b></p> <p>In this subgroup we found three relevant trials (n = 329). There was no significant difference between adjunctive antioxidants and placebo (MD ‐6.91 95% CI ‐15.86 to 2.04). This subgroup had important levels of heterogeneity (Chi<sup>2</sup> = 12.76; df = 2; P = 0.002; I<sup>2</sup> = 84%). </p> </section> <section id="CD008919-sec-0155"> <p><b>1.3.2.2 Ginkgo biloba</b></p> <p>In this subgroup we only found one relevant trial (n = 157). There was a statistically significant difference between adjunctive antioxidants and placebo (MD ‐3.30 95% CI ‐6.51 to ‐0.09). </p> </section> <section id="CD008919-sec-0156"> <p><b>1.3.2.3 Selegiline</b></p> <p>In this subgroup we found two relevant trials (n = 56). There was no significant difference between adjunctive antioxidants and placebo (MD ‐2.97 95% CI ‐15.68 to 9.74, <a href="./references#CD008919-fig-0009" title="">Analysis 1.6</a>). This subgroup had important levels of heterogeneity (Chi<sup>2</sup> = 4.06; df = 1; P = 0.044; I<sup>2</sup> = 75%). </p> </section> <section id="CD008919-sec-0157"> <p><b>1.3.2.4 NAC</b></p> <p>In this subgroup we only found one relevant trial (n = 42). There was a statistically significant difference between adjunctive antioxidants and placebo (MD ‐12.86 95% CI ‐19.82 to ‐5.90). </p> </section> </section> <section id="CD008919-sec-0158"> <h6 class="title">1.3.3 Mental state: 1c. General ‐ medium‐term PANSS</h6> <p>Only one relevant trial (randomising NAC) presented medium‐term mental state data (n = 135). There was no significant difference between adjunctive antioxidants and placebo (MD ‐1.71 95% CI ‐7.55 to 4.13, <a href="./references#CD008919-fig-0010" title="">Analysis 1.7</a>). </p> </section> <section id="CD008919-sec-0159"> <h6 class="title">1.3.4 Mental state: 1d. General ‐ long‐term BPRS</h6> <p>Again, only one trial (randomising vitamin E) presented long‐term mental state data. There was no significant difference between adjunctive antioxidants and placebo (n = 104, MD 1.20 95% CI ‐2.47 to 4.87, <a href="./references#CD008919-fig-0011" title="">Analysis 1.8</a>). </p> </section> <section id="CD008919-sec-0160"> <h6 class="title">1.3.5 Mental state: 2a. Specific ‐ short‐term PANSS negative symptoms</h6> <p>Nine studies presented specific short‐term scores for negative symptoms using the PANSS. Overall, results showed no effect for antioxidants over placebo (9 RCTs, n = 653, MD ‐0.38, 95% CI ‐0.77 to 0.00) (<a href="./references#CD008919-fig-0012" title="">Analysis 1.9</a>). Significant levels of heterogeneity were found (i<sup>2</sup> = 79%) </p> <p>Data could be subgrouped into individual antioxidants.</p> <section id="CD008919-sec-0161"> <p><b>1.3.5.1 Selegiline</b></p> <p>In this subgroup we found three relevant trials (n = 111). There was a statistically significant difference between adjunctive antioxidants and placebo (standardised mean difference (SMD) ‐0.54 95% CI ‐1.76 to 0.68). This subgroup had important levels of heterogeneity (Chi<sup>2</sup> = 16.73; df = 2; P = 0.0; I<sup>2</sup> = 88%). </p> </section> <section id="CD008919-sec-0162"> <p><b>1.3.5.2 Allopurinol</b></p> <p>In this subgroup we found three relevant trials (n = 317). There was a statistically significant difference between adjunctive antioxidants and placebo (SMD ‐0.37 95% CI ‐0.98 to 0.23). This subgroup had important levels of heterogeneity (Chi<sup>2</sup> = 7.4; df = 2; P = 0.025; I<sup>2</sup> = 73%). </p> </section> <section id="CD008919-sec-0163"> <p><b>1.3.5.3 Ginkgo biloba</b></p> <p>In this subgroup we only found one relevant trial (n = 157) (<a href="./references#CD008919-bbs2-0022" title="ZhangWF , TanYL , ZhangXY , ChanRC , WuHR , ZhouDF . Extract of Ginkgo biloba treatment for tardive dyskinesia in schizophrenia: a randomized, double‐blind, placebo‐controlled trial. Journal of Clinical Psychiatry2011;72(5):615‐21. [PUBMED: 20868638] ZhangXY , ZhouDF , SuJM , ZhangPY . The effects of extract of ginkgo biloba added to haloperidol on superoxide dismutase in inpatients with chronic schizophrenia. Journal of Clinical Psychopharmacology2001;21(1):85‐8. ">Zhang 2011</a>). There was a statistically significant difference between adjunctive antioxidants and placebo (SMD ‐0.17 95% CI ‐0.49 to 0.14). </p> </section> <section id="CD008919-sec-0164"> <p><b>1.3.5.4 NAC</b></p> <p>In this subgroup we only found one relevant trial (n = 44) (<a href="./references#CD008919-bbs2-0013" title="FarokhniaM , AzarkolahA , AdinehfarF , Khodaie‐ArdakaniMR , HosseiniSM , YekehtazH , et al. N‐acetylcysteine as an adjunct to risperidone for treatment of negative symptoms in patients with chronic schizophrenia: a randomized, double‐blind, placebo‐controlled study. Clinical Neuropharmacology2013;36(6):185‐92. [PUBMED: 24201233] ">Farokhnia 2013</a>). There was a statistically significant difference between adjunctive antioxidants and placebo (SMD ‐1.10 95% CI ‐1.74 to ‐0.47). </p> </section> <section id="CD008919-sec-0165"> <p><b>1.3.5.5 DHEA</b></p> <p>In this subgroup we only found one relevant trial (n = 24) (<a href="./references#CD008919-bbs2-0018" title="RitsnerMS , GibelA , ShleiferT , BoguslavskyI , ZayedA , MaayanR , et al. Pregnenolone and dehydroepiandrosterone as an adjunctive treatment in schizophrenia and schizoaffective disorder: an 8‐week, double‐blind, randomized, controlled, 2‐center, parallel‐group trial. The Journal of Clinical Psychiatry2010;71(10):1351‐62. [PUBMED: 20584515] ">Ritsner 2010</a>). There was no significant difference between adjunctive antioxidants and placebo (SMD 0.63 95% CI ‐ 0.20 to 1.45,<a href="./references#CD008919-fig-0012" title="">Analysis 1.9</a>). </p> </section> </section> <section id="CD008919-sec-0166"> <h6 class="title">1.3.6. Mental state: 2b. Specific ‐ short‐term SANS negative</h6> <p>Three studies presented short‐term data for negative symptoms using the SANS scale. All three studies were assessing <i>Ginkgo biloba</i> compared with placebo. There was a statistically significant difference between the antioxidant <i>Ginkgo biloba</i> and placebo (3 RCTs, n = 667, MD ‐7.46 95% CI ‐12.46 to ‐2.46, <a href="./references#CD008919-fig-0013" title="">Analysis 1.10</a>). This subgroup had important levels of heterogeneity (Chi<sup>2</sup> = 8.32, df = 2 (P = 0.02); I² = 76%). </p> </section> <section id="CD008919-sec-0167"> <h6 class="title">1.3.7 Mental state: 2c. Specific ‐ medium‐term PANSS negative</h6> </section> <section id="CD008919-sec-0168"> <h6 class="title">1.11.1 NAC</h6> <p>Only one NAC trial (n = 135) presented medium‐term data for negative symptoms. There was a statistically significant difference between adjunctive antioxidants and placebo (MD ‐2.33 95% CI ‐4.24 to ‐0.42, <a href="./references#CD008919-fig-0014" title="">Analysis 1.11</a>). </p> </section> <section id="CD008919-sec-0169"> <h6 class="title">1.3.8 Mental state: 2d. Specific ‐ short‐term PANSS positive</h6> <p>Eight trials presented short‐term data for positive symptoms using the PANSS scale. No effect was found (8 RCTs, n = 611, MD ‐0.96 95% CI ‐2.50 to 0.58). Substantial levels of heterogeneity were found (I<sup>2</sup> = 83 %)(<a href="./references#CD008919-fig-0015" title="">Analysis 1.12</a>). </p> <p>Data could be subgrouped into individual antioxidants</p> <section id="CD008919-sec-0170"> <p><b>1.3.8.1 Selegiline</b></p> <p>In this subgroup we found two relevant trials (n = 71). There was no significant difference between adjunctive antioxidants and placebo (MD 0.57 95% CI ‐2.30 to 3.45). This subgroup had important levels of heterogeneity (Chi<sup>2</sup> = 9.23; df = 1; P = 0.002; I<sup>2</sup> = 89%). </p> </section> <section id="CD008919-sec-0171"> <p><b>1.3.8.2 Allopurinol</b></p> <p>In this subgroup we found three relevant trials (n = 317). There was no significant difference between adjunctive antioxidants and placebo (MD ‐3.55 95% CI ‐8.24 to 1.13). This subgroup had important levels of heterogeneity (Chi<sup>2</sup> = 18.02; df = 2; P = 0.0; I<sup>2</sup> = 89%). </p> </section> <section id="CD008919-sec-0172"> <p><b>1.3.8.3 Ginkgo biloba</b></p> <p>In this subgroup we only found one relevant trial (n = 157) (<a href="./references#CD008919-bbs2-0022" title="ZhangWF , TanYL , ZhangXY , ChanRC , WuHR , ZhouDF . Extract of Ginkgo biloba treatment for tardive dyskinesia in schizophrenia: a randomized, double‐blind, placebo‐controlled trial. Journal of Clinical Psychiatry2011;72(5):615‐21. [PUBMED: 20868638] ZhangXY , ZhouDF , SuJM , ZhangPY . The effects of extract of ginkgo biloba added to haloperidol on superoxide dismutase in inpatients with chronic schizophrenia. Journal of Clinical Psychopharmacology2001;21(1):85‐8. ">Zhang 2011</a>). There was a statistically significant difference between adjunctive antioxidants and placebo (MD ‐1.20 95% CI ‐2.31 to ‐0.09). </p> </section> <section id="CD008919-sec-0173"> <p><b>1.3.8.4 NAC</b></p> <p>In this subgroup we only found one relevant trial (n = 42) (<a href="./references#CD008919-bbs2-0013" title="FarokhniaM , AzarkolahA , AdinehfarF , Khodaie‐ArdakaniMR , HosseiniSM , YekehtazH , et al. N‐acetylcysteine as an adjunct to risperidone for treatment of negative symptoms in patients with chronic schizophrenia: a randomized, double‐blind, placebo‐controlled study. Clinical Neuropharmacology2013;36(6):185‐92. [PUBMED: 24201233] ">Farokhnia 2013</a>). There was no significant difference between adjunctive antioxidants and placebo (MD ‐1.14 95% CI ‐ 3.57 to 1.29). </p> </section> <section id="CD008919-sec-0174"> <p><b>1.3.8.5 DHEA</b></p> <p>In this subgroup we only found one relevant trial (n = 24) (<a href="./references#CD008919-bbs2-0018" title="RitsnerMS , GibelA , ShleiferT , BoguslavskyI , ZayedA , MaayanR , et al. Pregnenolone and dehydroepiandrosterone as an adjunctive treatment in schizophrenia and schizoaffective disorder: an 8‐week, double‐blind, randomized, controlled, 2‐center, parallel‐group trial. The Journal of Clinical Psychiatry2010;71(10):1351‐62. [PUBMED: 20584515] ">Ritsner 2010</a>). There was no significant difference between adjunctive antioxidants and placebo (MD 3.60 95% CI ‐ 1.30 to 8.50 ). </p> </section> </section> <section id="CD008919-sec-0175"> <h6 class="title">1.3.9 Mental state: 2e. Specific ‐ short‐term SAPS positive</h6> <p>Two <i>Ginkgo biloba</i> trials (n = 151) presented short‐term data using the SAPS positive. There was a statistically significant difference between adjunctive antioxidants and placebo (MD ‐5.06 95% CI ‐7.52 to ‐2.59, <a href="./references#CD008919-fig-0016" title="">Analysis 1.13</a>). </p> </section> <section id="CD008919-sec-0176"> <h6 class="title">1.3.10 Mental state: 2f. Specific ‐ medium‐term PANSS positive</h6> <section id="CD008919-sec-0177"> <p><b>1.3.10.1 NAC</b></p> <p>Only one NAC trial (n = 135) presented medium‐term positive mental state data (<a href="./references#CD008919-bbs2-0005" title="BerkM , CopolovD , DeanO , LuK , JeavonsS , SchapkaitzI , et al. N‐acetyl cysteine as a glutathione precursor for schizophrenia‐a double‐blind, randomized, placebo‐controlled trial. Biological Psychiatry2008;64(5):361‐8. ">Berk 2008b</a>). There was no significant difference between adjunctive antioxidants and placebo (MD 0.47 95% CI ‐1.43 to 2.37, <a href="./references#CD008919-fig-0017" title="">Analysis 1.14</a>). </p> </section> </section> </section> <section id="CD008919-sec-0178"> <h5 class="title">1.4 General functioning</h5> <section id="CD008919-sec-0179"> <h6 class="title">1.4.1 General functioning: 1a. General ‐ short‐term GAS total endpoint</h6> <p>Two small studies presented equivocal short‐term data for general functioning (2 RCTs, n = 52, MD ‐1.11 95% CI ‐8.07 to 5.86) (<a href="./references#CD008919-fig-0018" title="">Analysis 1.15</a>). </p> <p>Data could be subgrouped into individual antioxidants.</p> <section id="CD008919-sec-0180"> <p><b>1.4.1.1 Selegiline</b></p> <p>In this subgroup we only found one relevant trial (n = 28) (<a href="./references#CD008919-bbs2-0014" title="GoffDC , RenshawPF , SaridSegalO , DreyfussDA , AmicoET , CirauloDA . A placebo‐controlled trial of selegiline (L‐deprenyl) in the treatment of tardive dyskinesia. Biological Psychiatry1993;33(10):700‐6. [MEDLINE: 8102552] ">Goff 1993</a>). There was no significant difference between the antioxidant selegiline and placebo (MD 0.90 95% CI ‐3.25 to 5.05). </p> <p>1.4.1.2 DHEA<br/> Again, equivocal data were found for the antioxidant DHEA in one trial (n = 24, MD ‐7.40 95% CI ‐19.80 to 5.00) </p> </section> </section> <section id="CD008919-sec-0181"> <h6 class="title">1.4.2 General functioning: 1b. General ‐ medium‐term GAS total endpoint</h6> <p>One trial comparing NAC with placebo presented medium‐term general functioning data(<a href="./references#CD008919-bbs2-0005" title="BerkM , CopolovD , DeanO , LuK , JeavonsS , SchapkaitzI , et al. N‐acetyl cysteine as a glutathione precursor for schizophrenia‐a double‐blind, randomized, placebo‐controlled trial. Biological Psychiatry2008;64(5):361‐8. ">Berk 2008b</a>). There was no significant difference between adjunctive NAC and placebo (n = 135, MD 2.84 95% CI ‐2.09 to 7.77 ) (<a href="./references#CD008919-fig-0019" title="">Analysis 1.16</a>). </p> </section> <section id="CD008919-sec-0182"> <h6 class="title">1.4.3 General functioning; 1c. General ‐ long‐term GAS total endpoint</h6> <p>In this subgroup we only found one relevant trial (n = 104) (<a href="./references#CD008919-bbs2-0002" title="AdlerLA , RotrosenJ , EdsonR , LavoriP , LohrJ , HitzemannR , et al. Vitamin E treatment for tardive dyskinesia. Archives of General Psychiatry1999;56(9):836‐41. [MEDLINE: 12892048] ">Adler 1999</a>). There was no significant difference between adjunctive vitamin E and placebo (MD 0.10 95% CI ‐5.60 to 5.80) (<a href="./references#CD008919-fig-0020" title="">Analysis 1.17</a>). </p> </section> </section> <section id="CD008919-sec-0183"> <h5 class="title">1.5 Adverse effects:</h5> <p>Adverse effects were usually not reported in a usable way in most trials, with the exceptions of <a href="./references#CD008919-bbs2-0003" title="AkhondzadehS , SafarcheratiA , AminiH . Beneficial antipsychotic effects of allopurinol as add‐on therapy for schizophrenia: a double blind, randomized and placebo controlled trial. Progress in Neuro‐Psychopharmacology &amp; Biological Psychiatry2005;29(2):253‐9. [PUBMED: 15694232] ">Akhondzadeh 2005</a>; <a href="./references#CD008919-bbs2-0004" title="AmiriA , NoorbalaAA , NejatisafaAA , GhoreishiA , DerakhshanMK , Khodaie‐ArdakaniMR , et al. Efficacy of selegiline add on therapy to risperidone in the treatment of the negative symptoms of schizophrenia: a double‐blind randomized placebo‐controlled study. Human Psychopharmacology2008;23(2):79‐86. [MEDLINE: 17972359] ">Amiri 2008</a>; <a href="./references#CD008919-bbs2-0005" title="BerkM , CopolovD , DeanO , LuK , JeavonsS , SchapkaitzI , et al. N‐acetyl cysteine as a glutathione precursor for schizophrenia‐a double‐blind, randomized, placebo‐controlled trial. Biological Psychiatry2008;64(5):361‐8. ">Berk 2008b</a>; <a href="./references#CD008919-bbs2-0008" title="BrunsteinMG , GhisolfiES , RamosFL , LaraDR . A clinical trial of adjuvant allopurinol therapy for moderately refractory schizophrenia. Journal of Clinical Psychiatry2005;66(2):213‐9. [PUBMED: 15705007] ">Brunstein 2005</a>; <a href="./references#CD008919-bbs2-0010" title="DickersonFB , StallingsCR , OrigoniAE , SullensA , KhushalaniS , SandsonN , et al. A double‐blind trial of adjunctive allopurinol for schizophrenia. Schizophrenia Research2009;109(1‐3):66‐9. [PUBMED: 19195842] ">Dickerson 2009</a>; and <a href="./references#CD008919-bbs2-0020" title="ZhangXY , ZhouDF , ZhangPY , WuGY , SuJM , CaoLY . A double‐blind, placebo‐controlled trial of extract of Ginkgo biloba added to haloperidol in treatment‐resistant patients with schizophrenia. Journal of Clinical Psychiatry2001;62(11):878‐83. [PUBMED: 11775047] ">Zhang 2001a</a>. These trials reported different measures of adverse effects, including specific adverse effects, serious adverse effects and scale data. See <a href="./references#CD008919-fig-0021" title="">Analysis 1.18</a>; <a href="./references#CD008919-fig-0022" title="">Analysis 1.19</a>; <a href="./references#CD008919-fig-0023" title="">Analysis 1.20</a>. </p> <section id="CD008919-sec-0184"> <h6 class="title">1.5.1 Serious adverse effects (any time point)</h6> <section id="CD008919-sec-0185"> <p><b>1.5.1.1 Any 'serious' adverse effect</b></p> <p>Three relevant trials recorded 'any serious adverse effect) (n = 234). There was no significant difference between adjunctive antioxidants and placebo (3 RCTS, n = 234, RR 0.65 95% CI 0.19 to 2.27). </p> </section> <section id="CD008919-sec-0186"> <p><b>1.5.1.2 Myocardial infarction</b></p> <p>In this subgroup we only found one relevant trial (n = 59) (<a href="./references#CD008919-bbs2-0010" title="DickersonFB , StallingsCR , OrigoniAE , SullensA , KhushalaniS , SandsonN , et al. A double‐blind trial of adjunctive allopurinol for schizophrenia. Schizophrenia Research2009;109(1‐3):66‐9. [PUBMED: 19195842] ">Dickerson 2009</a>). There was no significant difference between adjunctive antioxidants and placebo (RR 2.72 95% CI 0.12 to 64.14). </p> </section> <section id="CD008919-sec-0187"> <p><b>1.5.1.3 Neutropenia</b></p> <p>In this subgroup we only found one relevant trial (n = 59) (<a href="./references#CD008919-bbs2-0010" title="DickersonFB , StallingsCR , OrigoniAE , SullensA , KhushalaniS , SandsonN , et al. A double‐blind trial of adjunctive allopurinol for schizophrenia. Schizophrenia Research2009;109(1‐3):66‐9. [PUBMED: 19195842] ">Dickerson 2009</a>). There was no significant difference between adjunctive antioxidants and placebo (RR 0.30 95% CI 0.01 to 7.13). </p> </section> <section id="CD008919-sec-0188"> <p><b>1.5.1.4 Pneumonia</b></p> <p>In this subgroup we found two relevant trials (n = 94). There was no significant difference between adjunctive antioxidants and placebo (RR 2.78 95% CI 0.30 to 25.75) </p> </section> <section id="CD008919-sec-0189"> <p><b>1.5.1.5 Seizure</b></p> <p>In this subgroup we only found one relevant trial (n = 35) (<a href="./references#CD008919-bbs2-0008" title="BrunsteinMG , GhisolfiES , RamosFL , LaraDR . A clinical trial of adjuvant allopurinol therapy for moderately refractory schizophrenia. Journal of Clinical Psychiatry2005;66(2):213‐9. [PUBMED: 15705007] ">Brunstein 2005</a>). There was no significant difference between adjunctive antioxidants and placebo (RR 0.32 95% CI 0.01 to 7.26, <a href="./references#CD008919-fig-0021" title="">Analysis 1.18</a>). </p> </section> </section> <section id="CD008919-sec-0190"> <h6 class="title">1.5.2 Adverse effects 2. Various ‐ less 'serious'</h6> <section id="CD008919-sec-0191"> <p><b>1.5.2.1 Allergy ‐ rash or other dermatological problems</b></p> <p>In this subgroup we found four relevant trials (n = 280). There was no significant difference between adjunctive antioxidants and placebo (RR 1.06 95% CI 0.61 to 1.84). </p> </section> <section id="CD008919-sec-0192"> <p><b>1.5.2.2 Cardiovascular ‐ dizziness</b></p> <p>In this subgroup we found two relevant trials (n = 82) (<a href="./references#CD008919-bbs2-0004" title="AmiriA , NoorbalaAA , NejatisafaAA , GhoreishiA , DerakhshanMK , Khodaie‐ArdakaniMR , et al. Efficacy of selegiline add on therapy to risperidone in the treatment of the negative symptoms of schizophrenia: a double‐blind randomized placebo‐controlled study. Human Psychopharmacology2008;23(2):79‐86. [MEDLINE: 17972359] ">Amiri 2008</a>; <a href="./references#CD008919-bbs2-0013" title="FarokhniaM , AzarkolahA , AdinehfarF , Khodaie‐ArdakaniMR , HosseiniSM , YekehtazH , et al. N‐acetylcysteine as an adjunct to risperidone for treatment of negative symptoms in patients with chronic schizophrenia: a randomized, double‐blind, placebo‐controlled study. Clinical Neuropharmacology2013;36(6):185‐92. [PUBMED: 24201233] ">Farokhnia 2013</a>). There was no significant difference between adjunctive antioxidants and placebo (RR 1.17 95% CI 0.46 to 2.96). </p> </section> <section id="CD008919-sec-0193"> <p><b>1.5.2.3 Cardiovascular ‐ systemic hypertension</b></p> <p>IIn this subgroup we found two relevant trials (n = 82) (<a href="./references#CD008919-bbs2-0004" title="AmiriA , NoorbalaAA , NejatisafaAA , GhoreishiA , DerakhshanMK , Khodaie‐ArdakaniMR , et al. Efficacy of selegiline add on therapy to risperidone in the treatment of the negative symptoms of schizophrenia: a double‐blind randomized placebo‐controlled study. Human Psychopharmacology2008;23(2):79‐86. [MEDLINE: 17972359] ">Amiri 2008</a>; <a href="./references#CD008919-bbs2-0013" title="FarokhniaM , AzarkolahA , AdinehfarF , Khodaie‐ArdakaniMR , HosseiniSM , YekehtazH , et al. N‐acetylcysteine as an adjunct to risperidone for treatment of negative symptoms in patients with chronic schizophrenia: a randomized, double‐blind, placebo‐controlled study. Clinical Neuropharmacology2013;36(6):185‐92. [PUBMED: 24201233] ">Farokhnia 2013</a>). There was no significant difference between adjunctive antioxidants and placebo (RR 3.30 95% CI 0.99 to 11.04) </p> </section> <section id="CD008919-sec-0194"> <p><b>1.5.2.4 Central nervous system ‐ agitation</b></p> <p>In this subgroup we only found one relevant trial (n = 40) (<a href="./references#CD008919-bbs2-0004" title="AmiriA , NoorbalaAA , NejatisafaAA , GhoreishiA , DerakhshanMK , Khodaie‐ArdakaniMR , et al. Efficacy of selegiline add on therapy to risperidone in the treatment of the negative symptoms of schizophrenia: a double‐blind randomized placebo‐controlled study. Human Psychopharmacology2008;23(2):79‐86. [MEDLINE: 17972359] ">Amiri 2008</a>). There was no significant difference between adjunctive antioxidants and placebo (RR 2.50 95% CI 0.55 to 11.41, <a href="./references#CD008919-fig-0022" title="">Analysis 1.19</a>). </p> </section> <section id="CD008919-sec-0195"> <p><b>1.5.2.5 Central nervous system ‐ appetite increase</b></p> <p>In this subgroup we found three relevant trials (n = 128). There was no significant difference between adjunctive antioxidants and placebo (RR 1.00 95% CI 0.54 to 1.87, <a href="./references#CD008919-fig-0022" title="">Analysis 1.19</a>). </p> </section> <section id="CD008919-sec-0196"> <p><b>1.5.2.6 Central nervous system ‐ headache</b></p> <p>In this subgroup we found four relevant trials (n = 281). There was no significant difference between adjunctive antioxidants and placebo (RR 0.99 95% CI 0.60 to 1.64, <a href="./references#CD008919-fig-0022" title="">Analysis 1.19</a>). </p> </section> <section id="CD008919-sec-0197"> <p><b>1.5.2.7 Central nervous system ‐ insomnia</b></p> <p>In this subgroup we only found one relevant trial (n = 40) (<a href="./references#CD008919-bbs2-0004" title="AmiriA , NoorbalaAA , NejatisafaAA , GhoreishiA , DerakhshanMK , Khodaie‐ArdakaniMR , et al. Efficacy of selegiline add on therapy to risperidone in the treatment of the negative symptoms of schizophrenia: a double‐blind randomized placebo‐controlled study. Human Psychopharmacology2008;23(2):79‐86. [MEDLINE: 17972359] ">Amiri 2008</a>). There was no significant difference between adjunctive antioxidants and placebo (RR 2.50 95% CI 0.55 to 11.41, <a href="./references#CD008919-fig-0022" title="">Analysis 1.19</a>). </p> </section> <section id="CD008919-sec-0198"> <p><b>1.5.2.8 Central nervous system ‐ sedation</b></p> <p>In this subgroup we only found two relevant trials (n = 88) (<a href="./references#CD008919-bbs2-0003" title="AkhondzadehS , SafarcheratiA , AminiH . Beneficial antipsychotic effects of allopurinol as add‐on therapy for schizophrenia: a double blind, randomized and placebo controlled trial. Progress in Neuro‐Psychopharmacology &amp; Biological Psychiatry2005;29(2):253‐9. [PUBMED: 15694232] ">Akhondzadeh 2005</a>; <a href="./references#CD008919-bbs2-0013" title="FarokhniaM , AzarkolahA , AdinehfarF , Khodaie‐ArdakaniMR , HosseiniSM , YekehtazH , et al. N‐acetylcysteine as an adjunct to risperidone for treatment of negative symptoms in patients with chronic schizophrenia: a randomized, double‐blind, placebo‐controlled study. Clinical Neuropharmacology2013;36(6):185‐92. [PUBMED: 24201233] ">Farokhnia 2013</a>). There was no significant difference between adjunctive antioxidants and placebo (RR 1.34 95% CI 0.70 to 2.59, <a href="./references#CD008919-fig-0022" title="">Analysis 1.19</a>). </p> </section> <section id="CD008919-sec-0199"> <p><b>1.5.2.9 Central nervous system ‐ tremor</b></p> <p>In this subgroup we found two relevant trials (n = 86). There was no significant difference between adjunctive antioxidants and placebo (RR 0.70 95% CI 0.32 to 1.54, <a href="./references#CD008919-fig-0022" title="">Analysis 1.19</a>). </p> </section> <section id="CD008919-sec-0200"> <p><b>1.5.2.10 Gastrointestinal ‐ abdominal pain</b></p> <p>In this subgroup we only found one relevant trial (n = 40) (<a href="./references#CD008919-bbs2-0004" title="AmiriA , NoorbalaAA , NejatisafaAA , GhoreishiA , DerakhshanMK , Khodaie‐ArdakaniMR , et al. Efficacy of selegiline add on therapy to risperidone in the treatment of the negative symptoms of schizophrenia: a double‐blind randomized placebo‐controlled study. Human Psychopharmacology2008;23(2):79‐86. [MEDLINE: 17972359] ">Amiri 2008</a>). There was no significant difference between adjunctive antioxidants and placebo (RR 2.00 95% CI 0.41 to 9.71). </p> </section> <section id="CD008919-sec-0201"> <p><b>1.5.2.11 Gastrointestinal ‐ nausea</b></p> <p>In this subgroup we found four relevant trials (n = 281). There was no significant difference between adjunctive antioxidants and placebo (RR 1.04 95% CI 0.67 to 1.62). </p> </section> </section> <section id="CD008919-sec-0202"> <h6 class="title">1.5.3 Adverse effects: 3. Average scores ‐ endpoint total TESS</h6> <p>For this outcome, we only found one relevant trial (n = 109) (<a href="./references#CD008919-bbs2-0020" title="ZhangXY , ZhouDF , ZhangPY , WuGY , SuJM , CaoLY . A double‐blind, placebo‐controlled trial of extract of Ginkgo biloba added to haloperidol in treatment‐resistant patients with schizophrenia. Journal of Clinical Psychiatry2001;62(11):878‐83. [PUBMED: 11775047] ">Zhang 2001a</a>). There was a statistically significant difference between adjunctive antioxidants and placebo (MD ‐0.90 95% CI ‐2.34 to 0.54, <a href="./references#CD008919-fig-0023" title="">Analysis 1.20</a>). </p> </section> </section> <section id="CD008919-sec-0203"> <h5 class="title">1.6 Laboratory data (serum tests)</h5> <section id="CD008919-sec-0204"> <h6 class="title">1.6.1 MDA levels</h6> <p>In this subgroup we only found one relevant trial (n = 40) (<a href="./references#CD008919-bbs2-0009" title="DakhaleGN , KhanzodeSD , KhanzodeSS , SaojiA . Supplementation of vitamin C with atypical antipsychotics reduces oxidative stress and improves the outcome of schizophrenia. Psychopharmacology2005;182(4):494‐8. [MEDLINE: 16133138] ">Dakhale 2005</a>). There was a statistically significant difference between adjunctive antioxidants and placebo (SMD ‐2.18 95% CI ‐2.98 to ‐1.38, <a href="./references#CD008919-fig-0024" title="">Analysis 1.21</a>). </p> </section> <section id="CD008919-sec-0205"> <h6 class="title">1.6.2 SOD levels</h6> <p>In this subgroup we found two relevant trials (n = 123). There was no significant difference between adjunctive antioxidants and placebo (SMD 0.27 95% CI ‐0.56 to 1.10, <a href="./references#CD008919-fig-0024" title="">Analysis 1.21</a>). This subgroup had important levels of heterogeneity (Chi<sup>2</sup> = 4.66; df = 1; P = 0.031; I<sup>2</sup> = 79%). </p> </section> </section> </section> </section> </section> </section> <section class="discussion"> <div class="section-header section-collapse-header" id="CD008919-sec-0206" lang="en"> <h2 class="title section-collapse-title"> Discussion <i aria-hidden="true" class="fa fa-caret-up section-collapse-icon"></i> </h2> </div> <section class="discussion" lang="en"> <div class="section-header" id="CD008919-sec-0206"></div> <section id="CD008919-sec-0207"> <h3 class="title" id="CD008919-sec-0207">Summary of main results</h3> <p>With 22 trials, including over 2000 participants, studies testing adjunctive drugs with antioxidant potential are mostly preliminary. They are characterised by a short follow‐up period, mostly underpowered, do not offer data on the most clinically meaningful outcomes and are of a relatively low quality. Efficacy data on psychopathology scale scores is highly heterogenous, which can be explained by the use of drugs with a different pharmacological profile. Safety appeared not to be a concern for the studies, with most studies not reporting relevant adverse events at all. All these issues make it difficult to interpret the effect of adding an antioxidant to the standard treatment of schizophrenia. </p> <p>Regarding particular drugs, <i>Ginkgo biloba</i> is the most studied agent, overwhelmingly in Chinese participants, who were all inpatients. In these studies, ginkgo significantly reduced rating scale scores in the short term, mostly for positive symptoms. In the Chinese trials, there was also a lower rate of patients leaving the study early when compared with placebo. </p> <p>A very recent independently run, high quality and adequately powered trial comparing allopurinol with placebo (<a href="./references#CD008919-bbs2-0019" title="WeiserM , GershonAA , RubinsteinK , PetcuC , LadeaM , SimaD , et al. A randomized controlled trial of allopurinol vs. placebo added on to antipsychotics in patients with schizophrenia or schizoaffective disorder. Schizophrenia Research2012;138(1):35‐8. [PUBMED: 22483162] ">Weiser 2012</a>) changed an initial impression of benefit given by three previous small trials (<a href="./references#CD008919-bbs2-0003" title="AkhondzadehS , SafarcheratiA , AminiH . Beneficial antipsychotic effects of allopurinol as add‐on therapy for schizophrenia: a double blind, randomized and placebo controlled trial. Progress in Neuro‐Psychopharmacology &amp; Biological Psychiatry2005;29(2):253‐9. [PUBMED: 15694232] ">Akhondzadeh 2005</a>; <a href="./references#CD008919-bbs2-0008" title="BrunsteinMG , GhisolfiES , RamosFL , LaraDR . A clinical trial of adjuvant allopurinol therapy for moderately refractory schizophrenia. Journal of Clinical Psychiatry2005;66(2):213‐9. [PUBMED: 15705007] ">Brunstein 2005</a>; <a href="./references#CD008919-bbs2-0010" title="DickersonFB , StallingsCR , OrigoniAE , SullensA , KhushalaniS , SandsonN , et al. A double‐blind trial of adjunctive allopurinol for schizophrenia. Schizophrenia Research2009;109(1‐3):66‐9. [PUBMED: 19195842] ">Dickerson 2009</a>). Although allopurinol was as tolerable as placebo, at present there is no evidence for benefit in terms of improvement, total scale scores or positive or negative symptoms of schizophrenia. </p> <p>For selegiline, data from four fairly small trials and of low quality do not suggest any benefit in terms of scale scores. One study suggested worsening of positive symptoms (<a href="./references#CD008919-bbs2-0015" title="JungermanT , RabinowitzD , KleinE . Deprenyl augmentation for treating negative symptoms of schizophrenia: a double blind, controlled study. Journal of Clinical Psychopharmacology1999;19(6):522‐5. [MEDLINE: 10587287] ">Jungerman 1999</a>), and pooled data showed a trend towards lower tolerability for adjunctive selegiline. </p> <p>We identified two studies comparing adjunctive N‐acetyl cysteine (NAC) with placebo, one short term (<a href="./references#CD008919-bbs2-0013" title="FarokhniaM , AzarkolahA , AdinehfarF , Khodaie‐ArdakaniMR , HosseiniSM , YekehtazH , et al. N‐acetylcysteine as an adjunct to risperidone for treatment of negative symptoms in patients with chronic schizophrenia: a randomized, double‐blind, placebo‐controlled study. Clinical Neuropharmacology2013;36(6):185‐92. [PUBMED: 24201233] ">Farokhnia 2013</a>) and one medium term (<a href="./references#CD008919-bbs2-0005" title="BerkM , CopolovD , DeanO , LuK , JeavonsS , SchapkaitzI , et al. N‐acetyl cysteine as a glutathione precursor for schizophrenia‐a double‐blind, randomized, placebo‐controlled trial. Biological Psychiatry2008;64(5):361‐8. ">Berk 2008b</a>). The data indicate a benefit in terms of negative symptoms, with no difference in positive symptoms, functioning or tolerability. One small short‐term trial and two long‐term trials investigated vitamin E effects, albeit they were mostly interested in tardive dyskinesia outcomes (<a href="./references#CD008919-bbs2-0001" title="AdlerLA , PeselowE , RotrosenJ , DuncanE , LeeM , RosenthalM , et al. Vitamin E treatment of tardive dyskinesia. American Journal of Psychiatry1993;150(9):1405‐7. Adler LA , EdsonR , LavoriP , PeselowE , DuncanE , RosenthalM , et al. Long‐term treatment effects of vitamin E for tardive dyskinesia. Biological Psychiatry 1998;15:868‐72. ">Adler 1993a</a>; <a href="./references#CD008919-bbs2-0002" title="AdlerLA , RotrosenJ , EdsonR , LavoriP , LohrJ , HitzemannR , et al. Vitamin E treatment for tardive dyskinesia. Archives of General Psychiatry1999;56(9):836‐41. [MEDLINE: 12892048] ">Adler 1999</a>; <a href="./references#CD008919-bbs2-0011" title="DorevitchA , KalianM , ShlafmanM , LernerV . Treatment of long‐term tardive dyskinesia with vitamin E. Biological Psychiatry1997;41(1):114‐6. [MEDLINE: 8988802] ">Dorevitch 1997a</a>). They were not able to establish meaningful differences between adjunctive vitamin E and placebo in terms of symptoms of tolerability. One small trial showed a very large benefit for adjunctive vitamin C over placebo in terms of total psychopathology scores (<a href="./references#CD008919-bbs2-0009" title="DakhaleGN , KhanzodeSD , KhanzodeSS , SaojiA . Supplementation of vitamin C with atypical antipsychotics reduces oxidative stress and improves the outcome of schizophrenia. Psychopharmacology2005;182(4):494‐8. [MEDLINE: 16133138] ">Dakhale 2005</a>). </p> </section> <section id="CD008919-sec-0208"> <h3 class="title" id="CD008919-sec-0208">Overall completeness and applicability of evidence</h3> <section id="CD008919-sec-0209"> <h4 class="title">1. Completeness</h4> <p>Albeit we were able to identify a number of trials, with two trials being appreciably larger than the rest (<a href="./references#CD008919-bbs2-0017" title="LuoHC , ShenYC , MengFQ . Therapeutic effect of shuxuening combining neuroleptics for the treatment of chronic schizophrenia‐‐a double blind study. Zhongguo Zhong xi yi jie he za zhi Zhongguo Zhongxiyi jiehe zazhi = Chinese Journal of Integrated Traditional and Western Medicine / Zhongguo Zhong xi yi jie he xue hui, Zhongguo Zhong yi yan jiu yuan zhu ban1997;17(3):139‐42. ">Luo 1997</a>; <a href="./references#CD008919-bbs2-0019" title="WeiserM , GershonAA , RubinsteinK , PetcuC , LadeaM , SimaD , et al. A randomized controlled trial of allopurinol vs. placebo added on to antipsychotics in patients with schizophrenia or schizoaffective disorder. Schizophrenia Research2012;138(1):35‐8. [PUBMED: 22483162] ">Weiser 2012</a>), we were not able to identify our primary outcomes of interest. Most data pertained to rating scale scores, with hardly any measure of clinical improvement, functioning or quality of life. </p> </section> <section id="CD008919-sec-0210"> <h4 class="title">2. Applicability</h4> <p>Trials recruited both inpatients and outpatients who would be recognisable in everyday care. All trials in China using adjunctive ginkgo, however, were conducted exclusively in inpatients. The interventions are accessible. Outcomes, nonetheless, were wanting in clinical applicability. </p> </section> </section> <section id="CD008919-sec-0211"> <h3 class="title" id="CD008919-sec-0211">Quality of the evidence</h3> <p>Most trials included were very small and underpowered, with an overall poor quality of reporting. Some data were highly heterogenous. There was a recent trend, however, for better standards of reporting (for instance, see <a href="./references#CD008919-bbs2-0005" title="BerkM , CopolovD , DeanO , LuK , JeavonsS , SchapkaitzI , et al. N‐acetyl cysteine as a glutathione precursor for schizophrenia‐a double‐blind, randomized, placebo‐controlled trial. Biological Psychiatry2008;64(5):361‐8. ">Berk 2008b</a>; <a href="./references#CD008919-bbs2-0021" title="ZhangXY , ZhouDF , CaoLY , XuCQ , Chen daC , WuGY . The effect of vitamin e treatment on tardive dyskinesia and blood superoxide dismutase: a double‐blind placebo‐controlled trial. Journal of Clinical Psychopharmacology2004;24(1):83‐6. [MEDLINE: 14709952] ">Zhang 2004</a>; <a href="./references#CD008919-bbs2-0022" title="ZhangWF , TanYL , ZhangXY , ChanRC , WuHR , ZhouDF . Extract of Ginkgo biloba treatment for tardive dyskinesia in schizophrenia: a randomized, double‐blind, placebo‐controlled trial. Journal of Clinical Psychiatry2011;72(5):615‐21. [PUBMED: 20868638] ZhangXY , ZhouDF , SuJM , ZhangPY . The effects of extract of ginkgo biloba added to haloperidol on superoxide dismutase in inpatients with chronic schizophrenia. Journal of Clinical Psychopharmacology2001;21(1):85‐8. ">Zhang 2011</a>). The largest trial by far (<a href="./references#CD008919-bbs2-0017" title="LuoHC , ShenYC , MengFQ . Therapeutic effect of shuxuening combining neuroleptics for the treatment of chronic schizophrenia‐‐a double blind study. Zhongguo Zhong xi yi jie he za zhi Zhongguo Zhongxiyi jiehe zazhi = Chinese Journal of Integrated Traditional and Western Medicine / Zhongguo Zhong xi yi jie he xue hui, Zhongguo Zhong yi yan jiu yuan zhu ban1997;17(3):139‐42. ">Luo 1997</a>), however, did not report allocation concealment. Grading of the quality of evidence can be seen in the <a href="./full#CD008919-tbl-0001">summary of findings Table for the main comparison</a>. </p> </section> <section id="CD008919-sec-0212"> <h3 class="title" id="CD008919-sec-0212">Potential biases in the review process</h3> <section id="CD008919-sec-0213"> <h4 class="title">1. Missing studies</h4> <p>We made a significant effort to identify relevant trials. However, these are small studies generally and it is likely that we have failed to identify other studies of limited power. A few studies were reported only in abstract form and we were not able to obtain data from the authors. We were able to obtain unpublished data for two studies (<a href="./references#CD008919-bbs2-0005" title="BerkM , CopolovD , DeanO , LuK , JeavonsS , SchapkaitzI , et al. N‐acetyl cysteine as a glutathione precursor for schizophrenia‐a double‐blind, randomized, placebo‐controlled trial. Biological Psychiatry2008;64(5):361‐8. ">Berk 2008b</a>; <a href="./references#CD008919-bbs2-0007" title="BordbarMR , AbdollahianE , HojjatK , SamaricA . Effects of selegiline on negative symptoms in schizophrenia: A double‐blind clinical trial. Iranian Journal of Psychiatry and Clinical Psychology2008;14(2):131‐9. ">Bordbar 2008</a>), and for two Chinese papers (<a href="./references#CD008919-bbs2-0017" title="LuoHC , ShenYC , MengFQ . Therapeutic effect of shuxuening combining neuroleptics for the treatment of chronic schizophrenia‐‐a double blind study. Zhongguo Zhong xi yi jie he za zhi Zhongguo Zhongxiyi jiehe zazhi = Chinese Journal of Integrated Traditional and Western Medicine / Zhongguo Zhong xi yi jie he xue hui, Zhongguo Zhong yi yan jiu yuan zhu ban1997;17(3):139‐42. ">Luo 1997</a>; <a href="./references#CD008919-bbs2-0046" title="XuX , JiY , HeM . The efficacy of Ginkgo biloba tablet inadjuvant treatment of schizophrenia. Shanghai Medical andPharmaceutical Journal2002;23:456‐7. ">Xu 2002</a>); we were also able to obtain help from a native speaker. </p> </section> </section> <section id="CD008919-sec-0214"> <h3 class="title" id="CD008919-sec-0214">Agreements and disagreements with other studies or reviews</h3> <p>There is a published Cochrane review on vitamin E for tardive dyskinesia (TD) (<a href="./references#CD008919-bbs2-0081" title="Soares‐WeiserK , MaayanN , McGrathJ . Vitamin E for neuroleptic‐induced tardive dyskinesia. Cochrane Database of Systematic Reviews2011, Issue 2. [DOI: 10.1002/14651858.CD000209.pub2; PUBMED: 21328246] ">Soares‐Weiser 2011</a>). This was mostly interested in TD, not schizophrenia, and only on vitamin E, so there is no particular disagreement or overlap between the two reviews. </p> <p>One recent systematic review investigated the use of <i>Ginkgo biloba</i> for schizophrenia (<a href="./references#CD008919-bbs2-0080" title="SinghV , SinghSP , ChanK . Review and meta‐analysis of usage of ginkgo as an adjunct therapy in chronic schizophrenia. International Journal of Neuropsychopharmacology / official scientific journal of the Collegium Internationale Neuropsychopharmacologicum (CINP)2010;13(2):257‐71. [PUBMED: 19775502] ">Singh 2010</a>). This review had a more liberal approach to inclusion (it included one trial that did not use a placebo comparison and an open‐label trial). The direction of results are generally the same and the authors conclude more data are needed to disentangle ginkgo's pharmacological properties. </p> </section> </section> </section> <div class="figures-list"> <div class="figure" id="CD008919-fig-0001"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD008919.pub2/media/CDSR/CD008919/urn:x-wiley:14651858:media:CD008919:CD008919-AFig-FIG01" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD008919.pub2/media/CDSR/CD008919/image_t/tCD008919-AFig-FIG01.png" target="_blank"><b></b></a></p> </div><img alt="'Risk of bias' graph: review authors' judgements about each risk of bias item presented as percentages across all included studies." data-id="CD008919-fig-0001" src="/cdsr/doi/10.1002/14651858.CD008919.pub2/media/CDSR/CD008919/image_n/nCD008919-AFig-FIG01.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Figure 1</div> <div class="figure-caption"> <p>'Risk of bias' graph: review authors' judgements about each risk of bias item presented as percentages across all included studies. </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD008919.pub2/full#CD008919-fig-0001">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD008919.pub2/media/CDSR/CD008919/image_n/nCD008919-AFig-FIG01.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD008919-fig-0002"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD008919.pub2/media/CDSR/CD008919/urn:x-wiley:14651858:media:CD008919:CD008919-AFig-FIG02" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD008919.pub2/media/CDSR/CD008919/image_t/tCD008919-AFig-FIG02.png" target="_blank"><b></b></a></p> </div><img alt="'Risk of bias' summary: review authors' judgements about each risk of bias item for each included study." data-id="CD008919-fig-0002" src="/cdsr/doi/10.1002/14651858.CD008919.pub2/media/CDSR/CD008919/image_n/nCD008919-AFig-FIG02.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Figure 2</div> <div class="figure-caption"> <p>'Risk of bias' summary: review authors' judgements about each risk of bias item for each included study. </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD008919.pub2/full#CD008919-fig-0002">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD008919.pub2/media/CDSR/CD008919/image_n/nCD008919-AFig-FIG02.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD008919-fig-0003"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD008919.pub2/media/CDSR/CD008919/urn:x-wiley:14651858:media:CD008919:CD008919-AFig-FIG03" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD008919.pub2/media/CDSR/CD008919/image_t/tCD008919-AFig-FIG03.png" target="_blank"><b></b></a></p> </div><img alt="Study flow diagram." data-id="CD008919-fig-0003" src="/cdsr/doi/10.1002/14651858.CD008919.pub2/media/CDSR/CD008919/image_n/nCD008919-AFig-FIG03.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Figure 3</div> <div class="figure-caption"> <p>Study flow diagram.</p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD008919.pub2/full#CD008919-fig-0003">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD008919.pub2/media/CDSR/CD008919/image_n/nCD008919-AFig-FIG03.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD008919-fig-0004"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD008919.pub2/media/CDSR/CD008919/urn:x-wiley:14651858:media:CD008919:CD008919-CMP-001-01" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD008919.pub2/media/CDSR/CD008919/image_t/tCD008919-CMP-001-01.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 1 ADJUNCTIVE ANTIOXIDANTS versus PLACEBO, Outcome 1 Global state: No clinically important response (20% improvement PANSS)." data-id="CD008919-fig-0004" src="/cdsr/doi/10.1002/14651858.CD008919.pub2/media/CDSR/CD008919/image_n/nCD008919-CMP-001-01.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 1.1</div> <div class="figure-caption"> <p>Comparison 1 ADJUNCTIVE ANTIOXIDANTS versus PLACEBO, Outcome 1 Global state: No clinically important response (20% improvement PANSS). </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD008919.pub2/references#CD008919-fig-0004">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD008919.pub2/media/CDSR/CD008919/image_n/nCD008919-CMP-001-01.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD008919-fig-0005"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD008919.pub2/media/CDSR/CD008919/urn:x-wiley:14651858:media:CD008919:CD008919-CMP-001-02" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD008919.pub2/media/CDSR/CD008919/image_t/tCD008919-CMP-001-02.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 1 ADJUNCTIVE ANTIOXIDANTS versus PLACEBO, Outcome 2 Leaving the study early: 1a. Short term." data-id="CD008919-fig-0005" src="/cdsr/doi/10.1002/14651858.CD008919.pub2/media/CDSR/CD008919/image_n/nCD008919-CMP-001-02.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 1.2</div> <div class="figure-caption"> <p>Comparison 1 ADJUNCTIVE ANTIOXIDANTS versus PLACEBO, Outcome 2 Leaving the study early: 1a. Short term. </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD008919.pub2/references#CD008919-fig-0005">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD008919.pub2/media/CDSR/CD008919/image_n/nCD008919-CMP-001-02.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD008919-fig-0006"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD008919.pub2/media/CDSR/CD008919/urn:x-wiley:14651858:media:CD008919:CD008919-CMP-001-03" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD008919.pub2/media/CDSR/CD008919/image_t/tCD008919-CMP-001-03.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 1 ADJUNCTIVE ANTIOXIDANTS versus PLACEBO, Outcome 3 Leaving the study early: 1b. Medium term." data-id="CD008919-fig-0006" src="/cdsr/doi/10.1002/14651858.CD008919.pub2/media/CDSR/CD008919/image_n/nCD008919-CMP-001-03.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 1.3</div> <div class="figure-caption"> <p>Comparison 1 ADJUNCTIVE ANTIOXIDANTS versus PLACEBO, Outcome 3 Leaving the study early: 1b. Medium term. </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD008919.pub2/references#CD008919-fig-0006">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD008919.pub2/media/CDSR/CD008919/image_n/nCD008919-CMP-001-03.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD008919-fig-0007"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD008919.pub2/media/CDSR/CD008919/urn:x-wiley:14651858:media:CD008919:CD008919-CMP-001-04" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD008919.pub2/media/CDSR/CD008919/image_t/tCD008919-CMP-001-04.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 1 ADJUNCTIVE ANTIOXIDANTS versus PLACEBO, Outcome 4 Leaving the study early: 1c. Long term." data-id="CD008919-fig-0007" src="/cdsr/doi/10.1002/14651858.CD008919.pub2/media/CDSR/CD008919/image_n/nCD008919-CMP-001-04.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 1.4</div> <div class="figure-caption"> <p>Comparison 1 ADJUNCTIVE ANTIOXIDANTS versus PLACEBO, Outcome 4 Leaving the study early: 1c. Long term. </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD008919.pub2/references#CD008919-fig-0007">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD008919.pub2/media/CDSR/CD008919/image_n/nCD008919-CMP-001-04.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD008919-fig-0008"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD008919.pub2/media/CDSR/CD008919/urn:x-wiley:14651858:media:CD008919:CD008919-CMP-001-05" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD008919.pub2/media/CDSR/CD008919/image_t/tCD008919-CMP-001-05.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 1 ADJUNCTIVE ANTIOXIDANTS versus PLACEBO, Outcome 5 Mental state: 1a. General ‐ average overall endpoint score ‐ short term (BPRS total, high = worse)." data-id="CD008919-fig-0008" src="/cdsr/doi/10.1002/14651858.CD008919.pub2/media/CDSR/CD008919/image_n/nCD008919-CMP-001-05.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 1.5</div> <div class="figure-caption"> <p>Comparison 1 ADJUNCTIVE ANTIOXIDANTS versus PLACEBO, Outcome 5 Mental state: 1a. General ‐ average overall endpoint score ‐ short term (BPRS total, high = worse). </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD008919.pub2/references#CD008919-fig-0008">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD008919.pub2/media/CDSR/CD008919/image_n/nCD008919-CMP-001-05.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD008919-fig-0009"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD008919.pub2/media/CDSR/CD008919/urn:x-wiley:14651858:media:CD008919:CD008919-CMP-001-06" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD008919.pub2/media/CDSR/CD008919/image_t/tCD008919-CMP-001-06.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 1 ADJUNCTIVE ANTIOXIDANTS versus PLACEBO, Outcome 6 Mental state: 1b. General ‐ average overall endpoint score ‐ short term (PANSS total, high = worse)." data-id="CD008919-fig-0009" src="/cdsr/doi/10.1002/14651858.CD008919.pub2/media/CDSR/CD008919/image_n/nCD008919-CMP-001-06.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 1.6</div> <div class="figure-caption"> <p>Comparison 1 ADJUNCTIVE ANTIOXIDANTS versus PLACEBO, Outcome 6 Mental state: 1b. General ‐ average overall endpoint score ‐ short term (PANSS total, high = worse). </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD008919.pub2/references#CD008919-fig-0009">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD008919.pub2/media/CDSR/CD008919/image_n/nCD008919-CMP-001-06.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD008919-fig-0010"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD008919.pub2/media/CDSR/CD008919/urn:x-wiley:14651858:media:CD008919:CD008919-CMP-001-07" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD008919.pub2/media/CDSR/CD008919/image_t/tCD008919-CMP-001-07.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 1 ADJUNCTIVE ANTIOXIDANTS versus PLACEBO, Outcome 7 Mental state: 1c. General ‐ average overall endpoint score ‐ medium term (PANSS total, high = worse)." data-id="CD008919-fig-0010" src="/cdsr/doi/10.1002/14651858.CD008919.pub2/media/CDSR/CD008919/image_n/nCD008919-CMP-001-07.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 1.7</div> <div class="figure-caption"> <p>Comparison 1 ADJUNCTIVE ANTIOXIDANTS versus PLACEBO, Outcome 7 Mental state: 1c. General ‐ average overall endpoint score ‐ medium term (PANSS total, high = worse). </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD008919.pub2/references#CD008919-fig-0010">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD008919.pub2/media/CDSR/CD008919/image_n/nCD008919-CMP-001-07.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD008919-fig-0011"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD008919.pub2/media/CDSR/CD008919/urn:x-wiley:14651858:media:CD008919:CD008919-CMP-001-08" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD008919.pub2/media/CDSR/CD008919/image_t/tCD008919-CMP-001-08.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 1 ADJUNCTIVE ANTIOXIDANTS versus PLACEBO, Outcome 8 Mental state: 1d. General ‐ average overall endpoint score ‐ long term (BPRS total, high = worse)." data-id="CD008919-fig-0011" src="/cdsr/doi/10.1002/14651858.CD008919.pub2/media/CDSR/CD008919/image_n/nCD008919-CMP-001-08.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 1.8</div> <div class="figure-caption"> <p>Comparison 1 ADJUNCTIVE ANTIOXIDANTS versus PLACEBO, Outcome 8 Mental state: 1d. General ‐ average overall endpoint score ‐ long term (BPRS total, high = worse). </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD008919.pub2/references#CD008919-fig-0011">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD008919.pub2/media/CDSR/CD008919/image_n/nCD008919-CMP-001-08.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD008919-fig-0012"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD008919.pub2/media/CDSR/CD008919/urn:x-wiley:14651858:media:CD008919:CD008919-CMP-001-09" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD008919.pub2/media/CDSR/CD008919/image_t/tCD008919-CMP-001-09.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 1 ADJUNCTIVE ANTIOXIDANTS versus PLACEBO, Outcome 9 Mental state: 2a. Specific ‐ average negative symptom endpoint score ‐ short term (PANSS negative, high = worse)." data-id="CD008919-fig-0012" src="/cdsr/doi/10.1002/14651858.CD008919.pub2/media/CDSR/CD008919/image_n/nCD008919-CMP-001-09.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 1.9</div> <div class="figure-caption"> <p>Comparison 1 ADJUNCTIVE ANTIOXIDANTS versus PLACEBO, Outcome 9 Mental state: 2a. Specific ‐ average negative symptom endpoint score ‐ short term (PANSS negative, high = worse). </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD008919.pub2/references#CD008919-fig-0012">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD008919.pub2/media/CDSR/CD008919/image_n/nCD008919-CMP-001-09.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD008919-fig-0013"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD008919.pub2/media/CDSR/CD008919/urn:x-wiley:14651858:media:CD008919:CD008919-CMP-001-10" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD008919.pub2/media/CDSR/CD008919/image_t/tCD008919-CMP-001-10.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 1 ADJUNCTIVE ANTIOXIDANTS versus PLACEBO, Outcome 10 Mental state: 2b. Specific ‐ average negative symptom endpoint score ‐ short term (SANS, high = worse)." data-id="CD008919-fig-0013" src="/cdsr/doi/10.1002/14651858.CD008919.pub2/media/CDSR/CD008919/image_n/nCD008919-CMP-001-10.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 1.10</div> <div class="figure-caption"> <p>Comparison 1 ADJUNCTIVE ANTIOXIDANTS versus PLACEBO, Outcome 10 Mental state: 2b. Specific ‐ average negative symptom endpoint score ‐ short term (SANS, high = worse). </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD008919.pub2/references#CD008919-fig-0013">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD008919.pub2/media/CDSR/CD008919/image_n/nCD008919-CMP-001-10.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD008919-fig-0014"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD008919.pub2/media/CDSR/CD008919/urn:x-wiley:14651858:media:CD008919:CD008919-CMP-001-11" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD008919.pub2/media/CDSR/CD008919/image_t/tCD008919-CMP-001-11.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 1 ADJUNCTIVE ANTIOXIDANTS versus PLACEBO, Outcome 11 Mental state: 2c. Specific ‐ average negative symptom endpoint score ‐ medium term (PANSS negative, high = worse)." data-id="CD008919-fig-0014" src="/cdsr/doi/10.1002/14651858.CD008919.pub2/media/CDSR/CD008919/image_n/nCD008919-CMP-001-11.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 1.11</div> <div class="figure-caption"> <p>Comparison 1 ADJUNCTIVE ANTIOXIDANTS versus PLACEBO, Outcome 11 Mental state: 2c. Specific ‐ average negative symptom endpoint score ‐ medium term (PANSS negative, high = worse). </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD008919.pub2/references#CD008919-fig-0014">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD008919.pub2/media/CDSR/CD008919/image_n/nCD008919-CMP-001-11.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD008919-fig-0015"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD008919.pub2/media/CDSR/CD008919/urn:x-wiley:14651858:media:CD008919:CD008919-CMP-001-12" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD008919.pub2/media/CDSR/CD008919/image_t/tCD008919-CMP-001-12.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 1 ADJUNCTIVE ANTIOXIDANTS versus PLACEBO, Outcome 12 Mental state: 2d. Specific ‐ average positive symptom endpoint score ‐ short term (PANSS positive, high = worse)." data-id="CD008919-fig-0015" src="/cdsr/doi/10.1002/14651858.CD008919.pub2/media/CDSR/CD008919/image_n/nCD008919-CMP-001-12.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 1.12</div> <div class="figure-caption"> <p>Comparison 1 ADJUNCTIVE ANTIOXIDANTS versus PLACEBO, Outcome 12 Mental state: 2d. Specific ‐ average positive symptom endpoint score ‐ short term (PANSS positive, high = worse). </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD008919.pub2/references#CD008919-fig-0015">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD008919.pub2/media/CDSR/CD008919/image_n/nCD008919-CMP-001-12.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD008919-fig-0016"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD008919.pub2/media/CDSR/CD008919/urn:x-wiley:14651858:media:CD008919:CD008919-CMP-001-13" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD008919.pub2/media/CDSR/CD008919/image_t/tCD008919-CMP-001-13.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 1 ADJUNCTIVE ANTIOXIDANTS versus PLACEBO, Outcome 13 Mental state: 2e. Specific ‐ average positive symptom endpoint score ‐ short term (SAPS, high = worse)." data-id="CD008919-fig-0016" src="/cdsr/doi/10.1002/14651858.CD008919.pub2/media/CDSR/CD008919/image_n/nCD008919-CMP-001-13.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 1.13</div> <div class="figure-caption"> <p>Comparison 1 ADJUNCTIVE ANTIOXIDANTS versus PLACEBO, Outcome 13 Mental state: 2e. Specific ‐ average positive symptom endpoint score ‐ short term (SAPS, high = worse). </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD008919.pub2/references#CD008919-fig-0016">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD008919.pub2/media/CDSR/CD008919/image_n/nCD008919-CMP-001-13.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD008919-fig-0017"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD008919.pub2/media/CDSR/CD008919/urn:x-wiley:14651858:media:CD008919:CD008919-CMP-001-14" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD008919.pub2/media/CDSR/CD008919/image_t/tCD008919-CMP-001-14.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 1 ADJUNCTIVE ANTIOXIDANTS versus PLACEBO, Outcome 14 Mental state: 2f. Secific ‐ average positive symptom endpoint score ‐ medium term (PANSS positive, high = worse)." data-id="CD008919-fig-0017" src="/cdsr/doi/10.1002/14651858.CD008919.pub2/media/CDSR/CD008919/image_n/nCD008919-CMP-001-14.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 1.14</div> <div class="figure-caption"> <p>Comparison 1 ADJUNCTIVE ANTIOXIDANTS versus PLACEBO, Outcome 14 Mental state: 2f. Secific ‐ average positive symptom endpoint score ‐ medium term (PANSS positive, high = worse). </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD008919.pub2/references#CD008919-fig-0017">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD008919.pub2/media/CDSR/CD008919/image_n/nCD008919-CMP-001-14.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD008919-fig-0018"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD008919.pub2/media/CDSR/CD008919/urn:x-wiley:14651858:media:CD008919:CD008919-CMP-001-15" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD008919.pub2/media/CDSR/CD008919/image_t/tCD008919-CMP-001-15.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 1 ADJUNCTIVE ANTIOXIDANTS versus PLACEBO, Outcome 15 General functioning: 1a. General ‐ average overall endpoint score ‐ short term (GAS total, high = worse)." data-id="CD008919-fig-0018" src="/cdsr/doi/10.1002/14651858.CD008919.pub2/media/CDSR/CD008919/image_n/nCD008919-CMP-001-15.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 1.15</div> <div class="figure-caption"> <p>Comparison 1 ADJUNCTIVE ANTIOXIDANTS versus PLACEBO, Outcome 15 General functioning: 1a. General ‐ average overall endpoint score ‐ short term (GAS total, high = worse). </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD008919.pub2/references#CD008919-fig-0018">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD008919.pub2/media/CDSR/CD008919/image_n/nCD008919-CMP-001-15.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD008919-fig-0019"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD008919.pub2/media/CDSR/CD008919/urn:x-wiley:14651858:media:CD008919:CD008919-CMP-001-16" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD008919.pub2/media/CDSR/CD008919/image_t/tCD008919-CMP-001-16.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 1 ADJUNCTIVE ANTIOXIDANTS versus PLACEBO, Outcome 16 General functioning: 1b. General ‐ average overall endpoint score ‐ medium term (GAS total, high = worse)." data-id="CD008919-fig-0019" src="/cdsr/doi/10.1002/14651858.CD008919.pub2/media/CDSR/CD008919/image_n/nCD008919-CMP-001-16.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 1.16</div> <div class="figure-caption"> <p>Comparison 1 ADJUNCTIVE ANTIOXIDANTS versus PLACEBO, Outcome 16 General functioning: 1b. General ‐ average overall endpoint score ‐ medium term (GAS total, high = worse). </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD008919.pub2/references#CD008919-fig-0019">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD008919.pub2/media/CDSR/CD008919/image_n/nCD008919-CMP-001-16.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD008919-fig-0020"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD008919.pub2/media/CDSR/CD008919/urn:x-wiley:14651858:media:CD008919:CD008919-CMP-001-17" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD008919.pub2/media/CDSR/CD008919/image_t/tCD008919-CMP-001-17.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 1 ADJUNCTIVE ANTIOXIDANTS versus PLACEBO, Outcome 17 General functioning: 1c. General ‐ average overall endpoint score ‐ long term (GAS total, high = worse)." data-id="CD008919-fig-0020" src="/cdsr/doi/10.1002/14651858.CD008919.pub2/media/CDSR/CD008919/image_n/nCD008919-CMP-001-17.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 1.17</div> <div class="figure-caption"> <p>Comparison 1 ADJUNCTIVE ANTIOXIDANTS versus PLACEBO, Outcome 17 General functioning: 1c. General ‐ average overall endpoint score ‐ long term (GAS total, high = worse). </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD008919.pub2/references#CD008919-fig-0020">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD008919.pub2/media/CDSR/CD008919/image_n/nCD008919-CMP-001-17.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD008919-fig-0021"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD008919.pub2/media/CDSR/CD008919/urn:x-wiley:14651858:media:CD008919:CD008919-CMP-001-18" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD008919.pub2/media/CDSR/CD008919/image_t/tCD008919-CMP-001-18.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 1 ADJUNCTIVE ANTIOXIDANTS versus PLACEBO, Outcome 18 Adverse effects: 1. Serious (any time point)." data-id="CD008919-fig-0021" src="/cdsr/doi/10.1002/14651858.CD008919.pub2/media/CDSR/CD008919/image_n/nCD008919-CMP-001-18.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 1.18</div> <div class="figure-caption"> <p>Comparison 1 ADJUNCTIVE ANTIOXIDANTS versus PLACEBO, Outcome 18 Adverse effects: 1. Serious (any time point). </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD008919.pub2/references#CD008919-fig-0021">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD008919.pub2/media/CDSR/CD008919/image_n/nCD008919-CMP-001-18.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD008919-fig-0022"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD008919.pub2/media/CDSR/CD008919/urn:x-wiley:14651858:media:CD008919:CD008919-CMP-001-19" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD008919.pub2/media/CDSR/CD008919/image_t/tCD008919-CMP-001-19.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 1 ADJUNCTIVE ANTIOXIDANTS versus PLACEBO, Outcome 19 Adverse effects: 2. Various ‐ less serious." data-id="CD008919-fig-0022" src="/cdsr/doi/10.1002/14651858.CD008919.pub2/media/CDSR/CD008919/image_n/nCD008919-CMP-001-19.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 1.19</div> <div class="figure-caption"> <p>Comparison 1 ADJUNCTIVE ANTIOXIDANTS versus PLACEBO, Outcome 19 Adverse effects: 2. Various ‐ less serious. </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD008919.pub2/references#CD008919-fig-0022">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD008919.pub2/media/CDSR/CD008919/image_n/nCD008919-CMP-001-19.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD008919-fig-0023"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD008919.pub2/media/CDSR/CD008919/urn:x-wiley:14651858:media:CD008919:CD008919-CMP-001-20" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD008919.pub2/media/CDSR/CD008919/image_t/tCD008919-CMP-001-20.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 1 ADJUNCTIVE ANTIOXIDANTS versus PLACEBO, Outcome 20 Adverse effects: 3. Average score (TESS endpoint, high = worse)." data-id="CD008919-fig-0023" src="/cdsr/doi/10.1002/14651858.CD008919.pub2/media/CDSR/CD008919/image_n/nCD008919-CMP-001-20.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 1.20</div> <div class="figure-caption"> <p>Comparison 1 ADJUNCTIVE ANTIOXIDANTS versus PLACEBO, Outcome 20 Adverse effects: 3. Average score (TESS endpoint, high = worse). </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD008919.pub2/references#CD008919-fig-0023">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD008919.pub2/media/CDSR/CD008919/image_n/nCD008919-CMP-001-20.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD008919-fig-0024"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD008919.pub2/media/CDSR/CD008919/urn:x-wiley:14651858:media:CD008919:CD008919-CMP-001-21" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD008919.pub2/media/CDSR/CD008919/image_t/tCD008919-CMP-001-21.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 1 ADJUNCTIVE ANTIOXIDANTS versus PLACEBO, Outcome 21 Laboratory data (serum tests) ‐ short term." data-id="CD008919-fig-0024" src="/cdsr/doi/10.1002/14651858.CD008919.pub2/media/CDSR/CD008919/image_n/nCD008919-CMP-001-21.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 1.21</div> <div class="figure-caption"> <p>Comparison 1 ADJUNCTIVE ANTIOXIDANTS versus PLACEBO, Outcome 21 Laboratory data (serum tests) ‐ short term. </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD008919.pub2/references#CD008919-fig-0024">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD008919.pub2/media/CDSR/CD008919/image_n/nCD008919-CMP-001-21.png" target="_blank">Open in new tab</a></div> </div> </div> <div class="tables-list"> <div class="table"> <table data-id="CD008919-tbl-0002"> <div class="table-heading"><span class="table-label">Table 1.</span> <span class="table-title">Suggested design of future trial</span></div> <tbody> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>Methods</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Allocation: centralised sequence generation with table of random numbers or computer‐generated code, stratified by severity of illness, sequence concealed till interventions assigned.<br/> Blinding: those recruiting and assigning participants, those assessing outcomes, all blind to allocated group, blinding could be tested.<br/> Duration: minimum of 24 weeks </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>Participants</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Diagnosis: schizophrenia, if operational criteria used these should be in the context of routine care.<br/> N = 450*.<br/> Age: adults.<br/> Sex: men and women.<br/> Setting: anywhere. </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>Interventions</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>1. Adjunctive placebo</p> <p>2. Adjunctive antioxidant (preferably <i>Ginkgo biloba</i> EGb or NAC) </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>Outcomes</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Quality of life: healthy days,** SF‐36***.<br/> Service outcomes: days in hospital, time attending psychiatric outpatient clinic.<br/> Satisfaction with care: patients/carers.<br/> Global state: CGI.***<br/> Mental state: CGI.<br/> Social functioning: to include occupational status.<br/> Adverse effects: including mortality.<br/> Economic data. </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>Notes</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>* size of study to detect a 10% difference in improvement with 80% certainty.<br/> ** Primary outcome.<br/> *** If scales are used to measure outcome then there should be binary cut off points, defined before study starts, of clinically important improvement. </p> </td> </tr> </tbody> <tfoot> <tr> <td colspan="2"> <div class="table-footnote"> <p>CGI ‐ Clinical Global Impression; NAC ‐ N‐acetyl cysteine; SF 36 ‐ Short form 36</p> </div> </td> </tr> </tfoot> </table> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="table-viewer-caption"> <div class="table-heading"><span class="table-label">Table 1.</span> <span class="table-title">Suggested design of future trial</span></div> </div> <div class="tools"><a class="tableList" href="/cdsr/doi/10.1002/14651858.CD008919.pub2/full#CD008919-tbl-0002">Navigate to table in review</a></div> </div> <div class="table"> <table class="summary-of-findings framed" data-id="CD008919-tbl-0001"> <div class="table-heading"><span class="table-label">Summary of findings for the main comparison.</span> <span class="table-title">Adjunctive antioxidants for schizophrenia versus placebo</span></div> <tbody> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="7" rowspan="1" valign=""> <p><b>Adjunctive antioxidants for schizophrenia</b> </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="7" rowspan="1" valign=""> <p><b>Patient or population:</b> people with schizophrenia<br/> <b>Settings:</b> Inpatients and outpatients<br/> <b>Intervention:</b> Adjunctive antioxidants </p> </td> </tr> <tr class="table-header separated"> <td align="left" class="table-header" colspan="1" rowspan="3" valign="top"> <p><b>Outcomes</b> </p> </td> <td align="left" class="table-tint table-highlight" colspan="2" rowspan="1" valign="top"> <p><b>Illustrative comparative risks* (95% CI)</b> </p> </td> <td align="left" class="table-header" colspan="1" rowspan="3" valign="top"> <p><b>Relative effect<br/> (95% CI)</b> </p> </td> <td align="left" class="table-header" colspan="1" rowspan="3" valign="top"> <p><b>No of Participants<br/> (studies)</b> </p> </td> <td align="left" class="table-header" colspan="1" rowspan="3" valign="top"> <p><b>Quality of the evidence<br/> (GRADE)</b> </p> </td> <td align="left" class="table-header" colspan="1" rowspan="3" valign="top"> <p><b>Comments</b> </p> </td> </tr> <tr class="table-header separated"> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>Assumed risk</b> </p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>Corresponding risk</b> </p> </td> </tr> <tr class="table-header separated"> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b> Control</b> </p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b> Adjunctive antioxidants</b> </p> </td> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="4" valign="top"> <p><b>Global state: improvement, short term</b> <br/> PANSS<br/> Follow‐up: 6 to 8 weeks </p> </td> <td align="" class="table-tint table-highlight" colspan="2" rowspan="1" valign=""> <p><b>Study population</b> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="4" valign="top"> <p><b>RR 0.77</b> <br/> (0.53 to 1.12) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="4" valign="top"> <p>229<br/> (3 studies) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="4" valign="top"> <p>⊕⊕⊝⊝<br/> <b>low</b><sup>1,2</sup> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="4" valign="top"> <p>‐</p> </td> </tr> <tr class="separated"> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>1000 per 1000</b> </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>690 per 1000</b> <br/> (360 to 1000) </p> </td> </tr> <tr class="separated"> <td align="" class="table-tint table-highlight" colspan="2" rowspan="1" valign=""> <p><b>Moderate</b> </p> </td> </tr> <tr class="separated"> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>1000 per 1000</b> </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>690 per 1000</b> <br/> (360 to 1000) </p> </td> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Total PANSS scores, short term</b> <br/> PANSS<br/> Follow‐up: 6 to 12 weeks </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"></td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>The mean total PANSS scores in the intervention groups was<br/> <b>6.0 lower</b> <br/> (10.53 lower to 1.65 lower) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"></td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>584<br/> (7 studies) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>⊕⊝⊝⊝<br/> <b>very low</b><sup>1,2,3</sup> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>‐</p> </td> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Total BPRS scores, short term</b> <br/> BPRS<br/> Follow‐up: 6 to 16 weeks </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"></td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>The mean total BPRS scores in the intervention groups was<br/> <b>3.2 lower</b> <br/> (5.63 lower to 0.78 lower) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"></td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>843<br/> (8 studies) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>⊕⊕⊝⊝<br/> <b>low</b><sup>1,3,4</sup> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>‐</p> </td> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>General functioning ‐ short term</b> <br/> GAS<br/> Follow‐up: 6 weeks </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"></td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>The mean general functioning ‐ short term in the intervention groups was<br/> <b>1.11 lower</b> <br/> (8.07 lower to 5.86 higher) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"></td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>52</p> <p>(2 studies)</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>⊕⊕⊝⊝<br/> <b>low</b><sup>1,5</sup> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>‐</p> </td> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>General functioning ‐ medium term</b> <br/> GAS<br/> Follow‐up: 24 weeks </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"></td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>The mean general functioning ‐ medium term in the intervention groups was<br/> <b>2.84 higher</b> <br/> (2.09 lower to 7.77 higher) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"></td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>135<br/> (1 study) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>⊕⊕⊕⊕<br/> <b>high</b> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>‐</p> </td> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="4" valign="top"> <p><b>Leaving the study early, short term</b> <br/> Follow‐up: 6 to 16 weeks </p> </td> <td align="" class="table-tint table-highlight" colspan="2" rowspan="1" valign=""> <p><b>Study population</b> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="4" valign="top"> <p><b>RR 0.73</b> <br/> (0.48 to 1.11) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="4" valign="top"> <p>1584<br/> (16 studies) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="4" valign="top"> <p>⊕⊕⊕⊝<br/> <b>moderate</b><sup>1,4</sup> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="4" valign="top"> <p>‐</p> </td> </tr> <tr class="separated"> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>96 per 1000</b> </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>72 per 1000</b> <br/> (39 to 132) </p> </td> </tr> <tr class="separated"> <td align="" class="table-tint table-highlight" colspan="2" rowspan="1" valign=""> <p><b>Moderate</b> </p> </td> </tr> <tr class="separated"> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>91 per 1000</b> </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>68 per 1000</b> <br/> (37 to 126) </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="4" valign="top"> <p><b>Adverse effects: 1. Serious (any time point) ‐ any serious adverse effect</b> <br/> Various methods </p> </td> <td align="" class="table-tint table-highlight" colspan="2" rowspan="1" valign=""> <p><b>Study population</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="4" valign="top"> <p><b>RR 0.65</b> <br/> (0.19 to 2.27) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="4" valign="top"> <p>234<br/> (3 studies) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="4" valign="top"> <p>⊕⊕⊝⊝<br/> <b>low</b><sup>1</sup> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="4" valign="top"> <p>‐</p> </td> </tr> <tr class="separated"> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign=""> <p><b>60 per 1000</b> </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign=""> <p><b>39 per 1000</b> <br/> (11 to 137) </p> </td> </tr> <tr class="separated"> <td align="" class="table-tint table-highlight" colspan="2" rowspan="1" valign=""> <p><b>Moderate</b> </p> </td> </tr> <tr class="separated"> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign=""> <p><b>59 per 1000</b> </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign=""> <p><b>38 per 1000</b> <br/> (11 to 134) </p> </td> </tr> </tbody> <tfoot> <tr> <td colspan="7"> <div class="table-footnote"> <p><sup>1</sup> Unclear process of allocation concealment in included studies<br/> <sup>2</sup> High heterogeneity<br/> <sup>3</sup> Difference in rating scale scores not necessarily reflects meaningful clinical change<br/> <sup>4</sup> Heterogeneity high, but reduced when results are grouped by specific agent tested<br/> <sup>5</sup> Very limited number of patients available </p> </div> </td> </tr> </tfoot> </table> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="table-viewer-caption"> <div class="table-heading"><span class="table-label">Summary of findings for the main comparison.</span> <span class="table-title">Adjunctive antioxidants for schizophrenia versus placebo</span></div> </div> <div class="tools"><a class="tableList" href="/cdsr/doi/10.1002/14651858.CD008919.pub2/full#CD008919-tbl-0001">Navigate to table in review</a></div> </div> <div class="table"> <table class="comparison" data-id="CD008919-tbl-0003"> <div class="table-heading"><span class="table-label">Comparison 1.</span> <span class="table-title">ADJUNCTIVE ANTIOXIDANTS versus PLACEBO</span></div> <thead> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>Outcome or subgroup title</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>No. of studies</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>No. of participants</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Statistical method</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Effect size</p> </td> </tr> </thead> <tbody> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">1 Global state: No clinically important response (20% improvement PANSS) <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>3</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>229</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.77 [0.53, 1.12]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>1.1 allopurinol ‐ short term</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>2</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>94</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.69 [0.36, 1.32]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>1.2 n‐acetyl cysteine ‐ medium term</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>135</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>1.01 [0.53, 1.92]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">2 Leaving the study early: 1a. Short term <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>16</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>1584</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.73 [0.48, 1.11]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>2.1 allopurinol</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>4</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>388</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.83 [0.55, 1.24]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>2.2 DHEA</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>32</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.6 [0.17, 2.10]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>2.3 ginkgo biloba</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>4</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>857</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.42 [0.17, 1.03]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>2.4 n‐acetyl cysteine</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>46</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>1.0 [0.15, 6.51]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>2.5 selegiline</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>3</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>153</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>5.22 [0.90, 30.31]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>2.6 vitamin C</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>40</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.25 [0.03, 2.05]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>2.7 vitamin E</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>2</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>68</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.97 [0.06, 14.48]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">3 Leaving the study early: 1b. Medium term <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>140</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.99 [0.67, 1.48]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>3.1 n‐acetyl cysteine</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>140</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.99 [0.67, 1.48]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">4 Leaving the study early: 1c. Long term <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>2</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>195</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.90 [0.59, 1.35]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>4.1 vitamin E</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>2</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>195</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.90 [0.59, 1.35]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">5 Mental state: 1a. General ‐ average overall endpoint score ‐ short term (BPRS total, high = worse) <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>8</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>843</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (IV, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>‐3.20 [‐5.63, ‐0.78]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>5.1 ginkgo biloba</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>3</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>663</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (IV, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>‐2.74 [‐5.29, ‐0.20]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>5.2 selegiline</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>3</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>111</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (IV, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>‐0.31 [‐4.03, 3.41]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>5.3 vitamin C</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>40</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (IV, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>‐9.66 [‐13.27, ‐6.05]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>5.4 vitamin E</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>29</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (IV, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>‐7.92 [‐17.20, 1.36]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">6 Mental state: 1b. General ‐ average overall endpoint score ‐ short term (PANSS total, high = worse) <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>7</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>584</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (IV, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>‐6.00 [‐10.35, ‐1.65]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>6.1 allopurinol</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>3</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>329</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (IV, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>‐6.91 [‐15.86, 2.04]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>6.2 ginkgo biloba</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>157</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (IV, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>‐3.30 [‐6.51, ‐0.09]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>6.3 selegiline</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>2</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>56</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (IV, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>‐2.97 [‐15.68, 9.74]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>6.4 n‐acetyl cysteine</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>42</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (IV, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>‐12.86 [‐19.82, ‐5.90]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">7 Mental state: 1c. General ‐ average overall endpoint score ‐ medium term (PANSS total, high = worse) <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>135</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (IV, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>‐1.71 [‐7.55, 4.13]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>7.1 n‐acetyl cysteine</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>135</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (IV, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>‐1.71 [‐7.55, 4.13]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">8 Mental state: 1d. General ‐ average overall endpoint score ‐ long term (BPRS total, high = worse) <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (IV, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Subtotals only</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>8.1 vitamin E</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>104</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (IV, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>1.20 [‐2.47, 4.87]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">9 Mental state: 2a. Specific ‐ average negative symptom endpoint score ‐ short term (PANSS negative, high = worse) <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>9</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>653</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Std. Mean Difference (IV, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>‐0.38 [‐0.77, 0.00]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>9.1 selegiline</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>3</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>111</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Std. Mean Difference (IV, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>‐0.54 [‐1.76, 0.68]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>9.2 allopurinol</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>3</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>317</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Std. Mean Difference (IV, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>‐0.37 [‐0.98, 0.23]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>9.3 ginkgo biloba</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>157</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Std. Mean Difference (IV, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>‐0.17 [‐0.49, 0.14]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>9.4 n‐acetyl cysteine</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>44</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Std. Mean Difference (IV, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>‐1.10 [‐1.74, ‐0.47]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>9.5 DHEA</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>24</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Std. Mean Difference (IV, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.63 [‐0.20, 1.45]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">10 Mental state: 2b. Specific ‐ average negative symptom endpoint score ‐ short term (SANS, high = worse) <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>3</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>667</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (IV, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>‐7.46 [‐12.46, ‐2.46]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>10.1 ginkgo biloba</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>3</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>667</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (IV, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>‐7.46 [‐12.46, ‐2.46]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">11 Mental state: 2c. Specific ‐ average negative symptom endpoint score ‐ medium term (PANSS negative, high = worse) <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>135</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (IV, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>‐2.33 [‐4.24, ‐0.42]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>11.1 n‐acetyl cysteine</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>135</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (IV, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>‐2.33 [‐4.24, ‐0.42]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">12 Mental state: 2d. Specific ‐ average positive symptom endpoint score ‐ short term (PANSS positive, high = worse) <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>8</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>611</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (IV, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>‐0.96 [‐2.50, 0.58]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>12.1 allopurinol</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>3</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>317</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (IV, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>‐3.55 [‐8.24, 1.13]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>12.2 DHEA</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>24</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (IV, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>3.60 [‐1.30, 8.50]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>12.3 ginkgo biloba</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>157</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (IV, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>‐1.20 [‐2.31, ‐0.09]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>12.4 n‐acetyl cysteine</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>42</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (IV, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>‐1.14 [‐3.57, 1.29]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>12.5 selegiline</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>2</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>71</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (IV, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.57 [‐2.30, 3.45]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">13 Mental state: 2e. Specific ‐ average positive symptom endpoint score ‐ short term (SAPS, high = worse) <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>2</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>151</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (IV, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>‐5.06 [‐7.52, ‐2.59]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>13.1 ginkgo biloba</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>2</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>151</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (IV, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>‐5.06 [‐7.52, ‐2.59]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">14 Mental state: 2f. Secific ‐ average positive symptom endpoint score ‐ medium term (PANSS positive, high = worse) <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>135</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (IV, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.47 [‐1.43, 2.37]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>14.1 n‐acetyl cysteine</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>135</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (IV, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.47 [‐1.43, 2.37]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">15 General functioning: 1a. General ‐ average overall endpoint score ‐ short term (GAS total, high = worse) <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>2</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>52</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (IV, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>‐1.11 [‐8.07, 5.86]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>15.1 DHEA</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>24</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (IV, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>‐7.40 [‐19.80, 5.00]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>15.2 selegiline</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>28</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (IV, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.90 [‐3.25, 5.05]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">16 General functioning: 1b. General ‐ average overall endpoint score ‐ medium term (GAS total, high = worse) <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (IV, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Subtotals only</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>16.1 n‐acetyl cysteine</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>135</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (IV, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>2.84 [‐2.09, 7.77]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">17 General functioning: 1c. General ‐ average overall endpoint score ‐ long term (GAS total, high = worse) <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (IV, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Subtotals only</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>17.1 vitamin E</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>104</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (IV, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.10 [‐5.60, 5.80]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">18 Adverse effects: 1. Serious (any time point) <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>3</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Subtotals only</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>18.1 any serious adverse effect</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>3</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>234</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.65 [0.19, 2.27]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>18.2 myocardial infarction</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>59</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>2.72 [0.12, 64.14]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>18.3 neutropenia</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>59</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.30 [0.01, 7.13]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>18.4 pneumonia</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>2</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>94</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>2.78 [0.30, 25.75]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>18.5 seizure</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>35</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.32 [0.01, 7.26]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">19 Adverse effects: 2. Various ‐ less serious <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>6</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Subtotals only</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>19.1 allergy ‐ rash or other dermatological problems</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>4</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>280</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>1.06 [0.61, 1.84]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>19.2 cardiovascular ‐ dizziness</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>2</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>82</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>1.17 [0.46, 2.96]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>19.3 cardiovascular ‐ systemic hypertension</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>2</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>82</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>3.30 [0.99, 11.04]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>19.4 central nervous system ‐ agitation</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>40</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>2.5 [0.55, 11.41]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>19.5 central nervous system ‐ appetite increase</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>3</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>128</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>1.0 [0.54, 1.87]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>19.6 central nervous system ‐ headache</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>4</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>281</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.99 [0.60, 1.64]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>19.7 central nervous system ‐ insomnia</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>40</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>2.5 [0.55, 11.41]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>19.8 central nervous system ‐ sedation</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>2</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>88</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>1.34 [0.70, 2.59]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>19.9 central nervous system ‐ tremor</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>2</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>86</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.70 [0.32, 1.54]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>19.10 gastrointestinal ‐ abdominal pain</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>40</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>2.0 [0.41, 9.71]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>19.11 gastrointestinal ‐ nausea</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>4</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>281</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>1.04 [0.67, 1.62]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">20 Adverse effects: 3. Average score (TESS endpoint, high = worse) <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>109</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (IV, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>‐0.90 [‐2.34, 0.54]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">21 Laboratory data (serum tests) ‐ short term <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>3</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Std. Mean Difference (IV, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Subtotals only</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>21.1 MDA levels</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>40</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Std. Mean Difference (IV, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>‐2.18 [‐2.98, ‐1.38]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>21.2 SOD levels</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>2</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>123</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Std. Mean Difference (IV, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.27 [‐0.56, 1.10]</p> </td> </tr> </tbody> </table> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="table-viewer-caption"> <div class="table-heading"><span class="table-label">Comparison 1.</span> <span class="table-title">ADJUNCTIVE ANTIOXIDANTS versus PLACEBO</span></div> </div> <div class="tools"><a class="tableList" href="/cdsr/doi/10.1002/14651858.CD008919.pub2/references#CD008919-tbl-0003">Navigate to table in review</a></div> </div> </div> <noscript> <img height="1" src="/scolaris-auth/report/nonjs/fulltexthtmlreg?doi=10.1002%2F14651858.CD008919.pub2&amp;rf=&amp;articleType=CDSR" style="display:none" width="1"> </img></noscript> <section class="translation-notes-modal" data-modal-class="translation-notes" data-modal-title="Translation notes" data-ok-btn-selector=".ok-btn" style="display: none"> <div class="translation-notes"> <div class="section-language-toggles"> <nav class="section-languages"> <ul> <li class="section-languages-legend">Available in</li> <li class="section-language"> <a class="" href="de#CD008919-note-0001">Deutsch</a> </li> <li class="section-language"> <a class="" href="es#CD008919-note-0006">Español</a> </li> <li class="section-language"> <a class="" href="fa#CD008919-note-0012">فارسی</a> </li> <li class="section-language"> <a class="" href="hr#CD008919-note-0004">Hrvatski</a> </li> <li class="section-language"> <a class="" href="ja#CD008919-note-0003">日本語</a> </li> <li class="section-language"> <a class="" href="pl#CD008919-note-0005">Polski</a> </li> <li class="section-language"> <a class="" href="ru#CD008919-note-0002">Русский</a> </li> </ul> </nav> </div> <section class="translation-notes-content"> </section> <button class="btn primary ok-btn pull-right" type="button">Close</button> </div> </section></article> </div> <div class="citation-modal" style="display: none"> <div class="export-citation-header"> <p class="inset-message" data-load-error="Unable to load citation data" id="citeProcText"></p> </div> <div class="export-citation-body row-fluid"> <div class="span12"> <div class="addthis_toolbox addthis_default_style addthis_16x16_style"> <nav class="inline-nav-list is-bordered"> <li> <h4 class="heading">Save citation to:</h4> </li> <li><a class="citation-btn-refworks at300b btn btn-link" href="#" id="refWorksCitationBtn"><span class="citation-icon refworks"></span>RefWorks</a></li> <li><a class="citation-btn-sciwheel at300b btn btn-link disabled" href="#" id="sciWheelCitationBtn" target="_blank"><span class="citation-icon sciwheel"></span>SciWheel</a></li> </nav> </div> </div> </div> <div class="row-fluid"> <div class="span12"> <div class="citation-format"> <h4>Copy or download citation</h4> <a href="/en/help/exporting-search-results" rel="noopener noreferrer" target="_blank">Export help</a> </div> <nav class="inline-nav-list has-dividers"> <li class="citation-option" data-option="plain"><button class="btn btn-link" type="button">Plain text</button></li> <li class="citation-option" data-option="endnote"><button class="btn btn-link" type="button">EndNote</button></li> <li class="citation-option" data-option="refmanager"><button class="btn btn-link" type="button">Reference Manager</button></li> <li class="citation-option" data-option="procite"><button class="btn btn-link" type="button">ProCite</button></li> <li class="citation-option" data-option="bibtex"><button class="btn btn-link" type="button">BibteX</button></li> <li class="citation-option" data-option="csv"><button class="btn btn-link" type="button">CSV (Excel)</button></li> </nav> <div class="citation-content"> <pre data-load-error="Unable to load citation data" id="citationContent" tabindex="0"></pre> </div> <div class="clearfix"> <form class="download-citation-form" data-citation-citeproc-url="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentdisplay_WAR_scolariscontentdisplay&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=citation-citeproc&amp;p_p_cacheability=cacheLevelPage&amp;p_p_col_id=column-1&amp;p_p_col_count=1" method="GET" target="citation-download-iframe"> <input id="siteId" name="siteId" type="hidden" value=""> <input id="downloadType" name="downloadType" type="hidden" value=""> <input id="style" name="style" type="hidden" value=""> <input id="articleId" name="articleId" type="hidden" value=""> <input name="p_p_id" type="hidden" value="scolariscontentdisplay_WAR_scolariscontentdisplay"><input name="p_p_lifecycle" type="hidden" value="2"><input name="p_p_state" type="hidden" value="normal"><input name="p_p_mode" type="hidden" value="view"/><input name="p_p_resource_id" type="hidden" value="citation-download"/><input name="p_p_cacheability" type="hidden" value="cacheLevelPage"/><input name="p_p_col_id" type="hidden" value="column-1"/><input name="p_p_col_count" type="hidden" value="1"/> <button class="btn primary wide pull-right" type="submit">Download</button> <div class="inline-checkbox pull-right"> <label title=" for=" withabstract"=""> <input checked="" class="checkbox" name="withAbstract" type="checkbox"/> <span class="checkbox-label">Include abstract</span> </label> </div> </input></input></input></input></input></input></input></form> <iframe aria-hidden="true" name="citation-download-iframe" src="" style="display: none; visibility: hidden" title="Citation download frame"></iframe> </div> </div> </div> </div> <div class="print-modal" data-modal-title="Print this review" style="display: none;"> <div class="print-options-wrapper"> <p><strong>All sections are selected by default</strong>, please select the sections you do not wish to print or use the select or deselect all button to add or remove sections.</p> <div class="print-options-controls"> <input checked="checked" class="print-options-select-all" title="Select/deselect all" type="checkbox"/> <span class="checkbox-label">Select/deselect all</span> </div> <ul class="print-options checkbox-list"> </ul> <button class="btn primary print-article pull-right"><i aria-hidden="true" class="fa fa-print"></i> Print</button> </div> </div> <div class="download-stats-data-modal" data-modal-title="Download data package" style="display: none;"> <div> <p> The data available are protected by copyright and may only be used in accordance with the <a class="external" href="/about/data-download" target="_blank">Terms and Conditions.</a> </p> <div class="hide-for-zip"> <p> <a class="external" href="https://revman.cochrane.org/#/rm5Converter" target="_blank">RevMan 5 files</a> can be converted to a <a class="external" href="https://links.cochrane.org/review-datapack-userguide" target="_blank">data package.</a> </p> </div> <p> Files in the data package can be imported to <a class="external" href="https://revman.cochrane.org/info" target="_blank">Review Manager software</a> or opened in other tools that support CSV and RIS. </p> <form class="download-stats-data-form" method="GET" target="_blank"> <input name="content-disposition" type="hidden" value="attachment"/> <input name="mime-type" type="hidden" value="application/octet-stream"/> <p class="print-options-controls"> <input aria-label="I agree to these terms and conditions" class="download-stats-data-toc-check-box" type="checkbox"/> <span aria-hidden="true" class="checkbox-label">I agree to these terms and conditions</span> <button class="btn primary download-stats-data pull-right" disabled=""><i aria-hidden="true" class="fa fa-download"></i> Download data</button> </p> </form> </div> </div> <div class="share-modal" data-modal-title="Share this review" style="display:none;"> </div> <div class="viewer-thumbnail-pane-html" style="display:none;"> <div class="figure-viewer-options"> <nav class="inline-nav-list"> <li class="figure-options-btn-container"><button class="btn btn-link" id="figureOptionBtn" type="button">Figures</button></li> <li class="table-options-btn-container"><button class="btn btn-link" id="tableOptionBtn" type="button">Tables</button></li> </nav> </div> <div class="figure-viewer-thumbnails"> <div class="figure-thumbnails is-visible" id="figureThumbnails"></div> <div class="table-thumbnails" id="tableThumbnails"></div> </div> </div> <div class="utilities-html" style="display:none;"> <div class="figure-viewer-utilities"> <a class="figure-viewer-menu-toggle" href="#"> <i class="fa fa-chevron-left"></i><span class="toggle-label" data-figure-hide-text="Hide thumbnails" data-figure-show-text="Show thumbnails" data-table-hide-text="Hide table list" data-table-show-text="Show table list">Hide thumbnails</span> </a> <a class="figure-viewer-navigateback" href="#"> <i class="fa fa-chevron-left"></i> </a> <a class="figure-viewer-rotate" href="#"> <i class="fa fa-undo"></i> </a> <a class="figure-viewer-download" href="#"> <i class="fa fa-download"></i> </a> <a class="figure-viewer-share" href="#"> <i class="fa fa-share-alt"></i> </a> <a class="figure-viewer-zoomin" href="#"> <i class="fa fa-plus"></i><span>zoom in</span> </a> <a class="figure-viewer-zoomout" href="#"> <i class="fa fa-minus"></i><span>zoom out</span> </a> </div> </div> <div class="controls-html" style="display:none;"> <div class="figure-viewer-navigation"> <a class="figure-viewer-nav previous" href="#"> <i class="fa fa-chevron-left"></i><span>left</span> </a> <a class="figure-viewer-nav next" href="#"> <i class="fa fa-chevron-right"></i><span>right</span> </a> </div> </div> <div class="mobile-thumbnail-selector-html" style="display:none;"> <div class="figure-viewer-mobile-thumbnails"> <select class="figure-selection"> <option>Figures</option> </select> <select class="table-selection"> <option>Tables</option> </select> </div> </div> </div> </div> </div> <div style="display:none"> <input id="freelabel" name="freelabel" type="hidden" value="Free access"/>
<input id="openlabel" name="openlabel" type="hidden" value="Open access"/>
</div>
</section>
</div>
</div>
</div>
</div>
</div>
<div class="portlet-boundary portlet-boundary_1_WAR_kaleodesignerportlet_ portlet-static portlet-static-end kaleo-designer-portlet" id="p_p_id_1_WAR_kaleodesignerportlet_">
<span id="p_1_WAR_kaleodesignerportlet"></span>
</div>
<form action="#" id="hrefFm" method="post" name="hrefFm">
<span></span>
</form>
</div>
<footer class="footer">
<div class="main-footer">
<div class="main-footer-wrapper container">
<div class="brand">
<p class="brand-name">Cochrane</p>
<a href="http://www.cochrane.org/" title="Cochrane logo">
<img alt="Cochrane logo" class="footer-logo logo-part-1" src="https://www.cochranelibrary.com/cochrane-theme/images/footer-logo-part-1.png"> <img alt="" class="footer-logo logo-part-2" src="https://www.cochranelibrary.com/cochrane-theme/images/footer-logo-part-2.png"> </img></img></a> </div> </div> </div> <div class="aux-footer"> <div class="aux-footer-nav-container container"> <nav class="aux-footer-nav"> <ul class="aux-footer-nav-list"> <li><a class="aux-footer-nav-link" href="https://onlinelibrary.wiley.com/">Browse Publications</a></li> <li><a class="aux-footer-nav-link" href="https://onlinelibrary.wiley.com/">Browse by Subject</a></li> </ul> <ul class="aux-footer-nav-list"> <li><a class="aux-footer-nav-link" href="https://onlinelibrary.wiley.com/advertisers">Advertisers &amp; Agents</a></li> <li><a class="aux-footer-nav-link" href="https://hub.wiley.com/community/support/cochrane-library">Contact Us</a></li> </ul> <ul class="aux-footer-nav-list"> <li><a class="aux-footer-nav-link" href="https://hub.wiley.com/community/support/cochrane-library">Help &amp; Support</a></li> <li><a class="aux-footer-nav-link" href="https://onlinelibrary.wiley.com/terms-and-conditions">Terms &amp; Conditions</a></li> </ul> </nav> </div> <div class="brand"> <div class="brand-container container"> <p class="copyright"> Copyright © 2000 - 2025 by <a class="" href="http://www.wiley.com">John Wiley &amp; Sons, Inc.</a> All Rights Reserved <br> Review our <a href="https://www.wiley.com/privacy"><strong>Privacy Policy</strong></a> <a href="https://www.wiley.com/cookies"><strong>Cookie Policy</strong></a> <a href="#" onclick="Osano.cm.showDrawer('osano-cm-dom-info-dialog-open')"><strong>Cookie Preferences</strong></a> </br></p> <a href="http://eu.wiley.com/"><img alt="Wiley logo" class="logo" src="https://www.cochranelibrary.com/cochrane-theme/images/en-US_wiley-footer-logo.png"/></a> </div> </div> <span class="wiley-semi-circle"></span> </div> <!--BEGIN QUALTRICS WEBSITE FEEDBACK SNIPPET--> <script type="text/javascript"> (function(){var g=function(e,h,f,g){ this.get=function(a){for(var a=a+"=",c=document.cookie.split(";"),b=0,e=c.length;b<e;b++){for(var d=c[b];" "==d.charAt(0);)d=d.substring(1,d.length);if(0==d.indexOf(a))return d.substring(a.length,d.length)}return null}; this.set=function(a,c){var b="",b=new Date;b.setTime(b.getTime()+6048E5);b="; expires="+b.toGMTString();document.cookie=a+"="+c+b+"; path=/; "}; this.check=function(){var a=this.get(f);if(a)a=a.split(":");else if(100!=e)"v"==h&&(e=Math.random()>=e/100?0:100),a=[h,e,0],this.set(f,a.join(":"));else return!0;var c=a[1];if(100==c)return!0;switch(a[0]){case "v":return!1;case "r":return c=a[2]%Math.floor(100/c),a[2]++,this.set(f,a.join(":")),!c}return!0}; this.go=function(){if(this.check()){var a=document.createElement("script");a.type="text/javascript";a.src=g;document.body&&document.body.appendChild(a)}}; this.start=function(){var t=this;"complete"!==document.readyState?window.addEventListener?window.addEventListener("load",function(){t.go()},!1):window.attachEvent&&window.attachEvent("onload",function(){t.go()}):t.go()};}; try{(new g(100,"r","QSI_S_ZN_cGCHHvWNpnJb1zf","https://zncgchhvwnpnjb1zf-wiley.siteintercept.qualtrics.com/SIE/?Q_ZID=ZN_cGCHHvWNpnJb1zf")).start()}catch(i){}})(); </script><div id="ZN_cGCHHvWNpnJb1zf"><!--DO NOT REMOVE-CONTENTS PLACED HERE--></div> <!--END WEBSITE FEEDBACK SNIPPET--> </footer> <div class="scolaris-modal-overlay"></div> <div class="scolaris-modal"> <div class="scolaris-modal-titlebar clearfix"> <p class="scolaris-modal-title"></p> <a class="scolaris-modal-close" href="#"><span>close</span><span class="icon fa fa-times"></span></a> <div class="scolaris-modal-ui"></div> </div> <!-- Static injection of addtoAny as dynamic injection not working properly--> <div class="scolaris-share-modal-content clearfix"> <div class="scolaris-modal-ui clearfix"> <div class="a2a_kit a2a_kit_size_32 a2a_default_style"> <a class="a2a_button_facebook share-button">  Facebook</a> <a class="a2a_button_x share-button">  X(Twitter)</a> <a class="a2a_button_whatsapp share-button">  WhatsApp</a> <a class="a2a_dd share-button">  View more</a> </div> </div> </div> <div class="scolaris-modal-content clearfix"> <div class="scolaris-modal-ui clearfix"></div> </div> <div class="scolaris-modal-ui clearfix"></div> </div> <div class="english-only-modal-wrapper" data-modal-class="english-only-modal" data-modal-title="Feature in English only" style="display: none"> <div class="english-only-modal"> <p class="message"></p> <button class="btn primary ok-btn pull-right" type="button">OK</button> <button class="btn primary border-only cancel-btn pull-right" type="button">Cancel</button> </div> </div> <!--[if gte IE 9]><!--> <script src="/cochrane-theme/vendor/ie9.js?t=1738734739000" type="text/javascript"></script> <!--<![endif]--> <script src="https://www.cochranelibrary.com/cochrane-theme/js/theme.js?t=1738734739000" type="text/javascript"></script> <script src="https://content.readcube.com/cochrane/checkout.js"></script> <script src="https://content.readcube.com/cochrane/epdf_linker.js" type="text/javascript"></script> <script src="https://crossmark-cdn.crossref.org/widget/v2.0/widget.js" type="text/javascript"></script> <script src="https://d1bxh8uas1mnw7.cloudfront.net/assets/embed.js" type="text/javascript"></script> <script src="https://www.cochranelibrary.com/scolaris-content-display/js/hit-highlighting.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1739773465000" type="text/javascript"></script> <script src="https://www.cochranelibrary.com/scolaris-content-display/js/topics-lookup.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1739773465000" type="text/javascript"></script> <script src="https://www.cochranelibrary.com/scolaris-content-display/js/institution.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1739773465000" type="text/javascript"></script> <script src="https://www.cochranelibrary.com/scolaris-content-display/js/api-manager.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1739773465000" type="text/javascript"></script> <script src="https://www.cochranelibrary.com/scolaris-content-display/js/pico.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1739773465000" type="text/javascript"></script> <script src="https://www.cochranelibrary.com/scolaris-content-display/js/reference-linking.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1739773465000" type="text/javascript"></script> <script src="https://www.cochranelibrary.com/scolaris-content-display/js/rightsLink.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1739773465000" type="text/javascript"></script> <script src="https://www.cochranelibrary.com/scolaris-content-display/js/ui.submit.failed.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1739773465000" type="text/javascript"></script> <script src="https://www.cochranelibrary.com/scolaris-content-display/js/ui.comment.form.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1739773465000" type="text/javascript"></script> <script src="https://www.cochranelibrary.com/scolaris-content-display/js/safety-alerts.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1739773465000" type="text/javascript"></script> <script src="https://www.cochranelibrary.com/scolaris-content-display/js/ui.translation-notes-modal.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1739773465000" type="text/javascript"></script> <script src="https://www.cochranelibrary.com/scolaris-content-display/js/main.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1739773465000" type="text/javascript"></script> <script src="https://www.cochranelibrary.com/notifications-portlet/notifications/js/main.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1739773465000" type="text/javascript"></script> <script src="https://www.cochranelibrary.com/scolaris-search/js/main.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1739773542000" type="text/javascript"></script> <script src="https://www.cochranelibrary.com/scolaris-topics/js/main.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1739773465000" type="text/javascript"></script> <script src="https://www.cochranelibrary.com/scolaris-language-portlet/js/main.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1739773471000" type="text/javascript"></script> <script type="text/javascript">Liferay.Util.addInputFocus();</script> <script type="text/javascript">Liferay.Portlet.register("scolarislanguageselector_WAR_scolarislanguageportlet_INSTANCE_header");Liferay.Portlet.onLoad({canEditTitle:false,columnPos:0,isStatic:"end",namespacedId:"p_p_id_scolarislanguageselector_WAR_scolarislanguageportlet_INSTANCE_header_",portletId:"scolarislanguageselector_WAR_scolarislanguageportlet_INSTANCE_header",refreshURL:"\x2fen\x2fc\x2fportal\x2frender_portlet\x3fp_l_id\x3d20757\x26p_p_id\x3dscolarislanguageselector_WAR_scolarislanguageportlet_INSTANCE_header\x26p_p_lifecycle\x3d0\x26p_t_lifecycle\x3d0\x26p_p_state\x3dnormal\x26p_p_mode\x3dview\x26p_p_col_id\x3dnull\x26p_p_col_pos\x3dnull\x26p_p_col_count\x3dnull\x26p_p_static\x3d1\x26p_p_isolated\x3d1\x26currentURL\x3d\x252Fweb\x252Fcochrane\x252Fcontent\x253FtemplateType\x253Dfull\x2526urlTitle\x253D\x252Fcdsr\x252Fdoi\x252F10\x2e1002\x252F14651858\x2eCD008919\x2epub2\x2526doi\x253D10\x2e1002\x252F14651858\x2eCD008919\x2epub2\x2526type\x253Dcdsr\x2526contentLanguage\x253D\x26templateType\x3dfull\x26urlTitle\x3d\x252Fcdsr\x252Fdoi\x252F10\x2e1002\x252F14651858\x2eCD008919\x2epub2\x26contentLanguage\x3d\x26type\x3dcdsr\x26doi\x3d10\x2e1002\x252F14651858\x2eCD008919\x2epub2"});Liferay.Portlet.register("scolariscontentdisplay_WAR_scolariscontentdisplay");Liferay.Portlet.onLoad({canEditTitle:false,columnPos:0,isStatic:"end",namespacedId:"p_p_id_scolariscontentdisplay_WAR_scolariscontentdisplay_",portletId:"scolariscontentdisplay_WAR_scolariscontentdisplay",refreshURL:"\x2fen\x2fc\x2fportal\x2frender_portlet\x3fp_l_id\x3d20757\x26p_p_id\x3dscolariscontentdisplay_WAR_scolariscontentdisplay\x26p_p_lifecycle\x3d0\x26p_t_lifecycle\x3d0\x26p_p_state\x3dnormal\x26p_p_mode\x3dview\x26p_p_col_id\x3dcolumn-1\x26p_p_col_pos\x3d0\x26p_p_col_count\x3d1\x26p_p_isolated\x3d1\x26currentURL\x3d\x252Fweb\x252Fcochrane\x252Fcontent\x253FtemplateType\x253Dfull\x2526urlTitle\x253D\x252Fcdsr\x252Fdoi\x252F10\x2e1002\x252F14651858\x2eCD008919\x2epub2\x2526doi\x253D10\x2e1002\x252F14651858\x2eCD008919\x2epub2\x2526type\x253Dcdsr\x2526contentLanguage\x253D"});Liferay.provide(Liferay.Util,"openKaleoDesignerPortlet",function(c){var b=AUI();var e=Liferay.PortletURL.createURL("https://www.cochranelibrary.com/en/content?p_p_id=2_WAR_kaleodesignerportlet&p_p_lifecycle=0");e.setParameter("mvcPath","/designer/edit_kaleo_draft_definition.jsp");e.setParameter("availableFields",c.availableFields);e.setParameter("availablePropertyModels",c.availablePropertyModels);e.setParameter("ddmStructureId",c.ddmStructureId);e.setParameter("draftVersion",c.draftVersion);e.setParameter("kaleoProcessId",c.kaleoProcessId);e.setParameter("name",c.name);e.setParameter("openerWindowName",c.openerWindowName);e.setParameter("portletResourceNamespace",c.portletResourceNamespace);e.setParameter("propertiesSaveCallback",c.propertiesSaveCallback);e.setParameter("refreshOpenerOnClose",c.refreshOpenerOnClose);e.setParameter("saveCallback",c.saveCallback);e.setParameter("version",c.version);e.setWindowState("pop_up");c.uri=e.toString();var d=c.dialog;if(!d){var f=b.one(Liferay.Util.getOpener()).get("region");d={destroyOnHide:true};c.dialog=d}if(!("align" in d)){d.align=Liferay.Util.Window.ALIGN_CENTER}var a=c.dialogIframe;if(!a){a={closeOnEscape:false};c.dialogIframe=a}Liferay.Util.openWindow(c)},["liferay-portlet-url"]);Liferay.Portlet.register("1_WAR_kaleodesignerportlet");Liferay.Portlet.onLoad({canEditTitle:false,columnPos:0,isStatic:"end",namespacedId:"p_p_id_1_WAR_kaleodesignerportlet_",portletId:"1_WAR_kaleodesignerportlet",refreshURL:"\x2fen\x2fc\x2fportal\x2frender_portlet\x3fp_l_id\x3d20757\x26p_p_id\x3d1_WAR_kaleodesignerportlet\x26p_p_lifecycle\x3d0\x26p_t_lifecycle\x3d0\x26p_p_state\x3dnormal\x26p_p_mode\x3dview\x26p_p_col_id\x3dnull\x26p_p_col_pos\x3dnull\x26p_p_col_count\x3dnull\x26p_p_static\x3d1\x26p_p_isolated\x3d1\x26currentURL\x3d\x252Fweb\x252Fcochrane\x252Fcontent\x253FtemplateType\x253Dfull\x2526urlTitle\x253D\x252Fcdsr\x252Fdoi\x252F10\x2e1002\x252F14651858\x2eCD008919\x2epub2\x2526doi\x253D10\x2e1002\x252F14651858\x2eCD008919\x2epub2\x2526type\x253Dcdsr\x2526contentLanguage\x253D\x26templateType\x3dfull\x26urlTitle\x3d\x252Fcdsr\x252Fdoi\x252F10\x2e1002\x252F14651858\x2eCD008919\x2epub2\x26contentLanguage\x3d\x26type\x3dcdsr\x26doi\x3d10\x2e1002\x252F14651858\x2eCD008919\x2epub2"});Liferay.Portlet.register("scolarissearchportlet_WAR_scolarissearch");Liferay.Portlet.onLoad({canEditTitle:false,columnPos:0,isStatic:"end",namespacedId:"p_p_id_scolarissearchportlet_WAR_scolarissearch_",portletId:"scolarissearchportlet_WAR_scolarissearch",refreshURL:"\x2fen\x2fc\x2fportal\x2frender_portlet\x3fp_l_id\x3d20757\x26p_p_id\x3dscolarissearchportlet_WAR_scolarissearch\x26p_p_lifecycle\x3d0\x26p_t_lifecycle\x3d0\x26p_p_state\x3dnormal\x26p_p_mode\x3dview\x26p_p_col_id\x3dnull\x26p_p_col_pos\x3dnull\x26p_p_col_count\x3dnull\x26p_p_static\x3d1\x26p_p_isolated\x3d1\x26currentURL\x3d\x252Fweb\x252Fcochrane\x252Fcontent\x253FtemplateType\x253Dfull\x2526urlTitle\x253D\x252Fcdsr\x252Fdoi\x252F10\x2e1002\x252F14651858\x2eCD008919\x2epub2\x2526doi\x253D10\x2e1002\x252F14651858\x2eCD008919\x2epub2\x2526type\x253Dcdsr\x2526contentLanguage\x253D\x26templateType\x3dfull\x26urlTitle\x3d\x252Fcdsr\x252Fdoi\x252F10\x2e1002\x252F14651858\x2eCD008919\x2epub2\x26contentLanguage\x3d\x26type\x3dcdsr\x26doi\x3d10\x2e1002\x252F14651858\x2eCD008919\x2epub2"});Liferay.Portlet.register("scolariscontentlanguagebanner_WAR_scolarislanguageportlet");Liferay.Portlet.onLoad({canEditTitle:false,columnPos:0,isStatic:"end",namespacedId:"p_p_id_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_",portletId:"scolariscontentlanguagebanner_WAR_scolarislanguageportlet",refreshURL:"\x2fen\x2fc\x2fportal\x2frender_portlet\x3fp_l_id\x3d20757\x26p_p_id\x3dscolariscontentlanguagebanner_WAR_scolarislanguageportlet\x26p_p_lifecycle\x3d0\x26p_t_lifecycle\x3d0\x26p_p_state\x3dnormal\x26p_p_mode\x3dview\x26p_p_col_id\x3dnull\x26p_p_col_pos\x3dnull\x26p_p_col_count\x3dnull\x26p_p_static\x3d1\x26p_p_isolated\x3d1\x26currentURL\x3d\x252Fweb\x252Fcochrane\x252Fcontent\x253FtemplateType\x253Dfull\x2526urlTitle\x253D\x252Fcdsr\x252Fdoi\x252F10\x2e1002\x252F14651858\x2eCD008919\x2epub2\x2526doi\x253D10\x2e1002\x252F14651858\x2eCD008919\x2epub2\x2526type\x253Dcdsr\x2526contentLanguage\x253D\x26templateType\x3dfull\x26urlTitle\x3d\x252Fcdsr\x252Fdoi\x252F10\x2e1002\x252F14651858\x2eCD008919\x2epub2\x26contentLanguage\x3d\x26type\x3dcdsr\x26doi\x3d10\x2e1002\x252F14651858\x2eCD008919\x2epub2"});AUI().use("aui-base","liferay-menu","liferay-notice","liferay-poller","liferay-session",function(a){(function(){Liferay.Util.addInputType();Liferay.Portlet.ready(function(b,c){Liferay.Util.addInputType(c)});if(a.UA.mobile){Liferay.Util.addInputCancel()}})();(function(){new Liferay.Menu();var b=Liferay.Data.notices;for(var c=1;c<b.length;c++){new Liferay.Notice(b[c])}})();(function(){Liferay.Session=new Liferay.SessionBase({autoExtend:true,sessionLength:1800,redirectOnExpire:false,redirectUrl:"https\x3a\x2f\x2fwww\x2ecochranelibrary\x2ecom\x2fweb\x2fcochrane",warningLength:0})})()});</script> <script src="https://www.cochranelibrary.com/cochrane-theme/js/main.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1738734739000" type="text/javascript"></script> <script type="text/javascript"></script> <div class="mobile-righthand-nav"> <a class="rh-nav-close-btn" href="#"> <span>Close</span> <span class="fa fa-chevron-down"></span> </a> <div class="wrapper"> </div> <a class="rh-nav-open-btn" href="#"> <span>Review tools &amp; navigation</span> </a> </div> <iframe aria-hidden="true" id="printframe" name="printframe" style="position: absolute; left: -2000px; top: 0;" title="Print frame"></iframe> <iframe aria-hidden="true" id="citationExportFrame" name="citationExportFrame" style="position: absolute; left: -2000px; top: 0;" title="scolaris.citation.export.frame"></iframe> <nav> <div class="mobile-navigation"> <div class="close-container"> <a aria-label="Navigate back" class="main-nav-back-btn" href="#"><i class="fa fa-chevron-left"></i></a> <a class="main-nav-close-btn" href="#" title="Close menu">Close menu <i class="fa fa-times"></i></a> </div> <div class="mobile-search basic-search-container"> <div class="portlet-boundary portlet-boundary_scolarissearchportlet_WAR_scolarissearch_ portlet-static portlet-static-end" id="p_p_id_scolarissearchportlet_WAR_scolarissearch_"> <span id="p_scolarissearchportlet_WAR_scolarissearch"></span> <section class="portlet" id="portlet_scolarissearchportlet_WAR_scolarissearch"> <header class="portlet-topper"> <h1 class="portlet-title"> <span class="" onmouseover="Liferay.Portal.ToolTip.show(this, 'Scolaris\x20Search\x20Portlet')"> <img alt="" id="ymag__null__null" src="/scolaris-search/icon.png"> <span class="taglib-text hide-accessible">Scolaris Search Portlet</span> </img></span> <span class="portlet-title-text">Scolaris Search Portlet</span> </h1> <menu class="portlet-topper-toolbar" id="portlet-topper-toolbar_scolarissearchportlet_WAR_scolarissearch" type="toolbar"> </menu> </header> <div class="portlet-content"> <div class="portlet-content-container"> <div class="portlet-body"> <div class="header-search"> <form action="https://www.cochranelibrary.com/en/content?p_auth=9mpoajSI&amp;p_p_id=scolarissearchportlet_WAR_scolarissearch&amp;p_p_lifecycle=1&amp;p_p_state=normal&amp;p_p_mode=view&amp;_scolarissearchportlet_WAR_scolarissearch_scolarisAction=redirectSearchResult" method="post"> <input name="searchType" type="hidden" value="basic"> <input name="facetDisplayName" type="hidden" value=""> <input name="facetQueryTerm" type="hidden" value=""/> <input name="facetQueryField" type="hidden" value=""/> <input name="facetCategory" type="hidden" value=""/> <fieldset class="fieldset"> <legend class="sr-only">Basic Search</legend> <div class="select search-by"> <select aria-label="Search by options" class="custom-select-enabled search-type" name="searchBy" title="Search by options"> <option value="1">Title Abstract Keyword</option> <option value="2">Record Title</option> <option value="3">Abstract</option> <option value="4">Author</option> <option value="5">Keyword</option> <option value="6">All Text</option> <option value="7">Publication Type</option> <option value="8">Source</option> <option value="9">DOI</option> <option value="14">Language</option> <option value="10">Accession Number</option> <option value="11">Trial Registry Number</option> <option value="12">Cochrane Group</option> <option value="13">Cochrane Topic</option> </select> </div> <div class="search-select-crg-container select" style="display: none;"> <select class="search-select-crg-list"></select> </div> <div class="search-select-topic-container select" data-topic-list-url="https://www.cochranelibrary.com/en/content?p_p_id=scolaristopics_WAR_scolaristopics&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=topics-list&amp;p_p_cacheability=cacheLevelPage" style="display: none;"> <select class="search-select-topic-list"></select> </div> <div class="search-select-cl-container select" style="display: none;"> <select class="search-select-cl-list"></select> </div> <div class="search-text-container"> <div class="control-group control-group-inline search-input-wrapper"> <input aria-label="Enter search term" class="field browser-search search-text ui-autocomplete-input" id="searchText" name="searchText" placeholder="Search" size="30" type="text" value=""/>
<div id="autocomplete-results"></div>
</div>
<div class="control-group control-group-inline search-button-wrapper">
<button aria-label="Search" class="searchByBtn" type="submit">
<i aria-hidden="true" class="fa fa-search"></i>
</button>
</div>
</div>
</fieldset>
</input></input></form>
</div>
<script>
    window.displayResultURL = 'https://www.cochranelibrary.com/en/content?p_p_id=scolarissearchportlet_WAR_scolarissearch&p_p_lifecycle=2&p_p_state=normal&p_p_mode=view&p_p_resource_id=getSuggestions&p_p_cacheability=cacheLevelPage&_scolarissearchportlet_WAR_scolarissearch_templateType=full&_scolarissearchportlet_WAR_scolarissearch_urlTitle=%2Fcdsr%2Fdoi%2F10.1002%2F14651858.CD008919.pub2&_scolarissearchportlet_WAR_scolarissearch_contentLanguage=&_scolarissearchportlet_WAR_scolarissearch_type=cdsr&_scolarissearchportlet_WAR_scolarissearch_doi=10.1002%2F14651858.CD008919.pub2';
    window.searchByOption = '';
</script>
</div>
</div>
</div>
<div style="display:none">
<input id="freelabel" name="freelabel" type="hidden" value="Free access"/>
<input id="openlabel" name="openlabel" type="hidden" value="Open access"/>
</div>
</section>
</div>
<a class="btn secondary" href="/en/browse-by-topic">Browse </a>
<a class="btn secondary advanced-search-button" href="/en/advanced-search">Advanced search</a>
</div>
<div class="menu-items parent">
<div>
<div class="nav-root-item parent">
<a class="language-selection-title-link" href="#" title="Select language">
<span class="mobile-nav-language-title">Select your preferred language </span></a> <span class="icon fa fa-caret-down"></span>
<div class="mob-child">
<div class="portlet-boundary portlet-boundary_scolarislanguageselector_WAR_scolarislanguageportlet_ portlet-static portlet-static-end" id="p_p_id_scolarislanguageselector_WAR_scolarislanguageportlet_INSTANCE_mobilenav_">
<span id="p_scolarislanguageselector_WAR_scolarislanguageportlet_INSTANCE_mobilenav"></span>
<section class="portlet" id="portlet_scolarislanguageselector_WAR_scolarislanguageportlet_INSTANCE_mobilenav">
<header class="portlet-topper">
<h1 class="portlet-title">
<span class="" onmouseover="Liferay.Portal.ToolTip.show(this, 'Scolaris\x20Language\x20Selector')">
<img alt="" id="fdkn__null__null" src="/scolaris-language-portlet/icon.png"> <span class="taglib-text hide-accessible">Scolaris Language Selector</span> </img></span> <span class="portlet-title-text">Scolaris Language Selector</span> </h1> <menu class="portlet-topper-toolbar" id="portlet-topper-toolbar_scolarislanguageselector_WAR_scolarislanguageportlet_INSTANCE_mobilenav" type="toolbar"> </menu> </header> <div class="portlet-content"> <div class="portlet-content-container"> <div class="portlet-body"> <div class="language-display" data-content-languages="[de, en, es, fa, fr, hi, hr, id, ja, ko, hu, ms, nl, pl, pt, ru, ro, ta, th, zh_HANT, zh_HANS]"> <a class="language-select-mobile" href="#" title="Select your preferred language"> <i class="fa fa-file-text"></i> English </a> <a class="language-select-mobile" href="#" title="Select your preferred language"> <i class="fa fa-globe"></i> English </a> </div> <div class="form-content language-selector-modal child"> <div class="row-fluid"> <h3><i class="fa fa-file-text"></i> Cochrane review language</h3> <p>Select your preferred language for Cochrane reviews and other content. Sections without translation will be in English.</p> <div class="dropdown-trigger" id="active-content-language"> <span>English</span> <i aria-hidden="true" class="fa fa-caret-down"></i> </div> <div class="language-selector-dropdown"> <a class="content-language-selector" data-languagecode="de" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=de">Deutsch</a> <a class="content-language-selector is-active" data-languagecode="en" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=en">English</a> <a class="content-language-selector" data-languagecode="es" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=es">Español</a> <a class="content-language-selector" data-languagecode="fa" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=fa">فارسی</a> <a class="content-language-selector" data-languagecode="fr" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=fr">Français</a> <a class="content-language-selector" data-languagecode="hi" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=hi">हिन्दी</a> <a class="content-language-selector" data-languagecode="hr" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=hr">Hrvatski</a> <a class="content-language-selector" data-languagecode="id" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=id">Bahasa Indonesia</a> <a class="content-language-selector" data-languagecode="ja" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=ja">日本語</a> <a class="content-language-selector" data-languagecode="ko" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=ko">한국어</a> <a class="content-language-selector" data-languagecode="hu" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=hu">Magyar</a> <a class="content-language-selector" data-languagecode="ms" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=ms">Bahasa Malaysia</a> <a class="content-language-selector" data-languagecode="nl" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=nl">Nederlands</a> <a class="content-language-selector" data-languagecode="pl" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=pl">Polski</a> <a class="content-language-selector" data-languagecode="pt" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=pt">Português</a> <a class="content-language-selector" data-languagecode="ru" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=ru">Русский</a> <a class="content-language-selector" data-languagecode="ro" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=ro">Română</a> <a class="content-language-selector" data-languagecode="ta" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=ta">தமிழ்</a> <a class="content-language-selector" data-languagecode="th" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=th">ภาษาไทย</a> <a class="content-language-selector" data-languagecode="zh_HANT" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=zh_HANT">繁體中文</a> <a class="content-language-selector" data-languagecode="zh_HANS" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=zh_HANS">简体中文</a> </div> </div> <div class="row-fluid"> <h3 class="portal-language-header"><i class="fa fa-globe"></i> Website language</h3> <p>Select your preferred language for the Cochrane Library website.</p> <div class="dropdown-trigger" id="active-portal-language"> <span>English</span> <i aria-hidden="true" class="fa fa-caret-down"></i> </div> <div class="language-selector-dropdown"> <a class="portal-language-selector is-active" data-portallanguage="en" href="/en/cdsr/doi/10.1002/14651858.CD008919.pub2/full/en">English</a> <a class="portal-language-selector" data-portallanguage="es" href="/es/cdsr/doi/10.1002/14651858.CD008919.pub2/full/es">Español</a> </div> </div> <a class="btn secondary ok-btn pull-right" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage">Save</a> </div> </div> </div> </div> <div style="display:none"> <input id="freelabel" name="freelabel" type="hidden" value="Free access"/>
<input id="openlabel" name="openlabel" type="hidden" value="Open access"/>
</div>
</section>
</div>
</div>
</div>
<div class="parent">
<a class="mobile-link signin" data-redirect="false" href="https://www.cochranelibrary.com/c/portal/login?p_l_id=20757&amp;redirect=%2Fcdsr%2Fdoi%2F10.1002%2F14651858.CD008919.pub2%2Ffull" rel="nofollow">
                        Sign In
                    </a>
</div>
</div>
<div class="menu-items-footer">
<div class="utility-links">
<a class="cochrane-link" href="http://www.cochrane.org/" target="_blank">Visit Cochrane.org</a>
</div>
</div>
</div>
<div class="menu-items child"></div>
</div>
</nav><div class="basic-login-form-content" data-modal-title="Sign in" style="display: none;">
<div class="form-content">
<div class="row-fluid">
<div class="span12">
<div class="portlet-boundary portlet-boundary_58_ portlet-static portlet-static-end portlet-login" id="p_p_id_58_INSTANCE_MODAL_">
<span id="p_58_INSTANCE_MODAL"></span>
<section class="portlet" id="portlet_58_INSTANCE_MODAL">
<header class="portlet-topper">
<h1 class="portlet-title">
<span class="" onmouseover="Liferay.Portal.ToolTip.show(this, 'Sign\x20In')">
<img alt="" id="dbam__null__null" src="https://www.cochranelibrary.com/cochrane-theme/images/spacer.png" style="background-image: url('https://www.cochranelibrary.com/sprite/html/icons/_sprite.png'); background-position: 50% -592px; background-repeat: no-repeat; height: 16px; width: 16px;"> <span class="taglib-text hide-accessible">Sign In</span> </img></span> <span class="portlet-title-text">Sign In</span> </h1> <menu class="portlet-topper-toolbar" id="portlet-topper-toolbar_58_INSTANCE_MODAL" type="toolbar"> </menu> </header> <div class="portlet-content"> <div class="portlet-content-container"> <div class="portlet-body"> <form action="https://www.cochranelibrary.com/en/content?p_p_id=58_INSTANCE_MODAL&amp;p_p_lifecycle=1&amp;p_p_state=normal&amp;p_p_mode=view&amp;_58_INSTANCE_MODAL_struts_action=%2Flogin%2Flogin" autocomplete="on" class="form sign-in-form" id="_58_INSTANCE_MODAL_fm" method="post" name="_58_INSTANCE_MODAL_fm"> <fieldset class="input-container" disabled="disabled"> <legend class="sr-only">Cochrane Login</legend> <input name="_58_INSTANCE_MODAL_formDate" type="hidden" value="1740728218369"> <input class="field" id="_58_INSTANCE_MODAL_saveLastPath" name="_58_INSTANCE_MODAL_saveLastPath" type="hidden" value="false"> <input class="field" id="_58_INSTANCE_MODAL_redirect" name="_58_INSTANCE_MODAL_redirect" type="hidden" value="/cdsr/doi/10.1002/14651858.CD008919.pub2/full"> <input class="field" id="_58_INSTANCE_MODAL_doActionAfterLogin" name="_58_INSTANCE_MODAL_doActionAfterLogin" type="hidden" value="false"> <div class="control-group input-text-wrapper"> <label class="control-label" for="_58_INSTANCE_MODAL_login"> Email Address </label> <input class="field clearable" id="_58_INSTANCE_MODAL_login" name="_58_INSTANCE_MODAL_login" type="text" value=""> </input></div> <div class="control-group input-text-wrapper"> <label class="control-label" for="_58_INSTANCE_MODAL_password"> Password </label> <input class="field" id="_58_INSTANCE_MODAL_password" name="_58_INSTANCE_MODAL_password" type="password" value=""/> </div> <span id="_58_INSTANCE_MODAL_passwordCapsLockSpan" style="display: none;"> Caps Lock is on. </span> <div class="clearfix"> <div class="checkbox-list pull-left"> <div class="checkbox-list-item"> <div class="control-group form-inline input-checkbox-wrapper"> <label for="_58_INSTANCE_MODAL_rememberMeCheckbox"> <input id="_58_INSTANCE_MODAL_rememberMe" name="_58_INSTANCE_MODAL_rememberMe" type="hidden" value="true"/> <input checked="" class="field" id="_58_INSTANCE_MODAL_rememberMeCheckbox" name="_58_INSTANCE_MODAL_rememberMeCheckbox" onclick="Liferay.Util.updateCheckboxValue(this); " type="checkbox" value="true"/> Remember Me </label> </div> </div> </div> <div class="pull-right"> <a href="https://onlinelibrary.wiley.com/user/forgottenpassword" target="_blank">Forgotten password?</a> </div> </div> <div class="login-form-footer clearfix"> <div class="pull-left"> <button class="btn primary" type="submit">Sign in</button> <a class="btn secondary" href="https://onlinelibrary.wiley.com/user-registration" target="_blank">Register</a> </div> <div class="pull-right"> <a class="institutional-login-form-button" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentdisplay_WAR_scolariscontentdisplay&amp;p_p_lifecycle=0&amp;p_p_state=normal&amp;p_p_mode=view&amp;_scolariscontentdisplay_WAR_scolariscontentdisplay_action=institution-access">Institutional login</a> </div> </div> </input></input></input></input></fieldset> </form> </div> </div> </div> <div style="display:none"> <input id="freelabel" name="freelabel" type="hidden" value="Free access"/>
<input id="openlabel" name="openlabel" type="hidden" value="Open access"/>
</div>
</section>
</div>
</div>
</div>
</div></div>
<div class="institution-login-form-content" data-modal-title="Institutional login" style="display: none;">
<div class="form-content">
<div class="row-fluid access-content-wrapper">
<div class="span12">
<div class="section">
<div class="portlet-boundary portlet-boundary_scolariscontentdisplay_WAR_scolariscontentdisplay_ portlet-static portlet-static-end scolaris-content-display-portlet" id="p_p_id_scolariscontentdisplay_WAR_scolariscontentdisplay_INSTANCE_combinedloginform_">
<span id="p_scolariscontentdisplay_WAR_scolariscontentdisplay_INSTANCE_combinedloginform"></span>
<section class="portlet" id="portlet_scolariscontentdisplay_WAR_scolariscontentdisplay_INSTANCE_combinedloginform">
<header class="portlet-topper">
<h1 class="portlet-title">
<span class="" onmouseover="Liferay.Portal.ToolTip.show(this, 'Scolaris\x20Content\x20Display')">
<img alt="" id="obft__null__null" src="/scolaris-content-display/icon.png"> <span class="taglib-text hide-accessible">Scolaris Content Display</span> </img></span> <span class="portlet-title-text">Scolaris Content Display</span> </h1> <menu class="portlet-topper-toolbar" id="portlet-topper-toolbar_scolariscontentdisplay_WAR_scolariscontentdisplay_INSTANCE_combinedloginform" type="toolbar"> </menu> </header> <div class="portlet-content"> <div class="portlet-content-container"> <div class="portlet-body"> <div class="access-content-section"> <div class="section-content"> <p>Search for your institution's name below to login via Shibboleth</p> <form action="/shibboleth" id="institutionLoginForm" method="post"> <div class="fieldset"> <div class="form-group access-input-wrapper"> <div class="ui-widget ui-front"> <label class="sr-only" for="institutionName">Institution name</label> <input class="field" id="institutionName" name="institutionName" type="text" value=""/>
</div>
<button class="btn primary" name="button" type="submit">Go</button>
</div>
<div class="message error" id="institutionLookupErrorDiv" style="display:none">
                        '<span id="enteredInstitionNameSpan"></span>' is not set up for this type of access on Wiley Online Library. Please contact your institution's administrator to ask about access.
                    </div>
</div>
<input id="entityId" name="entityId" type="hidden" value=""/>
</form>
<h4>Previously accessed institutions</h4>
<ul class="plain" id="previousInstitutions">
<li>(none)</li>
</ul>
</div>
<div class="section-content">
<div class="open-athens-login">
                Login using <a href="/openathens">OpenAthens</a>
</div>
</div>
</div>
</div>
</div>
</div>
<div style="display:none">
<input id="freelabel" name="freelabel" type="hidden" value="Free access"/>
<input id="openlabel" name="openlabel" type="hidden" value="Open access"/>
</div>
</section>
</div>
<div class="portlet-boundary portlet-boundary_58_ portlet-static portlet-static-end portlet-login" id="p_p_id_58_INSTANCE_4_">
<span id="p_58_INSTANCE_4"></span>
<section class="portlet" id="portlet_58_INSTANCE_4">
<header class="portlet-topper">
<h1 class="portlet-title">
<span class="" onmouseover="Liferay.Portal.ToolTip.show(this, 'Sign\x20In')">
<img alt="" id="joiu__null__null" src="https://www.cochranelibrary.com/cochrane-theme/images/spacer.png" style="background-image: url('https://www.cochranelibrary.com/sprite/html/icons/_sprite.png'); background-position: 50% -592px; background-repeat: no-repeat; height: 16px; width: 16px;"> <span class="taglib-text hide-accessible">Sign In</span> </img></span> <span class="portlet-title-text">Sign In</span> </h1> <menu class="portlet-topper-toolbar" id="portlet-topper-toolbar_58_INSTANCE_4" type="toolbar"> </menu> </header> <div class="portlet-content"> <div class="portlet-content-container"> <div class="portlet-body"> <p>If you have a <strong>Wiley Online Library</strong> institutional username and password, enter them here.</p> <form action="https://www.cochranelibrary.com/en/content?p_p_id=58_INSTANCE_4&amp;p_p_lifecycle=1&amp;p_p_state=normal&amp;p_p_mode=view&amp;_58_INSTANCE_4_struts_action=%2Flogin%2Flogin" autocomplete="on" class="form sign-in-form" id="_58_INSTANCE_4_fm" method="post" name="_58_INSTANCE_4_fm"> <fieldset class="input-container" disabled="disabled"> <legend class="sr-only">Cochrane Login</legend> <input name="_58_INSTANCE_4_formDate" type="hidden" value="1740728218373"> <input class="field" id="_58_INSTANCE_4_saveLastPath" name="_58_INSTANCE_4_saveLastPath" type="hidden" value="false"> <input class="field" id="_58_INSTANCE_4_redirect" name="_58_INSTANCE_4_redirect" type="hidden" value="/cdsr/doi/10.1002/14651858.CD008919.pub2/full"> <input class="field" id="_58_INSTANCE_4_doActionAfterLogin" name="_58_INSTANCE_4_doActionAfterLogin" type="hidden" value="false"> <div class="control-group input-text-wrapper"> <label class="control-label" for="_58_INSTANCE_4_login"> Username </label> <input class="field clearable" id="_58_INSTANCE_4_login" name="_58_INSTANCE_4_login" type="text" value=""> </input></div> <div class="control-group input-text-wrapper"> <label class="control-label" for="_58_INSTANCE_4_password"> Password </label> <input class="field" id="_58_INSTANCE_4_password" name="_58_INSTANCE_4_password" type="password" value=""> </input></div> <input class="field" id="_58_INSTANCE_4_institutionalLogin" name="_58_INSTANCE_4_institutionalLogin" type="hidden" value="true"/> <span id="_58_INSTANCE_4_passwordCapsLockSpan" style="display: none;"> Caps Lock is on. </span> <div class="login-form-footer clearfix"> <div class="pull-left"> <button class="btn primary" type="submit">Sign in</button> </div> </div> </input></input></input></input></fieldset> </form> </div> </div> </div> <div style="display:none"> <input id="freelabel" name="freelabel" type="hidden" value="Free access"/>
<input id="openlabel" name="openlabel" type="hidden" value="Open access"/>
</div>
</section>
</div>
</div>
</div>
</div>
</div></div>
<div class="get-access-form-content" data-modal-title="Unlock gold-standard Cochrane evidence" style="display: none;">
<div class="portlet-boundary portlet-boundary_scolariscontentdisplay_WAR_scolariscontentdisplay_ portlet-static portlet-static-end scolaris-content-display-portlet" id="p_p_id_scolariscontentdisplay_WAR_scolariscontentdisplay_INSTANCE_getaccessform_">
<span id="p_scolariscontentdisplay_WAR_scolariscontentdisplay_INSTANCE_getaccessform"></span>
<section class="portlet" id="portlet_scolariscontentdisplay_WAR_scolariscontentdisplay_INSTANCE_getaccessform">
<header class="portlet-topper">
<h1 class="portlet-title">
<span class="" onmouseover="Liferay.Portal.ToolTip.show(this, 'Scolaris\x20Content\x20Display')">
<img alt="" id="wpdq__null__null" src="/scolaris-content-display/icon.png"> <span class="taglib-text hide-accessible">Scolaris Content Display</span> </img></span> <span class="portlet-title-text">Scolaris Content Display</span> </h1> <menu class="portlet-topper-toolbar" id="portlet-topper-toolbar_scolariscontentdisplay_WAR_scolariscontentdisplay_INSTANCE_getaccessform" type="toolbar"> </menu> </header> <div class="portlet-content"> <div class="portlet-content-container"> <div class="portlet-body"> <div class="readcube-checkout-container-outer"> <div class="row-fluid access-content-wrapper"> <div class="span6 access-left-content"> <div class="section"> <div class="section-content"> <p>Improve your health decisions with access to trusted, independent evidence from the Cochrane Library. Unlock this review for uninterrupted access.</p> <p>Still deciding? <a href="https://m.info.wiley.com/webApp/cochranenewsletter"> Sign up to our newsletter to learn more </a> </p> </div> </div> <div class="section"> <div class="access-content-section"> <h3 class="title">Institutional users</h3> <div class="section-content"> <p>Search for your institution's name below to login via Shibboleth</p> <form action="/shibboleth" id="institutionLoginForm" method="post"> <div class="fieldset"> <div class="form-group access-input-wrapper"> <div class="ui-widget ui-front"> <label class="sr-only" for="institutionName">Institution name</label> <input class="field" id="institutionName" name="institutionName" type="text" value=""/> </div> <button class="btn primary" name="button" type="submit">Go</button> </div> <div class="message error" id="institutionLookupErrorDiv" style="display:none"> '<span id="enteredInstitionNameSpan"></span>' is not set up for this type of access on Wiley Online Library. Please contact your institution's administrator to ask about access. </div> </div> <input id="entityId" name="entityId" type="hidden" value=""/> </form> <h4>Previously accessed institutions</h4> <ul class="plain" id="previousInstitutions"> <li>(none)</li> </ul> </div> <div class="section-content"> <div class="open-athens-login"> Login using <a href="/openathens">OpenAthens</a> </div> </div> </div> </div> <div class="section"> <div class="access-content-section"> <h3 class="title"> Other access options </h3> <div class="section-content"> <ul class="plain"> <li> <a class="get-access-individual-login-button" href="/c/portal/login"> Individual access - via Wiley Online Library </a> </li> </ul> </div> </div> </div> </div> <div class="span6 access-right-content readcube-checkout-container"> <div class="section"> </div> </div> </div> </div> </div> </div> </div> <div style="display:none"> <input id="freelabel" name="freelabel" type="hidden" value="Free access"/> <input id="openlabel" name="openlabel" type="hidden" value="Open access"/> </div> </section> </div> </div> <!-- Scolaris Version: --> <script type="text/javascript">if(window._satellite){_satellite.pageBottom()};</script> </div> <script>(function(){function c(){var b=a.contentDocument||a.contentWindow.document;if(b){var d=b.createElement('script');d.innerHTML="window.__CF$cv$params={r:'918ebf1ec9e3f46e',t:'MTc0MDcyODIxOC4wMDAwMDA='};var a=document.createElement('script');a.nonce='';a.src='/cdn-cgi/challenge-platform/scripts/jsd/main.js';document.getElementsByTagName('head')[0].appendChild(a);";b.getElementsByTagName('head')[0].appendChild(d)}}if(document.body){var a=document.createElement('iframe');a.height=1;a.width=1;a.style.position='absolute';a.style.top=0;a.style.left=0;a.style.border='none';a.style.visibility='hidden';document.body.appendChild(a);if('loading'!==document.readyState)c();else if(window.addEventListener)document.addEventListener('DOMContentLoaded',c);else{var e=document.onreadystatechange||function(){};document.onreadystatechange=function(b){e(b);'loading'!==document.readyState&&(document.onreadystatechange=e,c())}}}})();</script></body> </html> 